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Summary
Cell adhesion proteins osteopontin, CD44 and integrin aVp3 interact to form an 
adhesion complex between the embryo and endometrial surface forming an 
attachment that can lead to implantation. Whilst receptivity has been investigated 
extensively, the expression of this adhesion complex has yet to be studied 
simultaneously in the endometrium. This thesis establishes the expression of the 
adhesion complex in fertile and infertile endometrium. In addition the regulation of 
the adhesion complex components by distinct signalling pathways and the key 
regulators estrogen receptor, nuclear factor kappa B and signal transducer and 
activator of transcription 1 have been investigated in endometrial cell lines.
Objectives:
To establish the expression profile of adhesion complex components in samples 
obtained from fertile and infertile women. To model in vitro hormonal regulation of 
adhesion complex components to mimic estrogen and progesterone stimulus in the 
menstrual cycle. To determine if adverse environments common to poly cystic 
ovarian syndrome and endometriosis affect uterine expression of the adhesion 
complex via high glucose and pro-inflammatory cytokines. To investigate the direct 
regulation of Osteopontin and CD44 by estrogen and cytokine signalling through 
estrogen receptor a, nuclear factor kappa B and signal transducer and activator of 
transcription 1.
Methodology:
Investigation of human biopsies and cell line models by immunohistochemistry, 
quantitative polymerase chain reaction, chromatin immunoprecipitation and 
enzyme linked immunosorbent assay.
Conclusions:
Adverse uterine environments including high glucose and pro-inflammatory 
cytokines may regulate the expression of the adhesion complex, and contribute to a 
lack of endometrial receptivity in endometriosis and poly cystic ovarian patients. 
CD44, ITGAV and ITGB3 levels may be used as markers for loss of receptivity in 
unexplained infertility.
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Chapter 1 
Introduction
1.1 Female infertility and reproductive disorders
Infertility is defined by the National Institute for Health and Care Excellence (NICE) 
as "the failure of a couple to conceive after 1 year of unprotected intercourse in the 
absence of a known reproductive pathology" (NICE, 2012). It is estimated that 
infertility affects one in every six heterosexual couples in the UK (2012), 30% of 
infertility cases are attributed to male factors whilst in infertile women 25% are 
caused by ovulatory disorders, 10% are caused by uterine or peritoneal disorders 
and 25% are classified as 'unexplained'. Standard investigations include semen 
analysis, ovulation assessment, tubal patency, uterine abnormalities and ruling out 
infections i.e. Chlamydia trachomatis (NICE, 2012). Following the results of the 
above tests there are three main treatment options; firstly medical treatment to 
restore ovulation through the use of drugs; secondly surgery to remove any 
abnormalities and; thirdly assisted reproduction techniques (ART). For patients that 
undergo in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ISCI), poor 
embryo quality or failures of the embryo to implant maybe detected in these 
patients. However infertility problems may still persist after conventional treatment 
or diagnostics. Endometrial receptivity and implantation are not currently used as a 
measure of infertile status.
1.1.1 Polycystic Ovarian Syndrome (PCOS)
Polycystic ovarian syndrome (PCOS) was originally named Stein-Leventhal syndrome
after it was first described by Irving F. Stein and Michael L. Leventhal in 1935 (Stein
and Leventhal 1935). It was later named after the physical characteristics of the
disease which occur in some women where the follicles in the ovary appear cystic
on investigation by ultrasound. Cystic ovaries are caused when the follicles become
arrested in development. Immature follicles can contribute to infertility due to lack
of ovulation of mature ovums. PCOS is currently diagnosed by the Rotterdam
criteria where it is recognised as a syndrome and the presence of cystic ovaries may
not occur. The syndrome is diagnosed if two of the following three criteria are met;
(1) oligoovulation (infrequent or irregular ovulation) or anovulation (absence of
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ovulation for >3 months), (2) clinical or biochemical signs of hyperandrogenism or 
(3) polycystic ovaries, all in the absence of other diseases (The Rotterdam 
ESHRE/ASRM-sponsored PCOS consensus workshop group 2004; Legro et al. 2013). 
Visual manifestations of hyperandrogenism such as hirsutism and acne can be used 
as indicators, and biochemical analysis of circulating androgens is also considered in 
this assessment. Polycystic ovaries are defined as 12 or more follicles in each ovary 
measuring 2-9 mm in diameter and/or increased ovarian volume (>10ml). Common 
conditions associated with PCOS include obesity, high body mass index, metabolic 
syndrome, insulin resistance and diabetes (Tan et al. 2010; Ciampelli et al. 1999). 
Common features of metabolic syndrome include insulin resistance, obesity and 
dyslipidemia which are often present in women with PCOS. Insulin resistance can 
lead to high levels of circulating glucose, and insulin sensitising treatments for this 
form of diabetes (type 2) may have positive effects on fertility (Sharpless 2003; 
Essah et al. 2007; Steiner et al. 2007; Froment and Touraine 2006). Women 
identified with PCOS are further sub divided into anovulatory and ovulatory PCOS 
based on their ovulation status. Women who fail to ovulate for more than three 
months are characterised as anovulatory. Women who are diagnosed with PCOS 
but ovulate infrequently or have menstrual cycles that are irregular or longer (more 
than 50 days) are classed as ovulatory PCOS. It is estimated that 5-10% of women in 
the UK are diagnosed with PCOS (Treasure et al. 2013; Kelly et al. 2001).
1.1.2 Endometriosis
An infertility associated disorder first described in 1860 by Carl Von Rokitansky 
(Rokitansky 1855; Batt 2011), endometriosis is where endometrial gland and 
stroma cells are found outside of the uterine cavity. A theory developed by 
Sampson describes the endometrial cells detaching from the endometrial layer. It is 
possible that as blood during a menstrual cycle can flow through the fallopian 
tubes and reside in the pelvic cavity detached cells may then be deposited there 
(Sampson 1927). These cells are still influenced by steroid hormones and continue 
to proliferate, differentiate and break down every month in response to sex steroid
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hormones of the menstrual cycle. This is what is thought to cause an exacerbation 
in symptoms including the pelvic pain that is commonly associated with 
endometriosis. Endometriosis affects between 6-10% of the general UK population 
and this increases to 25-50% within infertile women (Bulletti et al. 2010). 
Endometriosis is diagnosed by the presence of abnormalities in the pelvic region 
such as cysts or endometriomas on the outer wall of the reproductive organs, the 
presence of which can be confirmed by ultra sound. Current treatment methods 
are effective at pain management and include the administration of progestin, 
estrogen plus progestins, gonadotropin-releasing hormone agonist and 
antagonists, danazol and aromatase inhibitors. However these treatments render 
the patient infertile as they inhibit ovulation. Surgical options including laparoscopy 
can be conducted to confirm and ascertain the extent of endometriosis. 
Laparoscopic ablation of endometrial implants may serve to reduce pain and have 
shown to increase fertility (Grzechocinska and Wielgos 2012). Research 
investigating the role of inflammation in endometriosis and the possible impact on 
infertility has been conducted (Weiss et al. 2009; Kyama et al. 2003; Lebovic et al. 
2001) with studies focused on the role of pro-inflammatory cytokines present in 
the peritoneal fluid (Taketani et al. 1992; Bedaiwy et al. 2002); circulating blood 
(Pellicer et al. 1998; Sze et al. 2010) and expression by leukocytes on the 
endometrial epithelial surface (Kyama et al. 2003; Lebovic et al. 2001; van Mourik 
et al. 2009; Weiss et al. 2009).
1.1.3 Unexplained Infertility
Unexplained infertility (UIF) is diagnosed when all standard diagnostic tests for 
infertility show no reproductive pathology is identified in either partner. However, 
patients still have problems conceiving after a year of regular unprotected 
intercourse. The standard tests include ovulation assessment, analysis of semen 
quality and quantity, and a hysterosalpingogram. Further testing can establish 
ovarian reserve or investigative laparoscopy can be conducted. In infertile women 
approximately 25% are categorised as unexplained infertility (Department of
4
Health 2009). As there is no uterine and sperm dysfunction found there is currently 
no treatment. Guidelines advise couples to continue to attempt to conceive and 
following two years of unsuccessful conception (including a year prior to 
investigations) then IVF will be offered. Ovulatory stimulation is no longer offered 
as it has not shown to increase fertility rates. This suggests that an endometrial 
factor such as receptivity and/or implantation could be a possible cause for 
infertility. Currently, there are no biomarkers of receptivity identified for 
unexplained infertility.
1.2 Reproductive Biology
Mammalian reproductive biology focuses on factors that may affect successful 
reproduction. The reproductive organs, leukocytes, hormones and cytokines are 
essential to this process. A cascade of events works in harmony for successful 
reproduction to take place. This process involves gametogenesis, fertilisation, 
implantation and gestation.
1.2.1 Physiology of the human female reproductive system
The female reproductive organs consist of the ovaries, the fallopian tubes and the 
uterus (Figure 1-1). From puberty onwards ovaries in women are responsible for 
ovum production. The fallopian tubes are adjacent to the ovaries and connect to 
the uterus and provide a functional role in aiding the passage of the ovum to the 
uterus. The endometrium is a specialised layer of tissue in the uterus wall and has 
distinct functions in reproduction.
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Fallopian tube
Endometrium
Myometrium
Fundus o f uterus
Cervix 
Vlagina
Female reproductive organs
Fimbriae
Figure 1-1 Diagram of the structure of the female reproductive organs.
Adapted from (www.wellnessagro.com)
1.2.1.1 Ovaries
The ovaries are dynamic organs where changes in the structure and function can 
lead to drastic consequences for fertility. The follicular compartment where the 
follicles develop into ovums is highly specialised, receiving signals from pituitary 
derived hormones and cytokines throughout the menstrual cycle. This develops 
primordial follicles to graafian follicles ready for ovulation and regression of the 
corpus luteum to the corpus albicans are all driven by these signals. Ovulation is 
where the mature ovum is released from the ovaries. It is also responsible for 
developing the ovum for implantation and stimulating follicular growth to induce a 
surge in luteinising hormone expression to induce ovulation. If the ovum is not 
fertilised within 24 to 26 hours after ovulation it will be degraded by the immune 
system.
1.2.1.2 Fallopian tubes
The fallopian tubes are lined with ciliated epithelia and connect the uterus to the 
ovaries, and are typically 8 to 10 cms in length. The ovarian end o f the fallopian 
tubes have feathered like ends, called fimbriae. The fimbriae contain projections 
which are used to capture the ovum once ovulation from the ovary has taken place
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and ensure it can move into the fallopian tube. A specialised ciliated epithelial 
surface in the fallopian tube allows the ovum to travel from the fallopian tubes into 
the uterus providing nourishment and lubrication during this process. The ovum 
first travels into the fimbrial segment, into the infundibular segment, the ampullary 
segment, isthmic segment and finally into the interstitial segment where it enters 
the uterine cavity.
1.2.13 The uterine cavity
Surrounding the uterus is the peritoneal fluid. This fluid lines the outer surface of 
the uterus (serosa) providing lubrication between tissue that lines the abdominal 
wall and the pelvic cavity. This fluid functions to prevent friction between the uterus 
and digestive organs. The uterus contains three layers of cells; the perimetrium is 
the outer serosa layer of the uterus, the myometrium which is the muscular layer 
important for inducing contractions, and the endometrium which is the inner most 
lining.
1.2.1.4 Endometrium
The endometrium is the inner most lining of the uterus and thickens in response to 
ovarian derived hormones and cytokine signals to prepare the surface of the 
endometrium for embryo implantation if fertilisation occurs. This is achieved by the 
endometrial surface expressing the correct plethora of adhesion proteins which will 
allow for this attachment to take place. Following this initial attachment the embryo 
will implant into the endometrium during a preparation process called 
decidualization. The uterus will then provide the implanted embryo with nutrients 
and oxygen so that it will develop into a foetus and hence successful pregnancy 
occurs. However, if fertilisation or implantation does not occur the endometrial 
tissue will break down and shed as part of the menstrual cycle.
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1.2.2 Menstrual cycle
Changes in endometrial morphology throughout the menstrual cycle in response to 
hormones influence tissue proliferation, differentiation and degradation (Figure 
1-2). The menstrual cycle is a cyclic event that occurs in women approximately 
every 28 days where the endometrial tissue is regenerated under the influence of 
hormones and cytokines. The endometrium is a highly specialised tissue within the 
body with the unique ability to differentiate, proliferate and break down. This 
suggests that cell differentiation and proliferation are highly regulated. Proliferation 
of the endometrium is driven by estrogen in the proliferative phase (Figure 1-2). 
Following ovulation the endometrial tissue begins to vascularise and differentiate 
during the secretory phase, where progesterone is responsible for driving these 
changes up to approximately day 23 when progesterone levels start to decline. A 
lack of progesterone in the endometrium results in the constriction of the blood 
vessels leading to the shedding of the endometrium (menstruation). Days 20-24 of 
the menstrual cycle have been termed the 'window of implantation'. This is when 
the endometrial tissue is the thickest and the epithelium is most likely to bind the 
trophoblast layer of the blastocyst. This begins the implantation process; initially 
attachment of the blastocyst to the epithelium occurs followed by adhesion of the 
blastocyst to the endometrial epithelium and finally invasion. Decidualization of the 
endometrial tissue occurs in preparation for implantation where the blastocyst 
invades the epithelium and becomes embedded in the stroma where it can begin to 
differentiation and grow. If successful implantation does not take place the 
endometrium sheds and the cyclic process initiates again. The primary hormones 
responsible for these changes in the endometrium are estrogens, progesterone, 
follicle stimulating hormone and luteinising hormone.
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Figure 1-2 Changes in endometrial morphology during the menstrual in response 
to ovarian derived hormones and pituitary derived gonadotropins.
Endometrial morphology is influenced by ovarian derived hormones estrogen, 
progesterone, luteinising hormone and follicle-stimulating hormone. Proliferation 
of the tissue is driven by estrogen and differentiation by progesterone. FSH and 
LH signal to the ovary to release an egg and provide a negative feedback 
mechanism for estrogen production. Adapted from (www.antranik.org).
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1.3 Endometrial cellular structure and composition
The endometrial lining of the uterus contains two distinct cell types, epithelial and 
stromal, which interact with each other. The epithelial cells are the outer most cell 
layer. In these two layers of tissue glandular structures are present. Endometrial 
glands function to secrete proteins and cytokines to influence the expression of the 
epithelium in preparation for the blastocyst implantation. The luminal epithelial 
cells form the endometrial surface that will be in direct contact with the blastocyst. 
The stromal cells are located between the glandular and luminal epithelium (Figure 
1-3). These two distinct cell types utilise paracrine signalling to communicate and an 
example of this is the regulation of integrin receptor aV(33 by estrogen and 
progesterone from the stroma to the endometrial epithelium (Lessey and Arnold 
1998). The luminal surface functions to protect the tissue from bacterial infections 
w ith columnar epithelia and intracellular tight junctions.
Figure 1-3 IHC biopsy section showing structural elements of endometrium.
The luminal cell surface is indicated (L), along with the glands (G) and the stroma 
(S). Black bar represents 20pm, magnification, x40.
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1.3.1 Signalling mechanism involved in endometrial development.
The hypothalamus releases gonadotropin-releasing hormone (GnRH), resulting in 
anterior pituitary gland production of follicle stimulating hormone (FSH) and 
luteinizing hormone (LH). This in turn stimulates the ovaries to produce estrogen. 
The ovaries also produce inhibin which serves to regulate the ovarian; and therefore 
menstrual cycle, by forming a negative feedback loop. Estrogen itself then acts as a 
negative feedback inhibitor of GnRH production by the hypothalamus (Figure 1-4). 
Different signalling mechanisms are involved in endometrial development including 
hormone signalling from the pituitary gland. Gonadotropin releasing hormone from 
the hypothalamus stimulates the pituitary gland to release follicle stimulating 
hormone (FSH) and luteinising hormone (LH), which act on the ovaries. The anterior 
pituitary gland secretes FSH and this hormone works synergistically with LH to drive 
maturation of the developing follicle by increasing FSH in the proliferative phase 
after levels of progesterone and estradiol fall (Figure 1-4). LH peaks in concentration 
causing ovulation to occur at day 14. Ovulation is the release of the egg from the 
mature graffian follicle of the ovaries. This surge also induces a change in the 
residual follicle to form the corpus luteum (Figure 1-4). Paracrine signalling then 
takes effect whereby estrogen and progesterone in the epithelium and stroma of 
the endometrium allow two cell types in the same tissue to communicate. All of 
these types of signalling are important in the endometrium to maintain its 
structural morphology and expression of adhesion proteins during implantation.
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Figure 1-4 The hypothalamic pituitary ovarian axis
The hypothalamic-pituitary-ovarian axis is the culmination of the individual 
endocrine glands involved in producing and regulating the hormone changes 
within the body. Importantly, changes to the ovaries and endometrium control 
reproduction (Goldman and Ausiello 2008).
1.4 Nuclear Hormone Receptor expression levels
The nuclear hormone receptors, estrogen receptor alpha (ERa), estrogen receptor 
beta (ERp) and progesterone receptor (PR) drive the essential signalling cascades in 
the endometrial tissue for adhesion protein expression in the window of 
implantation. These receptors are activated upon ligand binding in the cytosol, this 
is followed by receptor dimerisation which allows for translocation to the nucleus 
where they are able to bind regulatory sites on the gene promoters to mediate 
gene transcription.
1.4.1 Estrogen
Three main estrogens occur in the body, estrone (Ei), estradiol (E2) and estriol (E3). 
Estradiol is the most potent and predominant estrogen expressed within the body 
and circulating serum and is involved in influencing the morphological changes in
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the endometrium. The developing follicles in the ovaries and the corpus lutea 
produce estrogens. The biosynthesis of estrogens occurs in the theca cells in the 
ovaries. Androstenedione is synthesised from cholesterol, this compound is then 
converted in granulosa cells to estrone or testosterone. Testosterone can then be 
catalysed by aromatase to estradiol. Estradiol drives the regeneration of the 
endometrium after degradation (menses) by causing the tissue to proliferate. As 
such this phase of the menstrual cycle is termed the proliferative phase (Figure 1-2, 
days 5-14).
1.4.2 Progesterone
Progesterone is synthesized from cholesterol by the removal of a cholesterol side 
chain to produce pregnenolone, and this is then converted by 3-beta- 
hydroxysteriod dehydrogenase (3P-HSD) to progesterone. Progesterone can be 
produced in the ovaries, the adrenal glands and has been shown to be stored by 
adipose tissue. Progesterone acts on the endometrial surface by differentiating the 
tissue. This occurs in the 'secretory phase' where glandular structures become more 
irregular and start to secrete various cytokines, proteins and leukocytes (Figure 1-2, 
days 15-28).
1.4.3 Steroid hormone receptor expression in the endometrium
Physiological levels of estrogen are around 150 ng/ml at the beginning of the 
proliferative phase and gradually increase to day 13 where they peak at ~420 ng/ml. 
Levels then gradually decrease to day 17 before increasing during the secretory 
phase to peak at 300ng/ml during the window of implantation (Martin and 
Behbehani 2006). Estrogen signalling however is still active in the mid and late 
secretory phases. Progesterone concentrations are around 100 ng/ml at the 
beginning of the proliferative phase and increase to peak at ~350 ng/ml at day 21 
before decreasing back to 100 ng/ml at day 28 if pregnancy does not occur (Martin 
and Behbehani 2006; Francis et al. 2010). During the window of implantation there 
is a balance between both estrogen and progesterone signalling. After estrogen
peaks in the proliferative phase, progesterone expression increases. This is thought 
to be through an increase in activator protein 1 (AP-1) which can bind to the 
promoter and activate transcription of the PR receptor (Petz 2002). ERa and PR 
expression throughout the menstrual cycle, as determined by 
immunohistochemistry, demonstrates that maximal expression of both receptors 
occurs in the mid to late secretory phase (Lessey et al. 1988).
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Figure 1-5 Hormone, receptor and adhesion protein expression in menstrual cycle.
Levels of estrogen and progesterone indicate the balance of these hormones 
throughout the menstrual cycle and the effect of these hormones on endometrial 
morphology is shown. The changes in ERa, ERp and PR levels throughout the 
menstrual cycle are included. In addition to this adhesion molecules up regulated 
in the window of implantation are indicated. Adapted from (Francis et al. 2010).
Steroid signalling through progesterone and estrogen affects cells directly. The 
epithelium and stroma both express ER and PR. Expression of ERa, ERP and PR 
changes throughout the menstrual cycle as does the levels of estrogen and 
progesterone (Figure 1-5). Expression of both ER receptors increases from the 
proliferative phase to the early secretory phase. However, during the mid secretory 
phase expression of ERa increases while ERp expression decreases. In the late 
secretory phase expression of ERa then deceases whilst ERp increases (Critchley 
2002; Lecce et al. 2001). Endometrial PR expression increases in the late
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proliferative phase compared to the early proliferative phase. Expression decreases 
during the mid secretory phase and decreases further in the late secretory phase 
(Ingamells et al. 1996). The correct expression of estrogen and progesterone 
throughout the menstrual cycle and crucially during the window of implantation is 
important where endometrial receptivity is essential to the implantation process.
1.5 Embryo Implantation
The first stage of embryonic implantation is apposition where the trophoblast cells 
of the blastocyst bind to carbohydrate ligands that are localized on the luminal 
epithelium during the window of implantation. This is the initial attachment of the 
blastocyst to the endometrial surface. The adhesion phase is characterised by 
cellular adhesion molecules including integrin aV(33 and its ligand osteopontin 
(OPN) that co-localise and may play a role in endometrium or embryonic signalling, 
assisting embryo attachment to the apical surface before invasion occurs (Figure 
1-6). CD44 is expressed on the endometrial epithelium and trophoblast surface and 
can bind to OPN (Fazleabas and Kim 2003).
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Figure 1-6 Blastocyst implantation.
The attachment of the blastocyst surface (trophectoderm) to the endometrial 
epithelia, the three stages include apposition, adhesion and invasion for 
successful implantation. At the three different stages different proteins expressed 
on the trophectoderm and epithelial surface are key. Adapted from (Achache and 
Revel 2006).
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The last stage of implantation is invasion where the trophoblast adheres to the 
endometrial epithelial cells and through a paracrine mediated apoptotic reaction 
the blastocyst will pass through into the epithelial and stromal cell layer. It is crucial 
that repertoires of genes involved in degradation of the extracellular matrix are 
activated. The proteolytic enzyme matrix metalloproteinase 9 (MMP-9) has been 
linked with the invasive phenotype of trophoblasts (Skrzypczak et al. 2007). Finally 
the blastocyst traverses the basal membrane (Achache and Revel 2006; Geisert et 
al. 2006).
1.5.1 Uterine receptivity
Endometrial receptivity has been defined as "the capacity for the uterine mucosa to 
facilitate successful implantation" (Cavagna 2003). Biochemical, structural and 
molecular events in the endometrium must work in a synchronous fashion for 
receptivity to be maximal. It is understood for uterine receptivity to be optimal 
hormone, cytokine signalling and expression of adhesion markers on the 
endometrial surface is important, however the mechanisms behind their expression 
are still under investigation (Makker and Singh 2006; Fatemi and Popovic-Todorovic 
2013). The expression of adhesion proteins monitored throughout the menstrual 
cycle and peaking in expression during or around the window of implantation have 
been considered good candidate molecules to investigate in infertility. Examples of 
these adhesion proteins are CD44, osteopontin and integrins including aV|33 (Lessey 
2002; Goodison et al. 1999; Apparao et al. 2001).
1.5.2 Extra cellular matrix adhesion molecules
The extra cellular matrix (ECM) functions to provide structural support to cells and 
regulate communication between cells. The ECM is an interconnected mesh of 
proteins and polysaccharides, hyaluronic acid is an example of a polysaccharide 
present in the ECM. Hyaluronic acid, through its specific receptor CD44, can 
regulate cell behaviour using environmental cues such as in inflammation and the 
healing process (Goshen et al. 1996; Bellahcene et al. 2008). Collagens and laminins
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also make up the ECM and have been found to bind integrins expressed on the cell 
surface (Ponta et al. 2003). Fibronectins in the ECM contain both a variable region 
and an arginine-glycine-aspartic acid (RGD) region that has been identified to bind 
specific integrins such as aV|33 (Carvalho et al. 1998; Lee et al. 2007). Other 
molecules containing RGD domains are known as small integrin-binding ligand N- 
linked glycoproteins (SIBLINGS). These are a family of five identically orientated 
genes located on chromosome 4 in a region approximately 375,000bp in length 
(Bellahcene et al. 2008). One of these genes, secreted phosphoprotein 1 (SPP-1), 
encodes for Osteopontin.
1.6 Osteopontin
Osteopontin is a secreted phosphorylated glycoprotein initially described as a 
transformation associated phosphoprotein (Senger et al. 1979) and named later as 
secreted phosphoprotein 1 (SPP-1). During this time it had also been described as 
2ar (Smith and Denhardt 1987) and early T-lymphocyte activating gene (Eta-1). The 
name Osteopontin (OPN) was proposed by Ake Oldberg in 1986, who identified and 
isolated the protein as a bone sialoprotein from rat osteosarcoma. Hence, it was 
named osteopontin, which means bone-bridge (Oldberg et al. 1986). In humans, 
OPN is located on chromosome 4q22.1 and the SPP-1 gene contains 8 exons (Young 
et al. 1990) (Figure 1-7). The promoter region of OPN contains regulatory elements 
for nuclear factor kappa B (NFkB), estrogen receptor alpha (ERa), activator protein 1 
(AP-1), specificity protein 1 (SP-1) and signal transducer and activator of 
transcription 1 (STAT1). Previous studies have identified and validated regulatory 
elements on the OPN promoter. An SP-1 site was identified by both Sharma and 
Wang in independent studies (Wang et al. 2000a; Sharma et al. 2010) an AP-1 site 
has also been identified (Bidder et al. 2002), in addition to one NFkB site (Samant et 
al. 2007). Alternate splicing at the mRNA level gives rise to many protein isoforms of 
OPN.
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Figure i-7  Osteopontin gene and promoter structure
1.6.1 Normal physiology, structure, isoforms and function of osteopontin
OPN is expressed throughout the body in many different tissues and there is also 
evidence that OPN is secreted into body fluids. OPN expression has been 
characterized in luminal epithelia cells in the stomach, small and large intestine, 
liver, gall bladder, kidney, lung, breast tissue and the endometrium at the mRNA 
level (Brown et al. 1992). At the protein level OPN expression has been reported in 
the colon, gallbladder epithelium, pancreas epithelium, kidney distal tubular 
epithelium, fallopian tube epithelium and endometrial epithelium (Brown et al.
1992). Of note is the involvement of OPN in inflammatory processes and also that it 
is secreted by macrophages, leukocyte and lymphocytes (Rodrigues et al. 2007). 
OPN has been shown to exhibit both pro- (promoting IL-12) and anti-inflammatory 
behaviour during cell injury and infection (Renkl et al. 2005; Mazzali et al. 2002). 
Based on the diverse expression profile of OPN in the human body, it is thought to 
play a significant role in wound repair, cell survival, leukocyte recruitment and 
function, bio-mineralization and iNOS regulation (Mazzali et al. 2002). OPN is a
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negatively charged glycoprotein that functions as a component of the ECM (Figure 
1- 8 ).
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Figure 1-8 Protein structure of OPN.
OPN has a very complex protein structure consisting of multiple proteolytic 
cleavage, integrin and putative CD44 binding sites. Many heparin binding and 
phosphorylation sites exist on OPN's protein structure. A calcium binding and 
aspartate domain has been identified, as well as a transglutamination site.
OPN is a secreted protein that functions in many tissues to promote cell adhesion 
and cell migration, which are key physiological processes that OPN is involved in 
and dysfunction of these can lead to pathological processes in many tissues (Section 
1.6.2). OPN protein is involved in bone mineralisation through its hydroxyapatite 
site which is able to bind to collagen (Zurick et al. 2013). OPN protein has many 
phosphorylation sites and can be heavily phosphorylated (Figure 1-8). OPN 
phosphorylation in the endometrium is poorly understood however 34 
phosphoserine and 2 phosphothreonine site have been identified on OPN's protein 
structure. OPN protein has multiple cleavage sites for MMP and thrombin. MMPs 
are a family of proteases involved in the degradation of the extracellular matrix 
(ECM). They have also been shown to have roles in cell migration, adhesion and 
proliferation and are often found at sites of tissue regeneration (Kuzuya and Iguchi 
2003; Giannelli et al. 2002). Multiple MMP-3 and MMP-7 sites exist on OPN's
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protein structure. MMPs -3 and -7 are involved in the decidualization process prior 
to implantation, where OPN is also thought to play a role (Jones et al. 2006). A 
thrombin cleavage site located almost in the centre of the protein structure allows 
cleavage of OPN into two similar molecular weight protein fragments both 
functional (Grassinger et al. 2009). In addition to this, multiple integrin binding sites 
exist clustered together (Figure 1-8) (Christensen et al. 2010). Integrin aVP3 is able 
to bind to OPN through its RGD tri-peptide domain indicated in green (Casals et al. 
2012; Johnson et al. 1999; Peyghambari et al. 2010). Three CD44 binding sites on 
the OPN protein structure are putative, and are indicated in Figure 1-8. OPN-aV|33 
binding is one of the best characterised binding complexes between OPN and its 
integrins. OPN protein has also been shown to bind other molecules such as CD44, 
and in normal tissue physiology this binding functions to provide signal transduction 
to promote cell adhesion, migration and cell survival as with OPN-aVp3 binding 
(Figure 1-9) (Bellahcene et al. 2008). Binding of OPN to membrane bound CD44 
initiates a signalling pathway that promotes cell survival in cells. Initial binding 
activates phospholipase C-y, protein kinase-C (PKC) and phosphotidylinositol 3- 
kinase (PI3K) which activates the Akt pathway which in turn activates anti-apoptotic 
signals in cells. Binding of OPN to integrin aVP3 initiates two pathways that both up 
regulate AP-1 expression. This has been linked with cell adhesion and migration 
through the activation of nuclear factors inducing kinase (NIK), mitogen-activated 
protein kinase 1 (MAP3K1) and ERK activated AP-1. Alternately MEKK1 also known 
as MAP3K1 can activate MKK4, c-Jun N-terminal kinase 1 (JNK1) and finally AP-1. 
These signalling mechanisms in the endometrium have not been elucidated and the 
effect on endometrial surface expression has not been characterised.
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Figure 1-9 Signalling pathways initiated upon cell-matrix interaction.
OPN binding to membrane bound CD44 initiates a signalling complex that 
activates Akt which is associated with cell survival through anti-apoptotic 
activation. OPN integrin aVp3 results in the activation of AP-1 through two 
distinct pathways, activation of AP-1 is associated with cell adhesion and cell 
migration. Adapted from (Bellahcene et al. 2008).
1.6.2 Osteopontin Dysfunction
OPN has been implicated in the pathology of many different diseases and disorders 
including rheumatoid arthritis (Iwadate et al. 2013), asthma (Delimpoura et al. 
2010; Samitas et al. 2011), Graves disease (Xu et al. 2011), prostate cancer (Gupta 
et al. 2013) and breast cancer (Wang et al. 2010). Altered expression levels of OPN 
in the endometrium have been associated with infertility-related conditions 
including PCOS (DuQuesnay et al. 2009) and endometriosis (Cho et al. 2009; Wei et 
al. 2009; Casals et al. 2012).
1.6.3 Osteopontin and Inflammation
OPN is involved in several chronic inflammatory diseases including atherosclerosis 
(Giachelli et al. 1995; O'Brien et al. 1994), delayed-type hypersensitivity (Yu et al.
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1998; Ashkar et al. 2000) granulomatous disease (Ashkar et al. 2000; Yumoto et al.
2002), and arthritis (Nau et al. 1999). Chronic inflammation is marked by consistent 
presence of macrophages at a site of injury or disease (Lund et al. 2009). This has 
been found to be increased in tissues undergoing regeneration or at sites of 
inflammation within tissues (O'Brien et al. 1994; Nau et al. 1999). Secreted levels of 
OPN in plasma have been linked to many chronic inflammatory and leukocyte 
derived disorders as well as autoimmune disorders such as Crohn's disease (Agnholt 
et al. 2007), atherosclerosis (Golledge et al. 2007), lupus (Kariuki et al. 2009), 
multiple sclerosis (Comabella et al. 2005) and rheumatoid arthritis (Sennels et al. 
2008). OPN is responsible for inducing inflammatory responses in many different 
leukocytes including macrophages, T-cells and dendritic cells (Bruemmer and Collins
2003). A study by Weber concluded that OPN binding to integrins after thrombin 
cleavage is responsible for the activation and homing of monocytes (Weber et al. 
2002). OPN can function in many signalling mechanisms in inflammatory responses 
and this diverse molecule can be chemotactic to attract the migration of cells of the 
immune system. There it maintains the cells acting as an adhesive protein. OPN is 
capable of functioning as a pro-inflammatory cytokine, enhancing Thl cytokine 
production and increasing enzymes such as MMPs responsible for degradation of 
the ECM (Weber et al. 2002; Bruemmer et al. 2003). During the process of 
macrophage differentiation the expression of OPN is up-regulated however it is not 
present in circulating macrophages (Krause et al. 1996). Several inflammatory 
cytokines can induce OPN expression in macrophages including IL-ip, IL-6, IFNy and 
TNFa (Nakamachi et al. 2007; Ogawa et al. 2005; Bruemmer et al. 2003).
1.6.4 Expression of Osteopontin in endometrium
OPN expression has been found in the endometrium of healthy cycling women 
(Casals et al. 2008). Maximal OPN expression is observed during the mid secretory 
phase in the window of implantation at both the mRNA and protein level 
(DuQuesnay et al. 2009). OPN expression was localised to the glandular and luminal 
epithelium (Afify et al. 2006; Albers et al. 1995). Secreted levels of OPN are also
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increased in the secretory phase of the menstrual cycle when compared to the 
proliferative phase (Wolff, Thomas Strowitzki, et al. 2001). It has been proposed 
that OPN secretion through the endometrial glands is essential to activate integrins 
on the blastocyst surface to allow for an adhesive surface (Chaen et al. 2012). 
Secreted OPN is capable of binding to CD44 and integrin aV|33 separately. It is 
hypothesized that OPN may act as a bridging molecule between these by binding to 
both CD44 and integrin aV(33 simultaneously (Yen and Jaffe 2009). Therefore for the 
remainder of the study this binding will be referred to as the adhesion complex. 
CD44 and integrin aV|33 are both expressed on the endometrial epithelial and 
trophoblast surface, with maximal expression on the endometrial surface during the 
window of implantation. Therefore it has been hypothesised that these molecules 
are involved in the implantation process. These molecules are therefore good 
candidates for the study of the interaction between the developing blastocyst and 
the endometrial epithelial surface.
1.7 CD44
The CD44 gene is located on the short arm of chromosome 11 in region 1 band 3. 
The promoter region of CD44 contains regulation elements for ERa, AP-1, SP-1, 
STAT1, IRF-1 and NFkB (Figure 1-10). Its gene structure is subject to extensive 
splicing which results in multiple RNA splice variants (up to 20) being produced 
(Figure 1-11). The standard CD44 exons include 1-5 and 16-20 and exons 6-15 are 
variable exons which are alternatively spliced. This results in many possible 
combinations of exon transcripts, thus giving rise to a variety of different protein 
structures (Figure 1-11).
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Figure 1-10 CD44 promoter structure.
Regulation elements for ERa, AP-1, SP-1, STAT1, IRF-1 and NFkB are indicated.
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Figure 1-11 CD44 gene structure.
The standard CD44 molecule (CD44s) is coded for by the standard exons (sl-10). 
Due to alternative splicing a number of variant CD44 protein isoforms exist (v2-10) 
in humans between s5 and s6. (Goodison et al. 1999).
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1.7.1 CD44 tissue expression
CD44 is a glycoprotein which is membrane bound and expressed on some epithelial 
cells in humans. Proliferating epithelial cells have been shown to up-regulate the 
expression of CD44 during tissue repair (Alho and Underhill 1989). Expression of 
CD44 has been found on migrating mesenchymal stem cells and is markedly 
increased on chondrocyte cell surfaces, where it plays an important role in cartilage 
homeostasis (Knudson and Loeser 2002). CD44 expression has been shown in 
pancreatic duct epithelial cells (Ringel et al. 2001), gastric mucosa (Heider et al.
1993) and breast epithelial tissue (Afify et al. 2008; Hole et al. 1997). At the mRNA 
level CD44 expression has been characterised in the retinal corneal epithelia and 
cervical epithelia (Woerner et al. 1995). Epithelial protein expression of CD44 has 
been noted in the following tissues: cervix, colon and breast (Woerner et al. 1995; 
Trejdosiewicz et al. 1998). Furthermore, expression has been demonstrated on a 
variety of leukocytes including monocytes and intestinal mucosal smooth muscle 
cells (de La Motte et al. 1999). CD44 binding to OPN has been demonstrated in 
tissues including the prostate, substantia nigra and kidney (Ailane et al. 2013; 
Asselman 2003). CD44 expression on the trophoblast surface of the blastocyst has 
been shown (Goshen et al. 1996).
1.7.2 CD44 protein structure
Splicing at the RNA level results in several different CD44 variant proteins and 
different variant expression has been associated with different tissues (Figure 1-12). 
Expression of the standard CD44 (CD44s) has been identified in many cells and 
tissues throughout the body, whilst expression of CD44 protein variants (CD44v) has 
been found primarily in epithelial tissues including the oesophagus, skin and small 
intestine. Expression of CD44v4, CD44v6 and CD44v9 is found in these tissues 
(Mackay et al. 1994).
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Figure 1-12 CD44 protein structure
The standard form of CD44 protein structure is shown on the left, CD44 primarily 
binds to hyaluronic acid. The addition of the variant exons reduces its affinity for 
hyaluronic acid and allows for the binding of other molecules (Goodison et al. 
1999).
1.7.3 CD44 function
CD44 is the receptor for hyaluronic acid and through this interaction CD44 is 
capable of mediating cell-cell and cell-matrix interactions (P. Johnson et al. 2000). 
Its ability to bind other ligands such as OPN, collagens and MMPs is also thought to 
have an involvement in CD44 cellular interactions (Goodison et al. 1999). 
Functionally, CD44 was originally thought to be responsible for tethering cells to 
extracellular ligands only. However, evidence has shown it is able to monitor 
changes in the ECM through extracellular ligand binding that can influence cell 
characteristics such as growth, survival, and differentiation through interactions 
w ith associated proteins (Ponta et al. 2003; Lee et al. 2008) (Figure 1-9). CD44 has 
been shown to be part of the process that activates leukocytes such as lymphocytes 
and acts as a homing receptor for lymphocytes (Xu 2011).
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1.7.4 CD44 dysfunction
When CD44 expression is altered or the protein becomes dysfunctional the 
consequence can be pathogenic to cells and tissues. Up-regulation of CD44 has 
been correlated with many cancers such as liver, colon and prostate (Iczkowski 
2010; Orian-Rousseau et al. 2002; van der Voort 1999; Desai et al. 2009; Bates et al. 
2001). A study that focused on CD44 variants in breast cancer found that a 
particular isoform CD44v6, when elevated, was correlated positively with ER and PR 
expression in breast cancer tissue (Friedrichs et al. 1995). CD44 expression has been 
characterized in the glands of tissues. An example is the mammary glands where 
CD44 expression is required for the proliferation of the underlying mesenchymal 
cells (Yu et al. 2002; Hebbard et al. 2000). CD44 expression in the mammary gland is 
thought to be linked to its role as a mediator of epithelial-stromal signalling in 
addition to functional roles in proliferation, migration and invasion in cancer cells 
(Louderbough et al. 2011; Lokeshwar et al. 1995).
1.7.5 CD44 and inflammation
CD44 has been shown to be involved in T-cell recruitment at sites of inflammation, 
CD44 can activate inflammatory pathways on binding of its ligands (Baaten et al. 
2010). CD44 expression is found on most leukocytes in the body and functions to 
mediate the adhesion of glycosaminoglycans and hyaluronic acid to the ECM (Hutas 
et al. 2008). Inflammatory responses activate T-cells and induce CD44 binding to 
hyaluronic acid (Johnson and Ruffell 2009). CD44 is expressed on endothelial cells 
close to sites of inflammation, where activated T-cells expressing CD44 bind and a 
rolling interaction is initiated (Nacher et al. 2011; de La Motte et al. 1999). The 
interaction of these activated T-cells and endothelium activate integrin expression 
which mediates adhesion to arrest the cells and allows for migration to the site of 
inflammation. CD44 has a role in limiting the inflammatory response in tissues and 
aids in the resolution of inflammation in lung models (Johnson and Ruffell 2009). 
Human chondrocytes in vitro when exposed to hyaluronic acid, interact with CD44
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to induce NFkB activation, which activates the transcription of pro-inflammatory 
cytokines TNFa and IL-lp (Campo et al. 2010).
1.7.6 CD44 expression in endometrium
CD44 detected by immunohistochemistry in the endometrium has been described 
in fertile women and the expression of CD44 variants in the epithelium and stroma 
appears to differ. CD44 staining has been shown to be more prominent in the 
stroma than the glands or luminal epithelial cells. However, expression of variants 
CD44v7-8 was more prominent in the glandular epithelium than the luminal 
epithelium or stroma (Goshen et al. 1996). Another study of CD44 expression in 
endometrial epithelial cells identified CD44 expression at high levels and lower 
expression levels of CD44v9 were detected. The expression of CD44v4 and CD44v6 
has not been detected in the endometrial epithelium (Mackay et al. 1994). When 
the distinct phases of the menstrual cycle are considered in isolation expression of 
the CD44 variants in the endometrium appears to differ througout the menstrual 
cycle, in the proliferative phase luminal CD44 expression was lower than the 
secretory phase (Afify et al. 2006; Poncelet et al. 2010). Protein expression of CD44 
and CD44v6 has been detected in the stroma and epithelium respectively of the 
proliferative phase endometrium (Poncelet et al. 2002). In the secretory phase 
CD44 expression has been found to be prominent in the endometrium of healthy 
cycling women (Poncelet et al. 2010; Desai et al. 2007). Expression of CD44 has 
been identified in secretory phase epithelium and stroma, whilst CD44v6 has only 
been found in the epithelium during the secretory phase. No expression of CD44v3 
was found in the endometrium (Poncelet et al. 2002). CD44 expression in the 
endometrial stroma in the secretory phase is important in the processes after initial 
implantation. This is because CD44 is hypothesized to have a role in decidualization 
through the transcription activation of genes responsible (Wilms tumour- 
suppressor) for causing cells to decidualize ready for invasion of the developing 
trophoblast (Kim et al. 2011; Behzad et al. 1994; Goshen et al. 1996). In terms of 
implantation CD44 expression on the endometrial luminal surface during the
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window of implantation is essential to enable the OPN complex to assemble and for 
attachment of the blastocyst to the epithelia surface (Johnson et al. 2003). Secreted 
uterine OPN and membrane tethered CD44 have both been shown to be markedly 
increased in the secretory phase of the menstrual cycle compared to the 
proliferative phase (Wolff, Thomas Strowitzki, et al. 2001; Afify et al. 2006). The 
consequence of altered CD44 expression in the epithelia and stroma of endometrial 
tissue has been linked to the development of endometriotic lesions in women with 
endometriosis. This is thought to occur through increasing the ability of 
endometriotic cells to bind the outer peritoneal surface of the endometrium (Lucidi 
et al. 2005; Poncelet et al. 2002). Expression of CD44 has been shown to be 
decreased in the proliferative phase of women with infertile PCOS and UIF (Yaegashi 
et al. 1995; Saegusa et al. 1998).
1.8 Integrin aV63
1.8.1 Normal physiology
Integrin aV|33 is a receptor that is also a component of the extra cellular matrix and 
has a role in cellular signalling, cell shape, mobility, cell cycle regulation,
proliferation and invasion (Desgrosellier and Cheresh 2010; Assoian and Klein 2008; 
Huttenlocher and Horwitz 2011). Secreted OPN binding to membrane bound 
integrin aV|33 can initiate outside-in signalling which allows the cell to respond to 
external stimuli and initiate signal cascades for cell motility, cell migration or cell 
survival (Figure 1-9). Integrin aVP3 is also involved in cell-cell and cell-matrix 
interactions and communication between cells. Integrins have an important role in 
the remodelling of the extra cellular matrix through the regulation of localization 
and activity of proteases. Integrins are widely expressed throughout most tissues in 
the body but are predominantly expressed in hematopoietic cells such as
monocytes and macrophages, as well as angiogenic endothelial cells (Weerasinghe 
et al. 1998; Hsu et al. 2011).
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1.8.2 Integrin aV63 structure
Integrins consist of an a  and p sub-units, there are 18 a  sub-units variants and 8 p 
sub-units variants (Figure 1-13). The a and P sub-units can bind to one another in 
twenty five identified possible combinations, and are defined by their adhesion 
properties. Integrins consist of both a and P sub-unit that are transcribed by 
separate genes. Once the proteins are synthesized they dimerise and can bind a 
variety of different ECM components.
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Figure 1-13 Different a and p integrin subunits and possible binding combinations.
Integrins have many different a and p subunits that can bind in multiple 
combinations. There are four classes of a receptor, those that are specific 
receptors in leukocytes (yellow), collagen binding (pink), RGD binding (blue) or 
laminin binding (green) (Srichai and Zent 2010).
The aVp3 protein is capable of recognising and binding the RGD tri-peptide 
sequence on ligands. The active ligand recognition site of aVP3 is thought to be on 
the area of the protein where the a and P sub-units bind one another to form the 
extracellular active site. The active RGD binding site is formed by both sub-units 
equally (Millard et al. 2011). The integrin protein complex is anchored to the cell 
membrane via the p subunit and kindlin and talin proteins (Figure 1-14). Prior to
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ligand binding the inactive integrin conformation has two cytoplasmic tails in close 
proximity, and the entire structure is folded over (Figure l-14a). This structure 
changes, and both subunits extend following kindlin and talin binding. The 
cytoplasmic tails move apart, extending the sub-units and allowing their active site 
to become functional. Binding of intrinsic ligands such as tallins activate inside out 
signalling and aid in this change of conformation, activating the integrin receptors 
(Figure l-14b).
Inactive
(bent)
Active
(extended)
O Ligand
salt bridge
o  plPKI Intrinsic ligand 
“inside out" 
(talin, kindlins)
talm
Figure 1-14 Integrin a  and p subunits dimerised and expressed at the cell 
membrane surface.
Conformational change in the integrin structure from inactive to active form, (a) 
The integrin is inactive when in a bent conformation, (b) This changes to an 
extended conformation when the receptors are active for ligand binding.
1.8.3 Integrin aV63 expression in endometrium
Integrin p3 expression has been monitored throughout the menstrual cycle and 
found to be markedly increased around day 21. Integrin aVp3 is well characterized 
as a marker of implantation, and it is maximally expressed in the secretory phase of 
the menstrual cycle (DuQuesnay et al. 2009; Lessey and Arnold 1998). The
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expression of P3 has been characterised in the fertile endometrium (Gonzalez et al. 
2006) and is considered to be a key adhesion protein that contributes to the 
receptive state of the endometrium. A study by Lessey found that aVp3 was up 
regulated in the secretory phase of healthy, cycling fertile women (Lessey 2002). 
Other studies that have investigated the levels of aVP3 in infertile women in 
comparison to fertile women found no differences in the stromal levels (Ceydeli et 
al. 2006). In the epithelium of the endometrium maximal expression of aVP3 has 
been documented during the window of implantation (Apparao et al. 2001; Wolff, T 
Strowitzki, et al. 2001). Expression of aVP3 during implantation has been 
extensively studied in animal models including rabbit (lllera et al. 2003) and sheep 
(Wan et al. 2011). In both of these animal models aVP3 has been shown to be 
involved in the implantation process and expression has been shown on the 
trophoblast and the endometrial surfaces.
1.9 Potential factors affecting uterine receptivity
1.9.1 Hormone imbalance
If expression of hormones and secreted hormone receptor levels are increased or 
decreased this could have undesirable effects on the regulation of ovulation. 
Variations in estrogen expression in the menstrual cycle can result in delayed 
ovulation or anovulation (Longcope et al. 1990; Check 2007; Fanta 2013). The 
development of the egg can also be affected. Complex signalling pathways can be 
activated upon ER ligand binding to ER (Figure 1-15).
1.9.2 Estrogen receptor signalling
Estrogen signalling can occur through estrogen receptor a or p. Extracellular 
estrogen enters the cell and on ligand receptor binding in the cytoplasm will 
dimerise with another ligand-bound estrogen receptor. Once dimerised, the protein 
complex can then translocate to the nucleus and bind estrogen response elements 
(ERE) sites on gene promoters to activate or mediate gene transcription. Other 
signalling mechanisms induced via ER signalling include the up-regulation of AP-1
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and SP-1 transcription factors. This initiates a signalling pathway which ultimately 
leads to their activation (Figure 1-15). OPN and CD44 promoter regions both contain 
regulatory elements for ERa, AP-1 and SP-1 (Figure 1-7, Figure 1-10). It is possible 
that hormone imbalance w ithin the endometrium or a decrease in receptor levels 
could have undesirable consequences on the expression o f these genes. If OPN and 
CD44 expression was to be increased or decreased at the epithelial surface during 
the window of implantation the receptivity of the uterus could be affected.
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Figure 1-15 Estrogen ligand bound receptor signalling.
Estrogen signalling can activate many signalling pathways which lead to 
transcription factor activation. Classical Estrogen regulatory elements (EREs), 
Specificity Protein 1 (SP-1) and Activator Protein 1 (AP-1) transcription factors 
(Adapted from proteinlounge.com).
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1.9.3 Glucose
There is evidence to show that obesity and high body mass index (BMI) increase the 
risk of diabetes in PCOS women and has been shown to be associated with insulin 
resistance (Sarny et al. 2009). Some of these women will develop type II diabetes. 
Hyperglycemia could be a factor in infertility and metformin is used as a treatment 
to suppress glucose production by the liver (Nathan et al. 2009). It is commonly 
used to treat women who have insulin intolerance as a second medication option 
after emphasising natural ways to decrease glucose levels such as lifestyle 
modification (NICE 2012). PCOS women have similar symptoms to those associated 
with metabolic syndrome and therefore these patients may have excess circulating 
glucose (Essah et al. 2007). Metabolic syndrome is defined by obesity and two or 
more of the following factors; raised triglycerides, reduced HDL-cholesterol, raised 
blood pressure and raised fasting plasma glucose levels (Alberti et al. 2006). Excess 
levels of glucose may affect the expression of adhesion molecules at the epithelial 
endometrial surface. High levels of glucose have been shown to regulate OPN 
expression in mice and rat models (Takemoto et al. 2000; Asaumi et al. 2003). 
Whilst CD44 has been shown to have a role in insulin resistance (Kang et al. 2013) 
and in the regulation of glucose metabolism in cancer cells (Tamada et al. 2012).
1.9.4 Cytokines
The Tumour Necrosis Factor alpha TNFa gene (TNFA) is located on chromosome 
6p21.3 and was first cloned in 1985 (Old 1985). TNFa is a transmembrane protein 
that is cleaved by TNFa converting enzyme (TACE) to produce soluble TNFa. This is 
the biologically active form of TNFa expressed on activated macrophages and 
lymphocytes in addition to other cell types (Horiuchi et al. 2010). In the normal 
menstrual cycle TNFa and Interleukin 1 beta (IL-1|3) play a role in aiding follicular 
rupture through activation by FSH and LH. In the endometrium TNFa is involved in 
the proliferative and menses phases of a normal menstrual cycle, with expression 
peaking in epithelial cells in the secretory phase. However, in the proliferative phase 
TNFa expression is primarily expressed in the stromal compartment (Junt, Chen &
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Hu, 1992). Therefore it is possible that these cell types regulate TNFa differently 
(Tabibzadeh et al 1995; Horiuchi et al. 2010). In the endometrium TNFa is produced 
by activated cells of the immune system including lymphocytes, macrophages and 
natural killer cells. In combination with IL-1 it functions to induce the inflammatory 
response initiating a cascade of cytokines and chemokines (Lebovic et al. 2001). IL- 
16 gene is located on chromosome 2 and codes for the IL-lp protein. This is 
activated by the cleavage of caspase 1, produced by activated macrophages, 
endothelial cells, B-cells and fibroblast cells (Burke et al. 2013). IL-lp promotes 
prostaglandin production (Fakih et al. 1987). While it is important in inflammation, 
IL-ip is also involved in cell proliferation, differentiation and apoptosis (Kasza 2013). 
IL-1|3 is of interest in endometrial biology due to its part in hormonal regulation and 
its role as an inflammatory mediator. Maximal expression of IL-ip has been 
detected during the secretory phase of the menstrual cycle at both the mRNA level 
in tissue and protein level in blood serum (Giudice 1994). IFNy or type II interferon 
is encoded for by the IFNG gene (Gray and Goeddel 1982). IFNy protein structure 
contains six a-helices and is able to dimerise and is secreted by T cells after 
activation or NK cells (Schroder et al. 2004; Roman et al. 2010). IFNy is involved with 
cell proliferation and apoptosis, activation of bacteriocidal activity, and antigen 
presentation through MHC class I and II molecules (Schroder et al. 2004).
Disrupted expression of these pro-inflammatory cytokines have been found in PCOS 
and endometriosis (as discussed in section 5.1). PCOS and endometriosis are often 
associated with chronic inflammation, indicators of which include C-reactive protein 
(CRP), leukocytes, IL-18, TNFa, IL-ip and IFNy (Diamanti-Kandarakis, 2007). The 
disrupted levels of these pro-inflammatory cytokines may lead to increased or 
decreased signalling pathway activation. This will have consequences on the genes 
activated downstream of their signalling pathways. OPN and CD44 have shown to 
contain regulatory elements on their promoter regions for NFkB which can be 
activated upon TNFa or IL-ip signalling. Furthermore, they both contain STAT1 
regulatory elements which can be activated upon IFNy signalling. When TNFa binds 
to TNFR2 it initiates a signalling cascade that ultimately leads to the activation of
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NFkB (Bouwmeester et al. 2004). Upon ligand binding the following proteins are 
recruited to TNF Receptor Associated Factor (TRAF2); TRAF, Receptor interacting 
protein (RIP), and tumour necrosis factor receptor type 1-associated death domain 
protein (TRADD). This activates NFkB Inducing Kinase (NIK) to recruit inhibitor of 
NFkB kinase (IKK) which phosphorylates inhibitor of kappaB (Ik(3) and allows for 
dissociation between Ik(3 and NFkB. Ik(3 then becomes degraded and NFkB 
translocates to the nucleus to activate gene transcription (Beg et al. 1993) (Figure 
1-16). The genes encoding both OPN and CD44 have NFkB regulatory elements in 
their promoters and therefore it is possible that their expression could be 
modulated through the TNFa signalling pathway.
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Figure 1-16 TNFcx-NFkB signalling pathway
Extracellular TNFa binds to TNFR 1 or 2 to activate a signalling cascade that 
activates NFkB (Adapted from proteinlounge.com)
Upon IL-1(3 ligand binding to the IL-lRacP, Toll-interacting Protein (TOLLIP) and 
Myleloid Differentiation primary response gene-88 (MyD88) are then recruited to
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this complex. They then function as adaptors to recruit interleukin-1 receptor 
associated kinase (IRAK). This is responsible for the recruitment and activation of 
TRAF6. IRAK then becomes phosphorylated and ubiquitinated. TRAF6 can signal 
leading to the degradation of IkB through the kinase action of TGF-beta-activating 
kinase-1 (TAK1) and TAK1 binding protein 1 (TAB1). This complex can then link with 
TRAF6 initiating the activation of NIK. This leads to the activation of IKK and the 
subsequent phosphorylation of IkB, finally allowing NFkB to translocate to the 
nucleus to mediate gene transcription (Figure 1-17).
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Figure 1-17 IL-ip NFkB signalling.
IL-ip signalling through IL-lRacP induces a signalling cascade that activates NFkB 
(Adapted from Qiagen.com/pathways).
IFNy signalling is mediated through the Interferon gamma receptors 1 and 2 which 
dimerise at the cell membrane. Extracelluar IFNy binds to the interferon gamma 
receptor 1-recetor 2 (IFGR1-R2) complex receptor, which is followed by
autophosphorylation and activation of JAK2 (Schroder et al. 2004). Activated JAK2 
phosphorylates STAT1 allowing it to dimerise and translocate to the nucleus, there 
it can bind regulatory elements to influence gene transcription of interferon 
regulated genes (Figure 1-18). OPN and CD44 promoter regions both contain 
regulatory elements for STAT1 or IRF-1, to which activated STAT1 dimers can bind 
and modulate gene transcription. It is possible for IFNy to regulate the expression of 
OPN and CD44 through activation of STAT1 (Schroder et al. 2004).
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Figure 1-18 IFNy STAT1 signalling. 
IFNy signalling through the IFGR and IFR2 induces JAK-STAT signalling, activating 
STAT1 (Adapted from Qiagen.com/pathways).
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1.10 Research aims
The purpose of this study is to examine any potential role for the adhesion complex 
components OPN, CD44 and integrin aV|33 in infertility. It is hypothesized that the 
adhesion complex is involved in the attachment process of implantation and that in 
infertility disrupted levels may be a contributing factor. Therefore, the objectives of 
this study are:
To establish the expression profile of the adhesion complex components in tissue 
and supernatant samples obtained from fertile and infertile women. The following 
techniques are used; to obtain mRNA, intracellular protein and secreted protein 
levels, quantitative polymerase chain reaction (qPCR), Immunohistochemistry (IHC) 
and enzyme-linked immunosorbent assay (ELISA) respectively.
To establish if hormones in the healthy menstrual cycle regulate the adhesion 
complex components. This is carried out by utilising endometrial epithelial cell lines 
as in vitro model to mimic the estrogen and progesterone stimulus in the menstrual 
cycle. Levels of the adhesion complex expression are then to be measured in 
response to this at the mRNA, intracellular protein and secreted protein levels. The 
direct role of ERa in the regulation of the adhesion complex components OPN and 
CD44 are then investigated using chromatin immunoprecipitation (ChIP).
To determine if common conditions linked to PCOS and endometriosis such as 
obesity, diabetes, inflammation and elements of metabolic syndrome affected 
uterine expression of the adhesion complex as may be experienced in a sub set of 
these women. Treatment with glucose and pro-inflammatory cytokines is 
conducted to assess their role in regulating the adhesion complex components in an 
in vitro cellular model. Direct regulation by pro-inflammatory pathways is then 
investigated by ChIP, determining the occupation of STAT1, IRF-1 and NFkB on the 
promoters of OPN and CD44.
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Chapter 2 
Materials and methods
2.1 Collection of primary tissue and supernatants
Endometrial samples were obtained by pipelle biopsy, a standard outpatient 
procedure, from patients identified by the gynaecological department of Singleton 
Hospital, Swansea. According to standard clinical procedure all patients were 
referred to the clinic for laparoscopy, sterilisation or diagnostic purposes to identify 
pelvic inflammation, endometriosis or ovarian cysts. Trans-vaginal ultrasound 
identified patients who have a greater than normal endometrial thickness (>5mm) 
for investigation of menorrhagia and abnormal intermenstrual bleeding. Written 
consent was obtained for all biopsy samples obtained, subject to ethical approval 
from the South West Wales Research Ethics Committee (LREC nr. 05/W MW 02/45).
Pipelle biopsy obtains a ribbon of endometrial tissue, principally containing 
epithelial and stromal cells. Once collected, biopsies were placed immediately in 
15mls culture medium and kept at 4°C. On receipt of biopsies at Swansea 
University, the supernatant was removed, centrifuged, and aliquots (0.5mL) were 
taken and stored at -20°C. Biopsy tissue was either processed for RNA immediately 
or stored at -80°C. Biopsy material was grouped into four categories according to 
pathology (Table 2-1). Women with the following conditions were excluded from 
the qPCR and IHC study: tubular factor, endometrial hyperplasia, endometrial 
carcinoma, presence of polyps and sexually transmitted diseases. All patient groups 
were age and BMI matched as closely as possible.
Study group Diagnosis Section for reference
1 Fertile control 1.1.1
2 Infertile PCOS 1.1.2
3 Infertile Endometriosis 1.1.3
4 Unexplained Infertility 1.1.4
Table 2-1 Study Groups for clinical study.
Patients were separated to 3 study groups and compared to fertile women who 
were used as controls.
2.2 Secondary endometrial cell culture
First established in 1968 by Kuramoto, Hec-IA and Hec-IB were both derived from 
a 71 year old patient with stage 1A endometrial adenocarcinoma (Kuramoto 1972; 
Kuramoto et al. 1972). Later in 1983 the RL925 cell line was isolated from a 65 year 
old Caucasian with a grade 2 moderately differentiated adenosquamous carcinoma 
of the endometrium (Way et al. 1983). Ishikawa is another well differentiated 
epithelial endometrial adenocarcinoma cell line, which has been used extensively as 
an epithelial endometrial model for the past 25 years (Nishida et al. 1985). Isolated 
from a 39 year old Japanese patient with type I, stage 2 endometrial 
adenocarcinoma in October 1980, a small sample was taken and due to its fragility 
the epithelial and stroma compartments were easily separated. A further cell line 
has subsequently been developed, acknowledged in the literature, Hec-50 and 
nominally called Heraklio in this study (Kuramoto et al. 1991). This is also a type II 
endometrial epithelial cell line derived from an adenocarcinoma and was obtained 
from ECACC for this study (Albitar et al. 2007).
All epithelial cells were cultured on plastic culture vessels (Falcon T25, T75, T125) 
and maintained in Dulbecco's Modified Eagle's Medium; Nutrient Mixture F-12 
(DMEM/F12) in a 1:1 with GlutaMAX™ (2.5mM) supplemented with 10% Foetal 
Bovine Serum (FBS), Im M  sodium pyruvate, 1.5g/L sodium bicarbonate (stock 7.5%) 
and 1% Penicillin/streptomycin. Cells were incubated at 37°C in a humidified 5% CO2 
atmosphere (Nuaire, UK). Epithelial cells were sub-cultured 1:8 when 70% 
confluent. For sub-culture, the cells were first washed twice with phosphate 
buffered saline (PBS) (Lonza-BioWhittaker, UK) to remove serum from the cell 
monolayer. To detach the cells from the plastic substrate, 0.25% trypsin-EDTA was 
added and the flasks incubated for 5mins at 37°C. Detachment was confirmed by 
inverted light microscopy. DMEM/F-12 (lOmL) supplemented with FBS was added 
to the flask to neutralise the trypsin and the cell solution centrifuged for 5mins at 
2500g. Cell pellets were re-suspended in lOmL of DMEM/F-12 and split to the
appropriate ratio before seeding to the appropriate culture vessel. All reagents 
were obtained from Life Technologies unless otherwise stated.
2.3 Cell treatment
All cell treatments for this study were conducted in either 6 well plates (Nunc, UK) 
or on glass slides for IHC. In each case the cells were grown to 80% confluency and 
fully supplemented growth media was replaced with charcoal stripped media for a 
minimum of 24hrs before treatment. This removed any trace steroid and large 
molecular weight proteins, which may affect the efficiency of cell treatment. 
Outlined here are the compound preparation and volumes for final required 
concentration.
Charcoal stripped FBS preparation: Charcoal (Charcoal, Dextran coated Sigma lg) 
was add to a 500ml bottle of FBS and inverted 5 times to mix. Incubated at 56°C for 
2 hours and cooled for 1 hour at 25°C before filtering through a Stericup (Millipore, 
UK) using vacuum pump system in a lamina flow hood (ScanLife, UK).
2.4 Hormone preparations
Estradiol and Progesterone treatment regimes were chosen at concentrations and 
time points to the mimic menstrual cycle in vitro in a cell line model.
Estradiol (E2): 0.027g of powdered 17-p Estradiol (Cat: E8875 >98%, Sigma UK) was 
added to lmL of absolute ethanol (Fisher Scientific, UK) to make a stock 
concentration of Im M . Serial dilutions of 1:10 were then made by removing 100|iL 
of the Im M  stock and adding to 900pL absolute ethanol to give a working stock of 
IOjliM. 3|al of this stock was added to 3mLs of media to obtain a final concentration 
of lOnM.
Progesterone (P4): 0.031g of powdered Progesterone (Cat: P0130, Lot# 129K0061, 
Sigma UK) was added to lmL of absolute ethanol (Fisher Scientific) to a 
concentration of Im M , and serial dilutions of 1:10 were then made by removing
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lOOpL of the Im M  stock and adding to 900pL absolute ethanol to give a working 
stock at lOOpM. 3jnl of this stock was added to 3mLs of media to obtain a final 
concentration of lOOnM.
Estradiol (E2) and Progesterone (P4) co-treatment: 3jj.I of lOpM E2 was added to 
3mLs of media to obtain a final E2 concentration of lOnM plus 3pl of 100 pM of P4 
was added to 3mLs of media to obtain a final P4concentration of lOOnM
2.4.1 Glucose preparation
Two stocks of media containing different concentrations of glucose were prepared 
for the experiments in Section 5.2. For high glucose concentration (25mM), 0.09g 
powdered glucose (a-D-Glucose, Sigma Cat no. 158968 Lot# STBC1731V) was added 
to lOmLs of appropriate media to obtain 25mM final concentration. For the 
intermediate concentration of glucose (17mM), 0.0135g was added to lOmLs of 
appropriate media to obtain 17mM final concentration. Both stocks were then filter 
sterilised through an aero disc and all Glucose stimulation experiments were 
performed in basic, DMEM low glucose (5mM) medium phenol free containing 10% 
stripped serum.
2.4.2 Cytokine preparation
IL-ip: lOOpL of deionised filter sterilised water was added to lyophilised IL-1(3 
powder (lOpg Miltenyi biotec, GmbH Cat no. 130-093-895, Lot no. 5110831174), to 
obtain a stock concentration of lOOpg/mL. A working stock of lOOOng/mL was made 
by 1:100 dilution. 5pL of this working stock was added per mL of culture medium to 
obtain a final concentration of 5ng/mL.
TNFa: lOOOpL of deionised filter sterilised water was added to lyophilised TNFa 
powder (lOpg Miltenyi biotec, GmbH Cat no. 130-094-014, Lot no. 5110831175) to 
obtain a stock concentration of lOpg/mL. 2.5pL of this stock is added per mL of 
culture medium to obtain a final concentration of 25ng/mL.
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IFNy: 100 pL of deionised filter sterilised water was added to lyophilised IFNy 
powder (lOpg Miltenyi biotec, GmbH Cat no. 130-096-872, Lot no. 5110831178) to 
obtain a stock concentration of lOOpg/mL. lpL of this stock is added per mL of 
culture medium to obtain a final concentration of lOOng/mL (200 lU/mL).
All cytokines were purchased from Miltenyi biotec and are endotoxin free.
2.5 Isolation and quantification o f ribonucleic acid
Following cell treatments, total RNA was isolated according to the manufacturer's 
instructions (RNeasy Kit, Qiagen, UK see appendix A). Briefly, the cell culture media 
was removed and the cells washed with PBS. RLT (guanidine isothiocycanate lysis) 
buffer (350pLs) was then added to each sample. The cells were scraped from the 6 
well plates and cell lysate collected into clean (RNase/DNase/Pyrogen free) 
eppendorf tubes, before being added to the Qiashredder spin columns for 
homogenisation, to break open the cell membranes. RNA was then isolated by 
processing through a RNeasy column which contains a membrane that RNA binds 
too and is subject to a DNase digestion for removal of contaminating genomic DNA. 
After a series of washes in RPE (ethanol salt removal) buffer, RNA was eluted in 
25pL of RNase-free water and quantified by spectrophotometer (NanoDrop 2000c -  
Nucleic Acid program vl.4.2).
2.5.1 Reverse transcription synthesis of complementary ribonucleic acid from  
ribonucleic acid
RNA was adjusted to the concentration of lOOpg/mL in RNase-free water (Qiagen) 
and 10|iL of total RNA was reverse transcribed using random primers according to 
the manufacturer's protocol (High capacity cDNA conversion Applied Biosciences, 
UK). A master mix of components was made to avoid small volume pipetting errors. 
The master mix consisted of 2pL of lOx RT Buffer, 2pL of RT Random Primers, 0.8pL 
of 25X DNTP Mix (lOOmM), 3.2pL of nuclease free water (Ambion, UK), lpL RNase 
inhibitor and lpL of MultiScribe™ Reverse Transcriptase per sample. Samples were
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added to a 0.2mL thin walled tube (Corning, UK) and lOpL of master mix added 
(total volume 20pL). Samples were briefly mixed by vortexing and centrifuged. 
Samples were run on a thermocycler (iCycler, Bio-Rad, UK) using the following 
programme; samples were heated to 25°C for lOmins then 37°C for 120mins 
followed by 85°C for 5mins. Samples were then held at 4°C until removed from 
machine. Samples were stored at -20°C or -80°C for long-term storage. 2pL of the 
original RNA sample was transferred to a clean (DNase, RNase, pyrogen free) 
eppendorf for each sample and used as a negative PCR control (un-transcribed 
template) at a dilution of 1:10. Serial dilutions of cDNA stocks were made at 1:10, 
1:100 and 1:1000 from nuclease free water and used to generate standard curves 
for PCR cycle quantification. Target gene expression was assessed using cDNA at a 
1:10 concentration.
2.6 Quantitative Real Time Polymerase Chain Reaction
To obtain qPCR products between 75-150bp for each target gene under 
investigation cDNA was amplified using gene specific primer pairs (Beacon Design 
2.0, Premier Biosoft, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 
Ribosomal Protein 60s L-19 (RPL-19) were used as a reference gene, and genomic 
DNA and RNA were used as positive and negative controls respectively (Table 2.2). 
Amplification reactions were prepared in a volume of lOpL by adding 5pL of SsoFast 
evagGreen sSupermix (Bio-Rad, UK), lpL of each primer (lpM ), 2pL of diluted cDNA 
and lpL of dhhO. qPCR amplifications were performed in triplicate on 96-well 
optical reaction plates and run in the Bio-Rad CFX-96. Samples were first heated to 
95°C for 5mins to activate the hot-start DNA Polymerase enzyme and run for 
40 cycles of lsecs at 95°C followed by 15secs at the optimal annealing temperature 
for each primer pair. No amplicons were obtained using RNA directly in the qPCR 
reaction.
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Gene Primer Sequence (5'-3')
Ta
(°C)
Amplicon 
length (bp)
GAPDH
F GT CC ACT G G CGT CTT CAC
54.7 145
R CTTGAGGCTGTTGTCATACTT
RPL-19
F CCTGTACGGTCCATTC
54.3 144
R AAT CCTCATT CT CCT CAT CC
OPN2
F ATGGATGATATGGATGATGAAG
53.5 188
R TCGGTTGCTGGCGGTC
CD44
F G G ACC AATTACC AT AACT ATT
53.9 75
R AG GATT CGTTCT GT ATT CT
ITGAV
F GGAGATTAGACAGAGGAA
53.8 107
R CG ACTT CAG AG AAT AG G A
ITGB3
F AAGACTCATATAGCATTG
56.6 200
R TGATAGAGATTGACTACA
ERa
F CCT CAT CCT CT CCC AC AT CAG
53.5 115
R G G CGT CC AG CAT CT CC AG
ER8
F TGCTGAACGCCGTGACCGATG
60 75
R ATGGATTGCTGCTGGGAGGAGA
PRB
F CT G C ACT CG G CCT C A ACG G G
53.5 119
R TGTGGGCTCTGGCTGGCTTC
GREB1
F ATCAGCTGCTCGGACTTGCTG
62 135
R TGAGCTCCGGTCCTGACAGAT
AREG
F TGGACCTCAATGACACCTACTC
55 149
R AGGACGGTCACTACTAGAAGG
5PP1 iso A
F CTTT AC A AC A AAT ACCCAG AT G CT
60 113
R AAGTCATTGGTTTCTTCAGAGGA
SPP1 isoB
F CCTAGCCCCACAGACCCT
60 83
R GGTCATCATCATCTTCATCATCC
SPP1 isoC
F GGAGTTCTGAGGAACAAGCAGAAT
60 97
R TGGTCATGGCTTTCGTTGGA
5PP1 isoD
F GACCAAGGAAAACTCACTACCAT
60 131
R GACTTACTTGGAAGGGTCTGC
SPP1 isoE
F GTACCTACCCCTCCACAACA
60 118
R GCCTTTTATTCTGTTCAACTGGAA
Table 2-2 Quantitative PCR primer pairs for mRNA expression levels.
Primers used to amplify genes from cDNA are shown are with optimal annealing 
temperature and product amplicon length.
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2.6.1 Detection of Real time polymerase chain reaction products
Quantitative real-time PCR is a fluorescent based method allowing for detection and 
measurement of specific starting quantity of complementary DNA. SYBR green I is a 
cyanine dye that binds and intercalates double stranded DNA. The DNA-cyanine dye 
complex is excited with wavelength (A) 497nm of light and emits green light at A520. 
This signal is detected in each cycle and its intensity increases as more PCR product 
copies are made. This is used to generate a quantitative cycle plot which takes on 
the appearance of a sigmoid amplification curve (Figure 2-1). The intensity is 
measured as relative fluorescence units (RFU) and is plotted against cycle number. 
The quantitative cycle threshold (Qc) value is generated when RFU value is 
considered to be higher than the background. Where it intersects the cycle number, 
this is regarded as the Qc.
Amplification
4000 ■■
3000 ■■
2000
Cycle
Thresho ld
(Q c )
0 10 20 30 40
Cycles Log Scale
Figure 2-1 Quantitative PCR amplification plot.
A cDNA standard curve from the Ishikawa cell line. Samples were diluted 1/10, 
1/100 and 1/1000 in triplicate.
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2.6.2 Generation of a standard curve and melt curve
Relative quantification of gene expression data was determined from quantitative 
cycle (Qc) values for each sample. Serial dilutions of cDNA 1/ 10, 1/100 and 1/1000 
performed in triplicate were used to generate a standard curve and gene expression 
levels quantified by plotting Qc values on the curve (Figure 2-1). Expression levels 
were normalized with values obtained for the reference gene (GAPDH or RPL-19). 
Once normalized, fold expression was calculated as a ratio of transcript levels 
between treated and control samples for each gene. This was determined using the
2-aa c t method (Livak and Schmittgen 2001) incorporating a Pfaffl modification (Pfaffl 
2001) for primer efficiency. After analysis of qPCR data, starting quantities were 
used to determine if any statistical significance existed between treatment and 
control for example. This was done using the t-test to measure for variation in a pair 
wise manner.
To obtain a melting curve for each sample, a final step (after 40 cycles) of 60 cycles 
was performed for 5secs starting at 65°C and then increasing the set point 
temperature by 0.5°C per cycle up to a maximum temperature of 95°C. This slowly 
denatures the bonds between the bases of the product which will change its 
fluorescent properties. When the change in RFU is plotted against the temperature 
a peak of fluorescence can be detected at a specific temperature, this can be 
calculated and used to check the specificity of the reaction.
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Figure 2-2 Melt curve from a typical Quantitative PCR reaction
The melt curve indicates a peak at 86.5°C to validate the specificity of reaction 
product.
2.7 Chromatin Immunoprecipitation
ChIP was conducted using the Chromatrap® solid phase isolation technique, 
according to manufacturer's guidelines (http://www.chrom atrap.com /uploads/ 
documents/Chromatrap spin columns V6 A4.pdf). The ChIP process involved the 
fixation (cross-linking) and isolation of chromatin (DNA-protein complexes) from the 
nucleus of cells. Chromatin was then broken into smaller fragments between 100- 
500bps by sonication. Transcription factor complexes of interest were then selected 
by immunoprecipitation using a specific antibody for the target transcription factor 
complex. After reversing the cross-linking and digesting the protein transcription 
complexes the genomic DNA was detected using qPCR against the relevant positive 
and negative controls to ensure selective and specific amplification of target DNA 
(Figure 2-3).
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Figure 2-3 Experimental flow of a ChIP procedure
ChIP experimental flow to illustrate chromatin preparation, slurry preparation, 
Immunoprecipitation and analysis (http://www.chromatrap.com/).
2.7.1 Chromatin Isolation
Following cell treatments the culture media was decanted and the wells washed 
w ith 2mLs of PBS warmed to 37°C. This was decanted and 3mLs of fixation medium 
(1% formaldehyde in basal stripped media) was added. The cells were incubated in 
fixative for lOmins at room temperature on a rotating platform to enable the DNA-
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protein and protein-protein cross-linking to occur. The fixation media was then 
replaced with 1.5mL of 0.67M Glycine solution in each well, for 5mins, to quench 
the fixation reaction. The cells were then harvested by decanting the glycine 
solution and scraping cells from each well in lmL of ice-cold PBS, and stored in a 
clean eppendorf tube. The cells were then pelleted through centrifugation at 
3500xg (Microcentrifuge 5424R, Eppendorf UK) for 5mins. Following removal of the 
supernatant, the pellet was re-suspended and cells lysed in 400pL of hypotonic 
buffer by gentle pipetting and incubation on ice for lOmins. The intact nuclei 
fractions were then separated by further centrifugation at 5000xg for 5mins at 4°C. 
Following removal of the supernatant, the nuclei pellet was re-suspended and lysed 
in 300|iL lysis buffer by gentle pipetting and incubated once again for lOmins on ice. 
To obtain chromatin containing DNA fragments of 100-500bp these samples were 
then subject to sonication (800R, QSonica, UK) for 15mins using pulses of 30secs at 
an amplitude of 50 followed by a rest period of 30secs. The chromatin stock 
samples were then centrifuged at 16000xg at 4°C to remove any nuclear debris 
material and the supernatant was transferred to a clean eppendorf and lpL of 
protease inhibitor cocktail added and mixed by vortex. All chromatin samples were 
stored at -80°C.
In order to check the sonication efficiency and quantify the amount for chromatin 
harvested from each sample, 50pL aliquots of the stock solutions were taken and 
processed for agarose gel electrophoresis and nanodrop analysis respectively. To 
process the samples (50pL) they must be reverse cross-linked and then purified. 
Reverse cross-linking serves to remove any DNA protein bonds by incubating at 
65°C overnight with 5pL of 1M NaHCOs, 5pL of 5M NaCI and 40pL of water to make 
a total volume of lOOpL. After overnight incubation the samples are incubated at 
37°C with Proteinase K to degrade proteins. DNA is then purified to remove protein 
debris by using the Qiaquick purification kit (Qiagen, UK). 500pL of Buffer PB was 
then added to the lOOpL of sample and adjusted for pH by adding lOpL of 3M 
sodium acetate at pH 5.0. Following this the sample solution was added to the 
QIAquick column, allowing DNA to bind to the membrane and cell debris to be
removed by centrifuging at 17900xg for lmins. The flow through is discarded and 
750pL of Buffer PE was then added and again the column centrifuged at 17900xg 
for lmin. To elute the DNA 50pL of Buffer EB was added and immediately 
centrifuged at 17900xg for lmins into a clean eppendorf tube. These samples were 
then run on a 1% agarose gel to check the size of desired fragments (Figure 4-18).
2.7.2 Immunoprecipitation (IP)
Following chromatin isolation and sonication, stocks were standardised to 400ng of 
chromatin and added to the IP slurry mixture for each reaction conducted. Briefly, 
IP slurries were made for each reaction along with an isotype control IgG, (Table
2-3) and a DNA input (which is not processed through the IP columns) sample 
respectively. ChIP reactions contained 5pL of low salt (LS) Buffer, lpL of protease 
inhibitor cocktail (PIC), 5pL of sheared chromatin at 80ng/pL, 25pL of dH20 and 4pL 
of antibody of interest to make a total reaction volume of 40pLs. The IP slurries 
were incubated for 3hrs at 4°C on an end to end rotor. During this time the IP 
columns were prepared by washing in 600pL of dhhO, 600pL of ChIP dilution buffer 
three times and centrifuged dry at 900xg. The 40|iL target protein (e.g. ERa) and an 
isotype control IgG slurry were each added to an individual IP column and incubated 
at 4°C for a further hour. The input was placed on ice during this time. Columns 
were then washed with LS buffer three times, MS buffer three times and HS buffer 
three times and centrifuged to remove any liquid. The IP columns were then placed 
in clean dry eppendorfs and 50pL of Elution Buffer was added to the columns and 
incubated for 15mins at room temperature before the chromatin was eluted by 
centrifuging at top speed for 30 secs. To each sample including the DNA input the 
following was added; 5pL of 1M NaHC03, 5M of NaCI and 40pL of dhhO and they 
were incubated at 65°C overnight, to facilitate reverse cross-linking. lpL of 
proteinase K solution was added for lh r at 37°C to degrade bound antibody-protein 
complexes. The DNA was then purified using a standard protocol (Appendix B) or 
the Qiagen DNA purification kit (Qiagen, UK) and the eluted DNA was used directly 
in the qPCR reaction.
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2.7.3 Chromatin immunoprecipitation validated antibodies
Antibody Host & 
concentration
Supplier Product
Code
Specificity Reference
Anti-
ERalpha
(HC-20)
Rabbit
200pg/mL
Santa
Cruz
Cat SC-543 
Lot# L1911
C-terminus of ERa of 
human origin
(Shankaranaraya 
nan et al. 2011)
NFkB 
Anti p65 
(C-20)
Rabbit
200pg/mL
Santa
Cruz
Cat SC-372 
Lot# A1910
C-terminus of NFkB of 
human origin
(Allison et al. 
2012; Liu et al. 
2012)
STATI
Rabbit
200pg/mL
AbCam
Cat ab2415 
Lot# 
GR44902-8
Detects STAT1 alpha 
p91 & ST ATI beta p84
(Yao et al. 2008)
IgG
Rabbit
200pg/mL
Rocklan 
d Ltd
011-0102 
Lot# 22557
Precipitated against 
Anti-Rabbit Serum 
and IgG
Active Motif 
Europe
Pol II 
(H-224)
Rabbit
200|ig/mL
Santa
Cruz Cat SC-9001
Raised against amino 
acids 1-224 of Pol II of 
human origin
(Montes et al. 
2012)
Table 2-3 Table of antibodies used in Chromatin Immunoprecipitation reactions
Antibodies ERa, NFkB, STAT2, IgG and Pol II were used in chromatin 
immunoprecipitation reactions. All antibodies had been previously validated for 
ChIP by the supplier.
2.7.4 Promoter analysis for identification of regulatory elements
The promoter sequence of human OPN (NG_030362.1) and CD44 were identified 
from a web programme (mybioinfo.info). These sequences were downloaded in 
FASTA format and entered into the Alggen-Promo web programme 
(http://alggen.lsi.upc.es/cgi-bin/promo v3/promo/promoinit.cgi?dirDB=TF 8.3) to 
identify human putative regulatory elements. In addition to this a literature search 
identified positive sites confirmed by electrophoretic mobility shift assay or 
luciferase assay for SP-1 (Sharma et al. 2010; Wang et al. 2000a; Bidder et al. 2002) 
and NFkB on the OPN promoter (Samant et al. 2007). The following sites were 
searched; ERa [T00261], AP-1 [T00029], SP-1, NFkB [T00593], STAT1B [T01573], IRF-
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1 [T00432]. Following this primers were designed using Beacon Designer (Premier 
Biosoft, UK) for regions of the OPN and CD44 promoter where regulatory elements 
were identified. The coordinates for these response elements are listed relevant to 
the position of the transcription start site.
2.7.5 Quantitative polymerase chain reaction post chromatin 
immunoprecipitation
qPCR reactions were set up using the following master mix; 5pL of SsoFast evagreen 
sSupermix, 2pL DNA, lpL forward primer, lpL reverse primer and lpL nuclease free 
dhUO to make a total volume of lOpL per well. All reactions for each sample were 
performed in triplicate in natural Multiplate Low-Profile 96-Well un-skirted PCR 
plates. Plates were heated at 98°C for 2mins to irreversibly denature antibody- 
bound Sso-7-fusion polymerase to fully activate it. The samples were then 
denatured for 30secs at 98°C and annealing and extension performed in one step at 
the annealing temperature of the specific primer pair for 5secs (listed in Table 2-4). 
Primers were optimised for annealing temperature by running at three different 
temperatures and best annealing temperature chosen by melt curve analysis 
(Appendix D). Denaturation and anneal-extension is performed 40 times. The plate 
is then heated from 65°C to 95°C by 0.5°C increments for lsec to generate a melt 
curve.
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2.7.6 Genomic primers for quantitative polymerase chain reaction post
chromatin immunoprecipitation
Site Transcription Factor Sequence
Ta
(°C)
GAPDH 1 Pol I I  F TCGACAGTCAGCCGCATCT 60
Pol I I  R CTAGCCTCCCGGGTTTCTCT
XBP11 ERF ATACTTGGCAGCCTGTGACC 60
ERR G GTC C AC A AG C AG G A A A A A
OPN 1
ER API API F ATGGATGAGGGAACAAGGATAGG
52.3
ER API API R G C AG AAGT AAAG C AGTTT C
OPN 2
AP-1F TCTTCCTGGATGCTGAATGC
52.3
AP-1R CCAAGCCCTCCCAGAATTTA
OPN 3
API F GGAAACCACCGATGCTAATCAG
60
API R AG CAGT G G CAT ATT CAG AAAG G
OPN 4
API API ERF TGTATGATGAGTTATCGCATGTAAG
48.5
API API ER R AC AAAC AG CACACATAG ACTTT C
OPN 5 NFKB F CACAACTGAGAAAGCAAATGAAG 60
NFKB R TCCCAAGGTATGTAAAGTAGGC
OPN 6
NFkB F TCAG CCAAACG CCG ACCAAG
52.3
NFkB R CTAGACACCTTTGTTCCAGGAGACC
OPN 7 OPN ST ATI F GCTACTGGGTTGTGCATTC 48.5
OPN STAT1 R TTCTGATTAGCATCGGTGG
CD44 1
ER API F AG G CA AG GT CAC AC AACT AAG A AG C
60
ER API R ACCATTCCTAGAGAAGGGAGTCAC
CD44 2
SP1 ER F GCACAGTCGTTGTCTGGACT
60
SP1 R ACCC ATT G CC AG CTAGTC
CD44 3
STATIIRF F ACACTGGCTTGAACACATGGGTTAG
48.5
STATIIRF R GCTGGAGAGAGGGCGAGGTC
CD44 4
IRFF TGGGTGCG GGGTGCTCAG
60
IRF R T G CTT CCAC AG AC AC ATT CT CCAAC
CD44 5
IRF STAT1BF TGTGTCTAGGCAGGGCAGAG
60
IRF STAT1BR GCTTTGGAACAAGGCTCAGTG
CD44 6
NFkB F GCCTGGCAGCCTCAGAGCAGAGAG
55.1
NFkB R CG CAG CCCCTCCCCTCCATAG C
Table 2-4 Primer pairs used to amplify genomic DNA.
Transcription factor binding sites from genomic DNA with location relevant to 
start site and optimal annealing temperature.
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2.7.7 Analysis of quantitative polymerase chain reaction post chromatin
immunoprecipitation
All post qPCR analysis was conducted in the same manner for all antibodies. The 
average Cq for the antibody, isotype control IgG, and input were calculated from 
the triplicate wells. An antibody % signal relevant to the input amplification and PCR 
efficiency was calculated along with the equivalent isotype control IgG percentage 
value. The real signal was simply calculated by deducting the IgG % from the 
antibody % (Figure 2-4). The real signal percentage was used to assess the basal 
differences between ERa in the Ishikawa and Heraklio cell lines. All other data 
comparing treatment to controls used fold data. All statistical analysis was 
conducted on a minimum of three independent biological repeats as stated using a 
two tailed t-test of unequal variance to compare treatment to control or cell line to 
cell line.
TF(%) =  1 0 0 [2 ^ _c^ j
B(%) =  100 { 2 ^ “^ )}
R(%) =  TF(%) -  B (%)
Figure 2-4 Formulae for real signal from ChIP
Where TF is the transcription factor, B is the background, R is the real signal, Clq is 
the input cycle quantity, Cq is the transcription factor cycle quantity and Cqs the 
background cycle quantity.
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2.8 Immunohistochemistry fo r osteopontin and CD44
2.8.1 Endometrial sampling
The pipelle endometrial sampling method is used to obtain a sample of the 
endometrial tissue for diagnostic or research purposes. This technique was 
developed in 1984 (Cornier 1984) and involves a flexible plastic tube with piston 
that is used to create a vacuum for sampling. A hole at the distal end allows for the 
endometrial tissue to fill the tube as the piston is withdrawn and rotated. The 
sample obtained is then fixed in formalin for diagnostics or placed in media for 
research purposes.
2.8.2 Gold standard diagnostics
The gold standard diagnostic procedure for endometrial pathology is examination of 
haematoxylin and eosin (H&E) staining followed by immunohistochemistry to 
characterise tumour development. This involves a formalin fixed sample, embedded 
in paraffin wax and sectioned using a microtome. These thin sections (4pm) of 
preserved tissue are placed on to slides and stained with H&E to visualise the 
nucleus and cytoplasm. Structural elements of the tissue still intact can now be 
visualised under the microscope. The tissue structure is important to the 
pathologist to help identify the phase of the menstrual cycle, hyperplasia and 
cancer in the tissue.
2.8.3 Immunohistochemistry for paraffin embedded blocks
Samples were fixed in 10% buffered formalin for 24hrs, embedded in paraffin and 3- 
4pm thick sections cut and placed on positively charged slides before 
immunohistochemical studies. The sections were incubated with a rabbit anti-CD44 
or anti-OPN antibody (Table 2-5). Deparaffination was achieved by incubating at 
72°C and antigen retrieval was performed by incubating slides in cell concentration 
1 (CC1) buffer (Ventana) for 8mins on heated plates at 98°C on a Benchmark XT 
(Ventana) processor. Primary peroxidase inhibitor was added before the primary
antibody was incubated for 60mins at 1:200 dilution at 36°C. Detection of positive 
immunostaining was obtained through the interaction of avidin-biotin peroxidase 
complex with a biotinylated secondary antibody using a Ventanna I View DAB 
detection kit (Ventana BioTek Solutions, Tucson, AZ, USA). After 4min amplification 
stage at 36°C the slides were stained with haematoxylin for 8mins at 36°C. The 
slides were then dehydrated, cleared and mounted in DPX.
Antibody Host & concentration Supplier
Product
Code Specificity Reference
Anti- OPN
Rabbit
200pg/mL Millipore
Cat AB1870 
Lot#
NG1827385
Amino acid 75-90 
of human OPN 
(SwissProt 
Acession # P10451; 
PSKSNESHDHMDD 
MDD)
(Tsai et al. 
2012)
Anti-CD44
[H-CAM],
clone
EPR1013Y
Rabbit
200pg/mL Millipore
Cat 04-1123 
Lot# 
NG1883338
Residues in human 
CD44
(Tanabe et 
al. 1990)
Table 2-5 Table of antibodies used for immunohistochemistry 
2.8.4 Dating of menstrual phase
Dating of endometrial biopsies is conducted using the Noyes criteria: the
proliferative phase of the endometrium is classically characterized by the
morphological thinness (4-8mm) of the regenerating epithelium (Barker et al. 2009;
Aflatoonian and Mashayekhy 2011). The endometrial tissue in the secretory phase
is typically between 8 to 16mm in thickness as measured by ultrasound. Histological
sections are characterized by the shape of the glands; straight, short, narrow glands
are of proliferative type while the mid proliferative phase is identified by columnar
surface epithelium, longer, curving glands. The secretory phase post ovulation is
characterized by sub-nuclear vacuolation of the gland epithelium while glandular
changes are key in dating the first half of the secretory phase such as mitosis,
pseudostratification, basal vacuolation and secretion (Noyes et al. 1950). All
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samples were dated using the first day of the last menstrual period as day 1 and 
proliferative or secretory phase confirmed by criteria above.
2.8.5 Scoring and statistical analysis for paraffin embedded blocks
Using a light microscope three independent observers scored all slides blinded to 
the diagnosis, demographic or menstrual cycle stage. Two of the observers were 
trained gynaecological doctors in addition to myself, this ensured that the scoring 
was consistent between observers. The endometrial samples were scored (H-score) 
by compartment, the stroma and the epithelium containing the glands and lumen. 
Intensity and distribution of staining were scored separately with the following 
criteria intensity (0-4.5); 0-absent, 1-weak, 2-moderate, 3-intermediate, 4-strong, 
4.5-very strong. Distribution (0-4.5); 0-absent, l-<25%, 2-25%-50%, 3-50%-75%, 4 -  
75%-95%, 4.5-100%. This criteria allows for robust and reproducible assessment. 
The more red-brown staining observed in the sections, indicating positive antibody 
staining, was reflected in a higher score for staining intensity and distribution. The 
sum of these scores was obtained and all subsequent analysis was conducted on the 
sum H-score. All data were represented in box and whisker plots. The median data 
point represented by a crossed circle, the upper and lower quartiles of the data in 
the boxes each side and the whiskers representing the upper and lower quarter 
extremes of the data.
2.8.6 Statistical analysis
Due to the heterogeneity of the patient samples obtained from each group the 
Anderson Darling test (Appendix C) for normality was conducted on the data in 
order to identify the correct statistical method to employ for analysis of variation 
between fertile and infertile groups (Margarit et al. 2010; Darling 1952). Each group 
of data was tested for normality and several were observed to be significantly 
different from the normal distribution (p<0.05). All data were therefore treated as 
non-parametric. In the first instance the Kruskal-Wallace (K-W) test was applied to 
all groups in each category (i.e. all proliferative gland groups) to assess if any
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significant total variation in the data existed. If a result was significant for the K-W 
test (p<0.05) a Mann-Whitney U (M-WU) test was used to conduct a pairwise 
comparison of an individual infertile group to the fertile (control) group. This was 
conducted for each compartment and target retrospectively (Kruskal and Wallis 
1952; Mann and Whitney 1947).
Due to the small patient sample number and small number of comparisons applied 
to the data, a correction for multiple testing was not considered appropriate for the 
data set. Correcting for multiple testing, while reducing possible type I errors 
potentially increased the risk of type II errors if the expected type I error rate is 
below one (Lieberman and Cunningham 2009; Green and Britten 1998; Gelman et 
al. 2012). No more than four comparisons were made simultaneously (e.g. OPN 
(IHC), across 4 groups, Figure 3-5) during the study therefore the theoretical risk of 
a type I error at the 5% significance level would be 0.2, considerably lower than one.
2.9 Isolation and quantification o f Secreted Protein
All secreted proteins were harvested from the cell cultures, for both primary and 
secondary cell culture by decanting off the media. Following centrifugation at 600xg 
for 5mins all cell debris is removed. Supernatants containing secreted proteins were 
then transferred to a clean labelled eppendorf and stored at -80°C.
2.10 Enzyme linked immunosorbent assay
Cells were cultured as described in section 1.3; at the end time point of each 
experiment the supernatants were collected and aliquots were separated into 
1.5mL eppendorf tubes. The amount of secreted OPN in the supernatant was 
determined using a commercially available ELISA kit. All antibodies described below 
were included in the kit (R&D Systems, Inc., Minneapolis, MN, USA). The ELISA 
method uses a monoclonal (capture) antibody that is bound to a 96-well plate, 
which targets the C-terminal sequence of OPN common to all identified isoforms. 
ELISA plates were blocked using 1% BSA to remove non-specific binding of the
sample to the micro-well plate. Samples were then added and allowed to bind to 
the OPN capture antibody for 2hrs before being decanted and each well washed 
(wash buffer 0.05% Tween® 20 in PBS) to remove any unbound sample. The 
biotinylated detection antibody was added to bind OPN and on the addition of 
Streptavadin-horseradish peroxidase, following the addition of a substrate, an 
enzymatic reaction occured. The substrate containing hydrogen peroxide and 
tetramethylbenzidine was transformed in to a blue product that was directly 
proportional to the amount of OPN present in each well. Sulphuric acid (1M) was 
then added to stop this reaction so that the absorbance can be measured at 450nm 
on a spectrophotometer (FluoSTAR, BMG Labtech, UK). Known concentrations of 
OPN were used to produce serial dilutions and generate a standard curve 
(concentrations of 4000, 2000, 1000, 500, 250, 125 and 62.5pg/mL). A blank of the 
reagent diluent was added to account for background and subtracted from each 
reading. Using the Mars data analysis software (BMG Labtech, UK) optical density of 
all samples and standards are deduced from the blank optical density before further 
analysis to compare control and treatment values. A standard curve using the four 
parameter logistic curve-fit was generated and all optical densities from unknown 
samples were compared to this.
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Chapter 3
Expression of Osteopontin 
and CD44 in fertile and 
infertile endometrium
3.1 Introduction
The endometrium is a complex network of cells comprising of epithelia, stroma, 
endothelia and migrating leukocytes, and displays orchestrated phases of 
proliferation, differentiation and shedding (Tabibzadeh, 1991). These phases are 
driven by responses to ovarian steroid hormones, pituitary derived gonadotropins, 
growth factors and cytokines. The endometrial tissue functions to provide optimal 
conditions for fertility (Makrigiannakis et al. 2006). Multiple complex signalling 
patterns including autocrine, paracrine and endocrine signalling occur, affecting cell 
proliferation and differentiation. Increased ovarian steroid hormone receptor levels 
(estrogen and progesterone) observed in pathologies such as PCOS and 
endometriosis could contribute to the disrupted expression levels of various 
embryo adhesion proteins (Margarit et al. 2010; Igarashi et al. 2005). This makes 
the adhesion gene and protein expression levels strong candidates as biomarkers 
for determining what contributes to infertile endometrial pathology.
Candidate embryo-epithelial adhesion proteins OPN, CD44 and integrin aVp3 are 
hypothesized to form an adhesion complex at the epithelial surface, which may be 
crucial for blastocyst attachment during the window of implantation (Yen and Jaffe, 
2009; Singh and Aplin, 2009). Literature suggests that maximum expression of OPN 
in the glands and lumen of the endometrium is during the mid-secretory phase. 
When secreted from the glands, OPN can bind to luminal CD44 or aVp3 (Afify et al. 
2006; Albers et al. 1995). Integrin aVp3 is well characterized in the literature as a 
marker of implantation and it is maximally expressed in the secretory phase of the 
menstrual cycle (DuQuesnay et al. 2009; Lessey and Arnold 1998). The roles of OPN 
and CD44 as markers of implantation have not been studied extensively in the 
human endometrium in the context of infertile pathology, although some literature 
exists which hypothesizes their role during implantation. Secreted uterine OPN and 
membrane tethered CD44 have both been shown to be markedly increased in the 
secretory phase of the menstrual cycle when compared to the proliferative phase 
(Wolff, Thomas Strowitzki, et al. 2001; Afify et al. 2006).
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In this chapter a comprehensive analysis of the expression levels of candidate 
biomarkers for infertile pathologies was performed. In a cohort of 178 women 
attending the gynaecology clinic at ABMU HB Singleton Hospital. A total of 91 
women were included in the IHC study, 28 in the secreted OPN study and a further 
59 in the mRNA study. OPN and CD44 expression was assessed at the intracellular 
protein level, and secreted OPN levels analyzed in the culture media in which the 
biopsies were placed immediately following collection. Gene expression analysis 
was conducted in order to facilitate the understanding of OPN and CD44 gene 
regulation. The aim of this study was to characterize the expression of constituent 
components of this adhesion complex in the endometrium of a fertile cohort, and 
then compare them to an infertile cohort presenting with distinct pathologies. 
Samples were grouped by pathology and phase of menstrual cycle to ascertain the 
expression as a result of menstrual cycle development. It is important to note that 
the PCOS group has been sub-divided into two groups, anovulatory PCOS and 
ovulatory PCOS as defined by the Rotterdam criteria and confirmed using LMP and 
Noyes criteria. Therefore all women in the anPCOS group are in the proliferative 
phase of the menstrual cycle whilst the ovPCOS are in the secretory phase.
3.2 Results
3.2.1 IHC analysis o f OPN and CD44 protein expression in the endometrium
OPN and CD44 expression throughout the menstrual cycle in healthy fertile controls 
and infertile pathologies were observed in a retrospective study of archived uterine 
material, in relation to patient age and BMI. A pattern of OPN and CD44 expression 
levels from this fertile group was then compared to patients diagnosed with various 
endometrial disorders including; anovulatory PCOS (anPCOS), ovulatory PCOS 
(ovPCOS), endometriosis and unexplained infertility (UIF). Formalin fixed paraffin- 
embedded (FFPE) uterine tissue sections were grouped by pathology according to 
their recorded patient profiles and clinical diagnosis by pathology staff at Singleton 
Hospital. Samples were characterized and dated by Noyes (Noyes et al. 1950)
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criteria and separated into stages of the menstrual development. All samples were 
scored and statistical analysis conducted as in section 2.8.6.
3.2.2 Clinical Data and patient demographics
In order to ensure a robust comparison between groups, a strict selection criterion 
was employed. Patients who were over 42 years of age or with a BMI of 36 or over 
were deemed ineligible. The BMI limit of 36 was chosen as it included only the first 
class of obese women (BMI 30-35, Obese Class I) however most women in the study 
fell into the overweight category (BMI 25-29). Women with pathological features 
such as tubular defects and hyperplasia were excluded. Although every attempt was 
made to age and BMI match patients, a significant variation was observed in the age 
of the ovPCOS and secretory phase UIF patients compared to the fertile group, 
when analysed using the student t-test (p=0.001) (Table 3-1). Early onset of 
infertility in young women with ovPCOS (mean age 27.5) and UIF (mean age 30.8) 
are noted in this study. The fertile women included in this study were recruited 
whilst undergoing sterilization or hysterectomy and therefore tended to be older 
(mean age 35.6) than the infertile groups. Of the 91 patients selected for this study, 
53 were in the proliferative phase of the menstrual cycle; 18 had anPCOS, 6 had 
endometriosis and 19 were UIF, with 10 women in the fertile group (Table 3-1). 
Similarly in the secretory phase, a total of 38 women were available; 8 ovPCOS, 6 
endometriosis, 12 UIF and 12 fertile.
3.3 Osteopontin protein expression in fertile endometrium
OPN and CD44 have both been shown to be up-regulated in the secretory phase 
endometrium of healthy cycling women and could therefore be useful as predictive 
markers of fertility (DuQuesnay et al. 2009; Poncelet et al. 2010). OPN protein 
expression was analyzed in the endometrial tissue of healthy, fertile patients and 
separated into the proliferative and secretory phases of the menstrual cycle. OPN 
expression was first assessed in fertile women in the two distinct phases of the 
menstrual cycle. The staining patterns for OPN expression were separated into
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three compartments; glands, lumen and stroma to assess where OPN is expressed 
within the tissue (Figure 3-1). Significant differences were detected in OPN protein 
expression between the compartments (K-W p=0.000) and therefore a M-W U test 
was conducted to determine which compartments were significantly different in the 
secretory phase when compared to the proliferative phase by pairwise 
comparisons. OPN staining in the glands and luminal epithelium of the fertile group 
was stronger in the secretory phase when compared to the proliferative phase 
(Figure 3-1). Stromal staining meanwhile appeared similar between the two phases. 
The glandular expression of OPN was significantly increased in the secretory phase 
(H = 7.5) compared to the proliferative phase (H = 6.4; M-WU p=0.021). Luminal 
expression was not significantly increased, but rose from a median H-score value of 
6.7 to 7.3. No significant alteration in the stromal staining pattern of OPN was 
observed where consistent median H-score values (H = 5.5 and 5.4) were observed 
in the proliferative and secretory phases respectively (p=0.56). In both phases 
glandular and luminal OPN staining were more abundant than stromal expression 
(DuQuesnay et al. 2009; Franchi et al. 2008).
IHC
Fertile PCOS Endometriosis Unexplained Infertility
Pro Sec Anov Ov Pro Sec Pro Sec
AGE 34± 7.7
37.2 ±4 .6  
p=0.27
28.4± 5.2 
p=0.06
27.5 ±5 .7  
p=0.002
33.3±  7.7 
p=0.87
31.5 ±  6.5 
p=0.09
30.9 ±4 .7  
p=0.27
30.8 ±  4.1
p=0.001
BMI
(kg/m2)
28.8 ±  4.7
25.8 ±  3.8 
p=0.19
28.1± 6.3
p=0.80
27.4 ±  8 
p=0.63
28.4 ±  5.6 
p=0.90
26.3 ±  5.5 
p=0.90
25± 5.4 
p=0.11
24± 2.5 
p=0.25
n= 10 12 18 8 6 6 19 12
n=
cum
22 26 12 31
Table 3-1 Patient demographics for IHC study.
Retrospect IHC study using tissue biopsy material from a cohort of patients 
undergoing investigation for infertile pathology. Recorded parameters of age, BMI 
and total number of grouped patients, were statistical analyzed for variation 
between groups. Mean values, standard deviation and probability calculations 
(student's t-test) are displayed. Pro-proliferative; Sec-secretory; Anov- 
anovulatory; ov-ovulatory; BMI-body mass index; n-number; cum-cumulative.
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Figure 3-1 OPN protein expression in the proliferative and secretory phase of 
fertile endometrium.
OPN expression in fertile endometrium by compartment; (A-C) proliferative phase 
(n=10), (D-F) secretory phase (n=12). Sections of fertile endometrium were stained 
with OPN antibody and slides scored by three independent scorers at 40x 
magnification, scale bar (black) represents 20pm. A significant increase in 
glandular OPN expression was noted in the secretory phase when compared to 
the proliferative phase endometrium (M-WU p=0.02). (G) H-scores were grouped 
per compartment and semi-quantitative H-score used for statistical analysis 
performed using the Kruskal-Wallis (p<0.05) test followed by the Mann-Whitney 
U test (proliferative versus secretory)* P<0.05.
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3.3.1 Osteopontin protein expression in proliferative phase infertile 
endometrium
In order to assess the median level of OPN protein expression in infertile groups, 
the staining patterns were compared directly to those obtained in the healthy 
cycling fertile patients. Groups compared to the proliferative phase fertile group 
were anPCOS, endometriosis and UIF. Only the anPCOS group was compared to the 
proliferative phase fertile group as patients in this group were confirmed as 
proliferative phase. The ovPCOS group retrospectively chosen had been 
histologically confirmed as in the secretory phase and therefore were included in 
the secretory phase study only. To further understand how the two PCOS 
pathologies differed, anPCOS was also compared to the secretory phase.
3.3.2 Osteopontin glandular expression in proliferative phase endometrium
The staining patterns observed in the glands of the proliferative phase (Figure 3.2) 
showed increased OPN expression in the anPCOS (Figure 3-2B) and endometriosis 
(Figure 3-2C) groups when compared to the fertile group (Figure 3-2A). No change 
in staining intensity or distribution was observed in the glands of UIF women (Figure 
3-2D). These subtle changes in staining patterns were reflected in the H-scores 
obtained (Figure 3-2E). H-scores increased in women with anPCOS (H=7.7) and 
endometriosis (H=7.7) in the proliferative phase endometrium when compared 
directly to the fertile group (H=6.4). In women with unexplained infertility, the H- 
score decreased (H=6.0). However, no significant differences were detected 
between groups (K-W p>0.05) and therefore no further pairwise comparisons were 
conducted. The H-score values for all infertile groups were similar.
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Figure 3-2 Proliferative phase OPN protein expression in endometrial glands.
Proliferative phase endometrium from fertile (n=10), anPCOS (n=18), 
endometriosis (Endo) (n=6) and UIF (n=19) patients stained for OPN. (A) fertile, (B) 
anPCOS, (C) endometriosis, (D) UIF x40 magnification, scale bar (black) represents 
20pm. No significant alterations in OPN staining were observed between the 
fertile and infertile groups. (E) scores for OPN were plotted by group and 
expression analyzed using semi-quantitative H-scores. Statistical analysis was 
performed using the Kruskal-Wallis test (K-W; p=0.34).
3.3.3 Osteopontin luminal expression in proliferative phase endometrium
Similar patterns of altered OPN expression to the glands were observed in the 
luminal epithelial compartment of the endometrium (Figure 3-3). In the anPCOS 
(Figure 3-3B) and endometriosis (Figure 3-3C) groups increased intensity and 
distribution of OPN staining was observed when compared to the fertile group 
(Figure 3-3A). No change in staining was observed in the UIF group (Figure 3-3D) 
when compared to the fertile group. This was reflected in H-scores (Figure 3-3E). 
These observed differences were not significant (K-W p=0.42); as differences in OPN 
were not detected between groups therefore no further pairwise comparisons were 
conducted.
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Figure 3-3 Proliferative phase OPN protein expression in endometrial luminal 
epithelium.
Proliferative phase endometrium from fertile (0=10), anPCOS (n=18), 
endometriosis (Endo) (n=6) and UIF (n=19) patients stained for OPN. (A) fertile, (B) 
anPCOS, (C) endometriosis, (D) UIF x40 magnification, scale bar (black) represents 
20pm. No significant alterations in OPN staining were observed between the 
fertile and infertile groups. (E) scores for OPN were plotted by patient group and 
expression analyzed using semi-quantitative H-scores. Statistical analysis was 
performed using the Kruskal-Wallis test (K-W p=0.42).
3.3.4 Osteopontin stromal expression in proliferative phase endometrium
Altered patterns of OPN stromal staining were observed between the fertile group 
and those observed in each of the infertile groups (Figure 3-4). Stronger staining 
was evident in the stroma of anPCOS (Figure 3-4B) and endometriosis (Figure 3-4C) 
groups when compared to the fertile group (Figure 3-4A). In contrast the stromal 
compartment of the UIF group showed weaker staining for OPN when compared to 
the fertile group (Figure 3-4D). These changes are reflected in the H-scores (Figure
3-4E) and statistical comparisons. Significant variation was observed in OPN 
expression between the groups when the Kruskal-Wallis test was applied (K-W 
p=0.015). Therefore, the Mann-Whitney U test was conducted to determine which 
groups were significantly different to the fertile group by pairwise comparison. 
Stromal OPN expression was significantly increased in women w ith endometriosis 
(H = 7.0) when compared to the fertile group (H = 5.5; p=0.04). Women with
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anPCOS (H = 5.3) showed no significant alteration in OPN staining (H = 5.3) when 
compared to the fertile group (M-WU p= l), although it is noteworthy that the data 
were highly variable. UIF patients (H=4.4) displayed decreased stromal OPN 
expression and a tight distribution of data compared to the fertile group (H=5.5) but 
was insignificant (M-WU p=0.07).
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Figure 3-4 Proliferative phase OPN protein expression in endometrial stroma.
Proliferative phase endometrium from fertile (n=10), anPCOS (n=18)/ 
endometriosis (Endo) (n=6 ) and UIF (n=19) patients stained for OPN. (A) fertile, (B) 
anPCOS, (C) endometriosis and (D) UIF x40 magnification, scale bar (black) 
represents 20pm. Significant alterations in OPN staining were observed between 
the fertile and infertile groups. (E) The scores for OPN were plotted by patient 
group and expression analyzed using semi-quantitative H-scores. Statistical 
analysis was performed using the Kruskal-Wallis test (K-W p=0.02) followed by a 
Mann-Whitney U test. A significant up-regulation of OPN expression was noted in 
the endometriosis group (M-WU p=0.04). * P<0.05
3.4 Osteopontin protein expression in secretory phase endometrium
3.4.1 Osteopontin glandular expression in secretory phase endometrium
It has been proposed that OPN secretion through the endometrial glands is 
essential to activate integrins on the blastocyst surface, to allow it to become 
adhesive (Chaen et al. 2012). In this study, altered OPN staining intensity and 
distribution was observed in the glandular epithelium of some infertile groups when 
compared directly to the fertile group (Figure 3-5). (Figure 3-5B) In the anPCOS
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group OPN patterns of staining intensity were more abundant than those of the 
fertile group (Figure 3-5A), while the most abundant staining patterns were clearly 
observed in the tissue sections obtained from ovPCOS patients (Figure 3-5C). Tissue 
sections of endometriosis (Figure 3-5D) and UIF (Figure 3-5E) groups appeared to 
have less abundant OPN staining than the fertile group, reflected in Fl-scores (Figure
3-5F). Despite this clear staining pattern, no statistically significant variations in the 
OPN Fl-scores between all groups were observed when the Kruskal-Wallis test was 
applied (K-W p=0.13); therefore no further pair-wise comparisons for statistical 
significance were conducted.
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Figure 3-5 Secretory phase OPN expression in endometrial glands.
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Secretory phase endometrium from fertile (0 =1 2 ), anPCOS (n=18), ovPCOS (n=8 ), 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for OPN. (A) fertile, (B) 
anPCOS, (C) ovPCOS, (D) endometriosis, (E) UIF x40 magnification, scale bar 
(black) represents 20pm. No significant alterations in OPN staining were observed 
between the fertile and infertile groups. (F) Scores for OPN were plotted by 
patient group and expression analyzed using semi-quantitative H-scores. 
Statistical analysis was performed using the Kruskal-Wallis test (K-W p=0.13).
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3.4.2 Osteopontin luminal expression in secretory phase endometrium
Luminal staining of OPN showed very similar patterns of expression to those 
observed in the glandular epithelium (Figure 3-6). Stronger staining was observed in 
the luminal epithelium of anPCOS group (Figure 3-6B) and more so in the ovPCOS 
(Figure 3-6C) group when compared to the fertile group (Figure 3-6A). In contrast, 
sections obtained from the endometriosis group (Figure 3-6D) seemed to exhibit a 
less abundant staining intensity and distribution compared to the fertile group 
(Figure 3-6A). This pattern of less abundant staining was also observed in the UIF 
patients (Figure 3-6E). These patterns were reflected in the H-score values obtained 
(Figure 3-6F).
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Figure 3-6 Secretory phase OPN expression in endometrial luminal epithelium.
Secretory phase endometrium from fertile (n=12), anPCOS (n=18), ovPCOS (0 =8 ), 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for OPN. (A) fertile, (B) 
anPCOS, (C) ovPCOS, (D) endometriosis and (E) UIF x40 magnification, scale bar 
(black) represents 20pm. (F) The scores for OPN were plotted by patient group 
and expression analyzed using semi-quantitative H-scores. Statistical analysis was 
performed using the Kruskal-Wallis test (K-W p=0.07).
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No significant differences were detected in OPN protein expression between the 
patient groups (K-W p>0.05), therefore no further statistical analysis was 
conducted. The ovPCOS patients (H=8.0) had a very tight data distribution resulting 
from consistently strong staining patterns and an increase in OPN expression when 
compared to the fertile group (H=7.3). No significant variation was detected 
between anPCOS (H=7.7) and the fertile group (H=7.3). The endometriosis (H=6 ) 
and UIF (H=6.7) groups both exhibited decreased H-scores, neither of these 
however were significant changes, probably due in part to the variation observed in 
staining pattern within these groups.
3.4.3 Osteopontin stromal expression in secretory phase endometrium
Less abundant staining patterns for OPN were observed in the stromal 
compartment for all infertile groups when compared to the other endometrial 
compartments (Figure 3-7). Consistent staining was observed in each of the PCOS 
groups (Figure 3-7B and C) when compared to the fertile group (Figure 3-7A). No 
significant variations were observed in the data when the Kruskal-Wallis test was 
applied (K-W p=0.097) and therefore no further statistical analysis was conducted. 
Less abundant staining was observed in the endometriosis group (Figure 3-7D) as 
well as the UIF group (Figure 3-7E). The staining patterns observed were reflected in 
the H-score values obtained (Figure 3-7F). Consistent H-scores were obtained for 
the anPCOS (H=5.5) and fertile group (H=5.5). Women with endometriosis appeared 
to exhibit a decreased level of OPN expression in the stroma (H=3.4), obtaining a 
decreased H-score value and less variation within the data set. The UIF (H=4.3) 
group appeared to have a decreased expression however this decrease was not 
significant, possibly a result of the variable distribution of the data.
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Figure 3-7 Secretory phase OPN expression in endometrial stroma.
Secretory phase endometrium from fertile (0 =1 2 ), anPCOS (n=18), ovPCOS (n=8 ), 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for OPN. (A) fertile, (B) 
anPCOS, (C) ovPCOS, (D) endometriosis, (E) UIF x40 magnification, scale bar 
(black) represents 20pm. No significant alterations in OPN staining were observed 
between the fertile and infertile groups. (F) scores for OPN were plotted by 
patient group and expression analyzed using semi-quantitative H-scores. 
Statistical analysis was performed using the Kruskal-Wallis test (K-W p=0.1).
3.5 Secreted osteopontin from fertile and infertile endometrium
A  p i l o t  s t u d y  w a s  c o n d u c t e d  t o  i n v e s t i g a t e  w h e t h e r  t h e  s e c r e t e d  O P N  le v e ls  
o b s e r v e d  in  t h e  b i o p s ie s  o b t a i n e d  f r o m  S in g le t o n  H o s p i t a l  c o u ld  b e  c o r r e l a t e d  t o  
t h e  d a t a  o b t a i n e d  in  t h e  IHC s t u d y  ( S e c t io n  3 .1 ) .  P ip e l le  b i o p s y  s a m p le s  o b t a i n e d  
f r o m  2 0  w o m e n  a t t e n d i n g  t h e  i n f e r t i l i t y  c l i n i c  w e r e  t r a n s f e r r e d  t o  S w a n s e a  
U n i v e r s i t y  a n d  k e p t  in  m e d ia  a t  4 °C  ( m a x i m u m  4 h r s )  b e f o r e  c u l t u r e .  T h e  m e d ia  w a s  
a s p i r a t e d ,  c e n t r i f u g e d  a n d  a l i q u o t s  w e r e  t a k e n  in  o r d e r  t o  a sse ss  t h e  s e c r e t e d  le v e ls  
o f  O P N  b y  ELISA. S a m p le s  w e r e  n o t  s e p a r a t e d  i n t o  p h a s e  o f  m e n s t r u a l  c y c le  d u e  t o  
t h e i r  l i m i t e d  n u m b e r  in  t h i s  p r e l i m i n a r y  s t u d y .  T h e s e  s a m p le s  i n c l u d e d  6  f e r t i l e  
w o m e n ,  3 d i a g n o s e d  w i t h  a n P C O S ,  5 d i a g n o s e d  w i t h  e n d o m e t r i o s i s  a n d  6  w i t h  UIF
(Table 3.2). Patient grouping and statistical analysis were conducted using the 
identical methodology as the IHC study. All data are presented as box plots with the 
crossed circle indicating the median value of secreted OPN (pg/mL).
Fertile anPCOS Endometriosis UIF
AGE 33.8 ± 10.1
36.0 ±8.5 
p=0.7
36.4 ± 6
p=0.6
34.6 ±3.2 
p=0.9
BMI 26.8 ± 3.9
28 ±4.4 
p=0.7
28.7 ±6.3 
p=0.5
21.7 ±4.8
p=0.2
n= 6 3 5 6
Table 3-2 Patient demographics for secreted OPN pilot study.
Media samples containing biopsy material whiie being transferred from Singleton 
Hospital to Swansea University were analyzed using ELISA to detect secreted OPN 
levels. Recorded parameters of age, BMI and total number of grouped patients, 
were analyzed and any statistical variation between groups recorded show mean 
values standard deviation and probability calculations, using a student's t-test. 
Total number of samples n=20. anPCOS, anovulatory, BMI, body mass index, n, 
number.
3.5.1 Secreted osteopontin
Secreted OPN has been identified in uterine flushings from animal models (Johnson 
et al. 1999; Chaen et al. 2012). Here we aimed to measure secreted OPN in the 
media surrounding the biopsy. Levels o f secreted OPN detected by ELISA showed 
secreted OPN levels for fertile controls were 238 pg/mL (Figure 3-8). In the anPCOS 
group there was a large decrease in secreted OPN with a median value of 168 
pg/mL obtained. The distribution of OPN in this group showed less variation, 
possibly due to the smaller sample size (n=3) than the fertile group. The 
endometriosis group exhibited similar data variation and a similar median value of 
213pg/mL to the fertile group was recorded. The UIF group had a decreased median 
value o f 169 pg/mL, however this was not significant when compared to the fertile 
group. This could be due to more variation in the data set. No significant differences
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in secreted OPN were detected between groups and therefore no further pairwise 
comparisons were conducted (K-W p>0.05).
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Figure 3-8 Secreted OPN levels in culture media of biopsies.
Secreted OPN levels measured by ELISA in fertile and infertile groups. Fertile 
(n=6 ), anPCOS (n=3), Endo (n=5) and UIF (n=6 ) groups. A decrease in secreted OPN 
was observed in the anPCOS (164pg/mL) and UIF (198 pg/mL) groups when 
compared to the fertile group (238pg/mL). No significant alterations in secreted 
OPN were observed between the fertile and infertile groups when analyzed for 
statistical variation in a pairwise manner using a student's t-test (p>0.05).
3.6 CD44 expression in the fertile endometrium
There have been no previous studies simultaneously measuring the expression of 
OPN and CD44 throughout the menstrual cycle in the human endometrium. In this 
study, the protein expression o f CD44 was evaluated in the same patient cohort as 
for OPN in order to correlate the expression of both markers in the endometrium. 
CD44 expression on the epithelia is essential to enable OPN to form a complex with 
aVp3. CD44 expression is up regulated in the secretory phase, concurrent with the 
window of implantation, and has shown to bind OPN in other tissues and cell types 
such as the prostate, substantia nigra and kidney (Desai et al. 2009; Desai et al. 
2007; Bellahcene et al. 2008; Lee et al. 2007).
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Data presented here indicate CD44 expression in the proliferative phase 
endometrium was most abundant in the stroma when compared to the glands and 
luminal epithelium (Figure 3-9). Secretory phase glandular CD44 expression showed 
stronger staining than in the proliferative phase (Figure 3-9A and D). Luminal CD44 
staining was similar in the proliferative and secretory phase (Figure 3-9B and D) 
whilst stromal staining was decreased in the secretory phase when compared to the 
proliferative phase (Figure 3-9C and F). Staining was quantified by H-score analysis 
(Figure 3-9G). Significant differences were detected in CD44 protein expression 
between the different compartments and therefore a Mann-Whitney U test was 
conducted to determine which compartments were significantly different in the 
secretory phase when compared to the proliferative by pairwise comparisons (K-W 
p=0.001). Secretory phase glandular CD44 expression showed a significant 3-fold 
increase (H = 4.6) when compared to the proliferative phase (H = 1.5; M-WU 
p=0.02). Stromal CD44 expression decreased significantly in the secretory phase 
when compared to the proliferative phase (H = 5.7; H= 4.8 respectively; M-WU 
p=0.04). No significant variation in luminal CD44 expression was observed between 
the two phases; H-scores of 2.3 and 2.7 in the proliferative and secretory phases 
were obtained respectively (M-WU p=0.55).
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Figure 3-9 CD44 protein expression in the proliferative and secretory phase of the 
fertile endometrium.
CD44 expression in fertile endometrium by compartment; (A-C) proliferative 
phase (0 =1 0 ), (D-F) secretory phase (n=12). Sections of fertile endometrium were 
stained with CD44 antibody and slides scored by three independent scorers at x40 
magnification, scale bar (black) represents 20pm. A significant increase in 
glandular CD44 expression was noted in the secretory phase when compared to 
the proliferative phase endometrium (M-WU p=0.02), whilst stromal CD44 
expression significantly decreased in the secretory phase (p=0.04). (G) All H-scores 
were grouped and plotted. * P<0.05
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3.6.1 CD44 expression in the proliferative phase infertile endometrium
CD44 expression has been found to be less abundant in the secretory phase 
endometrium of healthy cycling women (Poncelet et al. 2010). CD44 expression in 
the endometrium was found to be different in endometrial pathologies. Up or 
down-regulation of CD44 expression in endometrial tissue has been shown in the 
epithelia and stroma and has been linked to the development of endometriotic 
lesions in endometriosis. This is thought to occur through an increasing ability to 
bind the outer peritoneal surface of the endometrium (Lucidi et al. 2005; Poncelet 
et al. 2002). Therefore, CD44 expression in infertile groups is compared to the 
fertile group to assess if any differences exist.
3.6.2 CD44 glandular expression in proliferative phase endometrium
Glandular staining of CD44 appeared to be stronger in the anPCOS (Figure 3-10B), 
endometriosis (Figure 3-10C) and UIF (Figure 3-10B) infertile groups compared to 
the fertile group (Figure 3-10A). This difference in staining was reflected in the Fl- 
scores (Figure 3-10E). No significant difference between groups was observed when 
the Kruskal-Wallis test (K-W p=0.17) was applied and therefore no further statistical 
analysis was conducted. Glandular CD44 expression measured by Fl-score in anPCOS 
and UIF groups was very similar to the fertile group with both obtaining Fl-score 
values of 2 compared to the fertile group (FI = 1.5). No significant differences were 
observed in the endometriosis group, possibly due to the wide data distribution 
when compared to the fertile group. With the exception of the endometriosis 
group, CD44 expression was very low in fertile and infertile pathologies in the 
proliferative phase endometrium as expected (Yaegashi et al. 1995; Saegusa et al. 
1998).
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Figure 3-10 Proliferative phase CD44 expression in the endometrial glands.
Proliferative phase endometrium from fertile (0 =1 0 ), anPCOS (n=18), 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for CD44. (A) fertile, 
(B) anPCOS, (C) endometriosis, (D) UIF x40 magnification, scale bar (black) 
represents 20pm. No significant alterations in CD44 staining were observed 
between the fertile and infertile groups. (E) scores for CD44 were plotted by 
patient group and expression analyzed using semi-quantitative H-scores (E). 
Statistical analysis was performed using the Kruskal-Wallis test (K-W p=0.2).
3.6.3 CD44 luminal expression in proliferative phase endometrium
In the proliferative phase, CD44 staining in the luminal compartment of the 
endometrium in anPCOS (Figure 3-11B), endometriosis (Figure 3-11C) and UIF 
(Figure 3-11D) exhibited similar patterns to the fertile group (Figure 3-11A). 
Quantitated by H-score values (Figure 3-11E), all groups displayed similar median H- 
score values and data distributions. No significant differences in CD44 expression 
were detected between groups (K-W p>0.05), therefore no further pair-wise 
comparisons were conducted. Luminal CD44 expression in the proliferative phase is 
expected to be decreased in agreement with current literature (Afify et al. 2006).
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Figure 3-11 Proliferative phase CD44 expression in the endometrial luminal 
epithelium.
Proliferative phase endometrium from fertile (n=10), anPCOS (n=18)/ 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for CD44. (A) fertile, 
(B) anPCOS, (C) endometriosis, (D) UIF x40 magnification, scale bar (black) 
represents 20pm. No significant alterations in CD44 staining were observed 
between the fertile and infertile groups (E). Scores for CD44 were plotted by 
patient group and expression analyzed using semi-quantitative H-scores. 
Statistical analysis was performed using the Kruskal-Wallis test (K-W p=0.8).
3.6.4 CD44 stromal expression in proliferative phase endometrium
CD44 staining in the stroma of the infertile groups was not as strong as in the fertile 
group (Figure 3-12). Weaker CD44 staining was observed in anPCOS (Figure 3-12B), 
endometriosis (Figure 3-12C) and the UIF (Figure 3-12D) group when compared to 
the fertile group (Figure 3-12A). This was additionally reflected in semi-quantitative 
Fl-scores (Figure 3-12E). Significant differences were detected in CD44 protein 
expression between the groups (K-W p=0.02); and therefore a Mann-Whitney U test 
was conducted to determine whether any of the infertile groups demonstrated a 
significant difference to the fertile group via a pairwise comparison. CD44 
expression in the UIF group was significantly decreased 1.7-fold when compared to 
the fertile group (H = 3.3; H = 5.7 respectively, M-WU p=0.009). The anPCOS and
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endometriosis groups displayed a similar level of CD44 expression to the fertile 
group (4.8 and 5.4 respectively; M-WU p=0.77 and p=0.64 respectively).
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Figure 3-12 Proliferative phase CD44 expression in the endometrial stroma.
Proliferative phase endometrium from fertile (n=10), anPCOS (n=18)/ 
endometriosis (Endo) (n=6 ) and UIF (n=19) patients stained for CD44. (A) fertile, 
(B) anPCOS, (C) endometriosis, (D) UIF x40 magnification, scale bar (black) 
represents 20pm. Significant alterations in OPN staining were observed between 
the fertile and infertile groups. (E) Scores for CD44 were plotted by patient group 
and expression analyzed using semi-quantitative H-scores. Statistical analysis was 
performed using the Kruskal-Wallis test (K-W p=0.02). CD44 decreased 
significantly in the stroma of the UIF group compared to the fertile group (M-WU  
p=0.009). * *  P<0.01
3.6.5 CD44 expression in the secretory phase endometrium of infertile women
Expression of CD44 in human endometrium has been linked to a role in the 
outcome of fertility. Endometrial CD44 expressed at the apical surface of luminal 
epithelium forms a complex with OPN to bind the integrin aV(33 presented by the 
blastocyst promoting embryo attachment. There are no studies describing the 
expression of CD44 in the endometrium of women with different pathological 
conditions associated with infertility. Our hypothesis is that CD44, through its 
function as OPN receptor, may contribute to the attachment of the embryo to the 
receptive endometrium during implantation. If expression of CD44 is an important
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factor in determining endometrial receptivity, then alteration in CD44 expression 
could contribute to endometrium-related infertility.
3.6.6 CD44 glandular expression in secretory phase endometrium
CD44 expression has been characterized in the glands of other tissues, such as 
mammary glands where CD44 expression is required for the proliferation of the 
underlying mesenchymal cells (Yu et al. 2002; Hebbard et al. 2000). CD44 
expression in the mammary gland is thought to be linked to its role as a mediator of 
epithelial-stromal signalling in addition to functional roles in proliferation, migration 
and invasion in cancer cells (Louderbough et al. 2011; Lokeshwar et al. 1995). CD44 
staining in the endometrium has been described in fertile samples and shown to be 
less pronounced in the glands and luminal epithelium compared to the stroma 
(Goshen et al. 1996). In this study CD44 expression in the secretory phase of the 
endometrium was measured in the glandular compartment of fertile and infertile 
groups. Glandular CD44 staining appeared weaker in anPCOS (Figure 3-13B), 
ovPCOS (Figure 3-13C) and endometriosis (Figure 3-13D) infertile groups when 
compared to the fertile group (Figure 3-13A). No differences in staining patterns 
were observed in the UIF group (Figure 3-13E). These changes in staining patterns 
were quantified using H-score analysis (Figure 3-13F). Significant differences were 
detected in glandular CD44 protein expression between the groups (K-W p=0.03) 
and the Mann-Whitney U test was therefore conducted to determine which infertile 
groups were significantly different to the fertile group by pairwise comparison. A 
significant decrease in glandular CD44 staining was observed in the ovPCOS group 
and H-score values showed a significant decrease of 3.6-fold (H = 4.7) when 
compared to the fertile group (H = 1.3; M-WU p=0.04). CD44 expression in the 
anPCOS group was similar to the fertile group, however there was larger variation 
within the data resulting in a decrease of CD44 expression. This was not judged to 
be significant (H = 2.0). The endometriosis group also had a lower H-score (H=2.5) 
but the variation in the data was very similar to that of the fertile group. No
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significant variation was observed in the UIF group when compared to the fertile 
group (H=4.2, M-WU p=0.68).
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Figure 3-13 Secretory phase CD44 protein expression in endometrial glands.
Secretory phase endometrium from fertile (n=12), anPCOS (n=18)/ ovPCOS (8 ), 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for CD44. (A) fertile, 
(B) anPCOS, (C) ovPCOS, (D) endometriosis, (E) UIF x40 magnification, scale bar 
(black) represents 20pm. Significant alterations in CD44 staining were observed 
between the fertile and infertile groups. (F) Scores for CD44 were plotted by 
patient group and expression analyzed using semi-quantitative H-scores. 
Statistical analysis was performed using the Kruskal-Wallis test (K-W p=0.03). 
CD44 decreased significantly in the glands of the ovPCOS group compared to the 
fertile group (M-WU p=0.04). * P<0.05
3.6.7 CD44 luminal expression in secretory phase endometrium
CD44 expression on the endometrial luminal surface during the window of
implantation is essential to enable OPN complex to assembly and attachment of the
blastocyst to the epithelia surface (Johnson et al. 2003). The lumen cells of the
epithelium is the first point of contact w ith the developing trophoblast; a process
known as apposition. This is followed by adhesion and molecules such as CD44 are
involved in stabilizing the attachment of the trophoblast to the endometrium
allowing the subsequent invasion of the developing blastocyst into the
8 6
endometrium. The luminal expression of CD44 was assessed in the secretory phase 
of the endometrium in fertile and infertile groups (Figure 3-14). Luminal CD44 
staining in anPCOS (Figure 3-14B), ovPCOS (Figure 3-14C), endometriosis (Figure 
3-14D) and UIF (Figure 3-14E) infertile groups appeared to be decreased compared 
to the fertile group (Figure 3-14A). This was confirmed by H-scores analysis (Figure 
3-14F). No significant difference in CD44 expression was detected between the 
fertile and infertile groups (K-W p>0.05) and therefore no further pairwise 
comparisons were conducted.
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Figure 3-14 Secretory phase CD44 protein expression in endometrial luminal 
epithelium.
Secretory phase endometrium from fertile (0 =1 2 ), anPCOS (n=18), ovPCOS (8 ), 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for CD44. (A) fertile, 
(B) anPCOS, (C) ovPCOS, (D) endometriosis, (E) UIF x40 magnification, scale bar 
(black) represents 20|im. No significant alterations in CD44 staining were 
observed between the fertile and infertile groups. (F) H-scores for CD44 were 
plotted by patient group and expression analyzed using semi-quantitative H- 
scores. Statistical analysis was performed using the Kruskal-Wallis test (K-W 
p=0.03).
The endometriosis group exhibited less variation in data distribution and a similar 
H-score to the fertile group (H=1.7). Similar variations in the data distribution and
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staining were observed between the fertile (H = 2.7), anPCOS (H = 2.3) and ovPCOS 
(H = 2) groups. The UIF group had a tighter data distribution than the fertile group 
and a similar H-score value (H=2.3).
3.6.8 CD44 stromal expression in secretory phase endometrium
CD44 expression in the endometrial stroma in the secretory phase is important in 
decidualization, a process that allows endometrial differentiation to sustain 
pregnancy. CD44 has been described to be expressed in decidual cells, that are 
differentiated stromal cells, and highly expressed in pregnant decidua (Behzad et al. 
1994; Goshen et al. 1996). In this study CD44 staining in the stroma of the secretory 
phase appeared similar in the anPCOS (Figure 3-15A), ovPCOS (Figure 3-15B) and 
endometriosis (Figure 3-15C) groups compared to the fertile group (Figure 3-15). 
Stromal staining in the UIF group appeared to be stronger (Figure 3-15E). This was 
confirmed by the H-score analysis (Figure 3-15F). Significant differences were 
detected in stromal CD44 protein expression between the groups (K-W p=0.03). A 
Mann-Whitney U test was therefore conducted to determine which infertile groups 
were significantly different to the fertile group by pairwise comparisons. In the UIF 
group (H=5.5) a significant increase in CD44 staining was observed in the secretory 
endometrium, reflected by a higher H-score than the fertile group (H= 4.8; M-WU 
p=0.018). H-score values obtained for both PCOS (anPCOS and ovPCOS, H = 4.8 and
3.9 respectively) groups were very similar to the fertile group (H = 4.8). No 
significant variation was observed. In the endometriosis group (H=5.5) however, the 
spread of the data was similar to the fertile group and therefore it was not 
statistically different.
88
Stroma
B
Fertile
20(im
OvPCOS
20(jin
UIF
20(im
20(Uii
9
AnPCOS 8
Endo
0
E ±
20(im
Figure 3-15 Secretory phase CD44 protein expression in endometrial stroma.
Secretory phase endometrium from fertile (n=12), anPCOS (n=18), ovPCOS (n=8 ), 
endometriosis (Endo) (n=6 ) and UIF (n=12) patients stained for CD44. (A) fertile, 
(B) anPCOS, (C) ovPCOS, (D) endometriosis, (E) UIF x40 magnification, scale bar 
(black) represents 20pm. Significant alterations in CD44 staining were observed 
between the fertile and infertile groups (F). Scores for CD44 were plotted by 
patient group and expression analyzed using semi-quantitative H-scores. 
Statistical analysis was performed using the Kruskal-Wallis test (K-W p=0.03). 
CD44 decreased significantly in the stroma of the UIF group compared to the 
fertile group (M-WU p=0.02). * P<0.05
3.6.9 Immunohistochemistry summary
Spatial distribution of CD44 (Figure 3-9) in the fertile  endometrial tissue differs from
that of OPN (Figure 3-1) in both phases of the menstrual cycle. OPN expression is up
regulated in the glands and luminal epithelium when compared to the stroma in
both phases o f the menstrual cycle. CD44 expression is up-regulated in the glands in
the secretory phase when compared to the proliferative phase. In both phases
stromal expression of CD44 was higher than for the other two compartments,
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stromal expression in proliferative phase was higher than secretory phase. In the 
proliferative phase CD44 glandular expression is 3.8-fold lower than stromal CD44. 
In the secretory phase however, CD44 expression in the glands and stroma was 
similar; reflected in similarity in variations of data and H-scores.
Glandular proliferative expression of CD44 was very low when compared to OPN 
staining in the glands (Figure 3-3). Although OPN luminal expression (Figure 3-4) in 
the proliferative phase was higher than CD44 expression (Figure 3-11), the same 
observation was made in the expression patterns between the infertile and fertile 
group. Stromal OPN and CD44 expression in the proliferative phase indicated similar 
staining and H-scores patterns with both OPN and CD44 showing decreased 
expression in the UIF group (Figure 3-5; Figure 3-12). This observation of altered 
stromal expression of both molecules suggests a role for OPN/CD44 complex during 
stromal proliferation.
In the secretory phase, glandular expression of CD44 (Figure 3-13) was less 
abundant than glandular OPN expression (Figure 3-5) in all fertile and infertile 
groups. This could be due to CD44 being most abundantly located in the cell 
membrane with little cytoplasmic and nuclear staining being observed. Therefore as 
the distribution of CD44 was lower, a low H-score was obtained. In comparison with 
CD44, luminal expression of OPN in the secretory phase (Figure 3-6) is more 
abundantly expressed in fertile and infertile groups. However, the expression of 
CD44 is much more varied in terms of data distribution than OPN expression, which 
is much tighter (Figure 3-14).
Stromal OPN expression in the secretory endometrium (Figure 3-7) was similar to 
CD44 (Figure 3-15) in terms of abundance with H-score values within the same 
range. However different patterns of expression of the two markers were noted in 
each pathology group. OPN expression decreased in the stroma of endometriosis 
patients while CD44 expression increased (compared to fertile group). However, 
both proteins showed decreased stromal expression in UIF patients. Although the 
differences observed for the UIF and endometriosis groups were not statistically
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significant, they indicated the need for a larger study to separate the different 
degrees of endometriosis and a larger cohort for the UIF group. Taken together, 
these subtle differences in both proteins may impact on the coordination of the 
events taken place during the secretory phase. For example, successful 
decidualization relays in the coordinate paracrine signalling between the glands and 
stroma to take place.
3 .7 Clinical data and patient demographics for gene expression study
In order to investigate if the gene expression of OPN and CD44 was a major factor 
involved in the observed protein expression changes, a small study was designed to 
measure the mRNA levels from a small group of tissue samples. Total RNA was 
extracted from fresh frozen biopsies obtained from women attending infertility 
clinics at Singleton Hospital. Quantitative Polymerase Chain Reaction (qPCR) was 
performed to determine the levels of mRNA present in pipelle biopsies of total 
endometrium. In addition, expression analysis was conducted for integrin aVp3 at 
the mRNA level. Each aV(33 sub-unit was analyzed separately with primers designed 
specifically for the aV (ITGAV) and (33 (ITGB3) genes which protein products form a 
dimer (aV(33).
3.7.1 Demographics and statistics
Women with proven fertility (at least 2 full term births) were recruited to the study; 
3 were in the proliferative phase and 6  in the secretory phase and they were 
selected according to the inclusion criteria in section 3.3.1. 15 women with PCOS 
were recruited and separated into anovulatory (13) and ovPCOS (2) groups (Table 
3-3). Nine women with endometriosis were recruited in each phase of the 
menstrual cycle. Sixteen women with unexplained infertility were recruited; 8  
proliferative and 9 secretory phase. A total of 57 women were included in this 
study. Significant differences were found between the mean age of the women in 
anPCOS and the proliferative UIF groups when compared to the fertile proliferative 
group (p=0.002; p=0.046 respectively). Despite limiting the effectiveness of this
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study, no significant outliers were found and therefore none were removed so that 
patient numbers for the study were preserved. All statistical analyses were 
conducted following the same methodology as the IHC study and data presented as 
box plots (section 3.3.1).
RNA
Fertile PCOS Endometriosis
Unexplained
Infertility
Pro Sec Anov Ov Pro Sec Pro Sec
AGE
36.0± 0 32.0± 5.5
p=0.18
28.2 ±6.0  
p=0.002
24.0± 7.1 
p=0.3
33.9± 5.2
p=0.26
30.8±6.4
p=0.75
29.3± 4.1 
p=0.046
28.6± 1.9 
p=0.25
BMI
(kg /m )
23.3±9.2 23.3± 1.2
p=0.16
23.4± 3.4
p=0.16
35.5± 4.9 
p=0.17
26.6 ±4.1  
p=0.25
27.0± 5.6 
p=0.13
24.2± 4.3 
p=0.17
25.4± 5.5 
p=0.41
n= 
cum n=
3 6 13 2 9 9 8 9
9 15 18 17
Table 3-3 Patient demographics for total RNA extraction study.
Total RNA was extracted from fresh frozen tissue biopsy material and assessed for 
OPN, CD44, ITGAV and ITGB3 gene expression. Recorded parameters of mean age 
(standard deviation), BMI, and total number of grouped patients were analyzed 
and any statistical differences between groups recorded using mean values 
standard deviation and probability calculations, using a student's t-test. Total 
number of samples n=59. Pro, proliferative, Sec, secretory, Anov, anovulatory, ov, 
ovulatory, BMI, body mass index, n, number, cum, cumulative.
3.8 Gene expression of adhesion complex components
3.8.1 Endometrial adhesion partner expression in fertile endometrium
Expression of all adhesion partner genes at the mRNA level was first assessed in the
fertile proliferative and secretory phases. No significant variation in expression was
observed between the groups when the Kruskal-Wallis test was applied and
consequently no further pairwise comparisons were conducted (K-W p=0.34). It was
noted that OPN expression increased in the secretory phase compared to the
proliferative phase (Figure 3-16). This increase was not found to be statistically
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significant. No significant change in the expression of CD44 was observed between 
the distinct phases o f the menstrual cycle despite an increase in the median value 
(0.05 to 0.09) in the secretory phase. Increased expression of ITGAV and ITGB3 
integrin subunits was observed in the secretory phase of the menstrual cycle when 
compared to the proliferative phase. ITGAV demonstrated a 3.8-fold (0.05 to 0.19) 
increase. A 10-fold increase in expression was observed for the ITGB3 subunit (0.05 
to 0.5) in the secretory phase. These differences were not found to be statistically 
significant however.
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Figure 3-16 Total RNA expression levels throughout the menstrual cycle.
Total biopsy tissue analyzed for OPN, CD44, ITGAV and ITGB3 transcript levels in 
the proliferative (n=3) and secretory phase (n=6 ) of the menstrual cycle. All 
starting quantity values are absolute and normalized against GAPDH. Values are 
represented in box plots. Statistical analysis was performed using a Kruskal-Wallis 
test.
3.8.2 Adhesion complex components proliferative phase expression in infertile 
endometrium
Expression levels of the adhesion complex components were measured in the 
proliferative phase (Figure 3-17) of the menstrual cycle in infertile women and 
compared to fertile women. No significant variation in mRNA expression was
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observed between the groups when the Kruskal-Wallis test was applied and 
therefore no further pairwise comparisons were conducted (K-W p=0.4).
3.8.3 Osteopontin proliferative phase expression in endometrium
OPN expression decreased in each of the three infertile groups compared to the 
fertile group however this trend was not statistically significant (Figure 3-17A). 
More variation in the 50% interquartile region of the data was observed in the 
fertile and endometriosis groups compared to the anPCOS and UIF groups. Despite 
this variation, the median scores for the data set obtained are indicative of large 
decreases in OPN gene expression. When compared to the fertile group expression 
decreased 13-fold in the anPCOS, 12-fold in the endometriosis group and 11-fold in 
the UIF group. Due to the small sample size these differences were not significant.
3.8.4 CD44 proliferative phase expression in endometrium
Decreased absolute starting quantities of CD44 gene expression levels were 
observed in the infertile groups when compared to the fertile group (Figure 3-17B). 
CD44 expression in the proliferative phase of the endometrium of anPCOS and UIF 
groups showed a decrease of 2.5 and 5.6-fold respectively when compared to the 
fertile group, but differences were not significant. A similar starting quantity was 
observed in CD44 expression in the endometriosis group compared to the fertile 
group.
3.8.5 Integrin AV proliferative phase expression in endometrium
ITGAV expression showed decreases in absolute starting quantities in the infertile 
groups when compared to the fertile group (Figure 3-17C). Expression of ITGAV 
exhibited a 2-fold decrease in anPCOS, a 2.3-fold decrease in endometriosis and a 
2.7-fold decrease in the UIF group.
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3.8.6 Integrin B3 proliferative phase expression in endometrium
ITGB3 exhibited a decrease in absolute starting quantity at the RNA level in each of 
the infertile groups (Figure 3-17D). A 2-fold decrease in ITGB3 expression is 
observed in the anPCOS group. This was higher in the UIF group where a 2.5-fold 
decrease was observed. The endometriosis group showed a similar expression 
pattern to the fertile group.
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Figure 3-17 Proliferative phase adhesion complex partner expression.
Quantitative PCR was conducted on total RNA reverse transcribed to cDNA in, 
fertile (n=3), anPCOS (n=13), endometriosis (Endo) (n=9) and UIF (n=8 ) for (A) 
OPN, (B) CD44, (C) ITGAV and (D) ITGB3 mRNA expression. All starting quantity 
values are absolute and normalized against the GAPDH housekeeping gene. No 
significant differences in expression were observed between fertile and infertile 
groups for all genes analyzed.
3.8.7 Proliferative phase correlation analysis
To identify if expression of the adhesion complex could be correlated in the
proliferative phase of infertile women, a Spearman's rank order correlation was
used to determine the relationship between gene products. A strong positive
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correlation was found between the expression of CD44 and ITGB3 in the 
endometriosis group of the proliferative phase (Spearman's rho =0.667 p=0.05). No 
other significant correlations were detected.
3.8.8 Adhesion complex secretory phase expression in infertile endometrium
Expression levels of the adhesion complex compartments were assessed in the 
secretory phase of the menstrual cycle in fertile and infertile women (Figure 3-18). 
Significant differences were detected by qPCR in mRNA expression between the 
infertile and fertile group and therefore a Mann-Whitney U test for pairwise 
comparison was conducted.
3.8.9 Osteopontin secretory phase expression in endometrium
In order to assess the significance of OPN gene expression in the secretory phase, 
the expression levels in the fertile group were compared directly to the four 
infertile groups (K-W p=0.007) (Figure 3-18A). When compared to the fertile control 
group, levels of OPN RNA were decreased significantly by 13-fold in anPCOS (M-WU 
p=0.007). In the ovPCOS group a 5-fold difference was detected but was not found 
to be statistically significant (M-WU p=0.9). In contrast OPN levels in the 
endometriosis and UIF groups were similar to the fertile control group (M-WU 
p=0.93; p=0.44).
3.8.10 CD44 secretory phase expression in endometrium
CD44 expression in the secretory endometrium of fertile and infertile groups of 
total biopsies (K-W p=0.044) (Figure 3-18B). CD44 expression is significantly reduced 
4.5-fold in the anPCOS group compared to the fertile group (M-WU p=0.024). A 
further significant 5-fold decrease in CD44 expression was observed in the UIF 
group compared to the fertile control (M-WU p=0.008). A 2-fold decrease was 
noted in the ovPCOS group while expression was decreased 4.7-fold in the 
endometriosis group however these decreases were not statistically significant (M- 
WU p=0.1).
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3.8.11 Integrin AV secretory phase expression in endometrium
ITGAV expression in all infertile groups was decreased compared to the fertile group 
(K-W p=0.001) (Figure 3-18C). The UIF group has significantly less ITGAV expression; 
48-fold less compared to the fertile group (M-WU p=0.002). ITGAV expression was 
decreased in expression in both the PCOS sub groups 8  and 11-fold in the anPCOS 
and ovPCOS groups respectively, however this was not statistically significant (M- 
WU p=0.22). The endometriosis group displayed a 6 -fold decrease in ITGAV 
expression but it was not statistically significant when compared to the fertile group 
(M-WU p=0.17).
3.8.12 Integrin B3 secretory phase expression in endometrium
aVp3 complex partner ITGB3 illustrated a decrease in expression in the secretory 
phase of the menstrual cycle in all infertile groups (K-W p=0.006) (Figure 3-18D). 
When compared to the fertile group significant decreases in ITGB3 were observed, 
in the anPCOS group a significant 17-fold decrease in ITGB3 was observed (M-WU 
p=0.003), the endometriosis group a significant 32-fold decrease in ITGB3 (M-WU 
p=0.008) and the UIF group a significant 26-fold decrease in ITGB3 expression was 
observed compared to the fertile group (M-WU p=0.003). The ovPCOS group 
displayed a 6 -fold reduction in ITGB3 expression which was not statistically 
significant.
3.8.13 Secretory phase correlation analysis
To identify if expression of the adhesion complex could be correlated in infertile 
women a Spearman's rank order correlation was used to determine the relationship 
between gene products. In the endometriosis group a very strong positive 
correlation between OPN and CD44 was noted in the secretory phase (Spearman's 
rho =0.857, p=0.014). In the secretory phase of women diagnosed with UIF, a strong 
positive correlation was observed between OPN and ITGAV (Spearman's rho =0.738 
p=0.037). As expected expression of ITGAV and ITGB3 was very strongly correlated
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in the secretory phase of the fertile group (Spearman's rho =0.900, p=0.037). No 
other significant correlations were detected.
0.30
0.252.0
IoQ.
§
a
S 0.20
0.15
0.10z
8
0.5 0.05
0.0 0.00
anPCOS ovPCOS Endo UIFFertileFertile anPCOS ovPCOS Endo UIF
0.8 0.7
0.7 0.6
■=■ 0.6 0.5
O 0.4
«  0.4
0.3
* *
0.1*0.1
0.0 0.0
Fertile anPCOS ovPCOS Endo UIFanPCOS ovPCOSFertile UIFEndo
Figure 3-18 Secretory phase adhesion complex partner expression.
Quantitative PCR was conducted on total RNA reverse transcribed to cDNA in, 
fertile (n=6 ), anPCOS (n=13), ovPCOS (n=2), endometriosis (Endo) (n=9) and UIF 
(n=9) for (A) OPN, (B) CD44, (C) ITGAV and (D) ITGB3 mRNA expression. All starting 
quantity values are absolute and normalized against the GAPDH housekeeping 
gene. Significant variations in expression were observed between fertile and 
infertile groups for all genes analyzed. All genes showed a decrease in expression 
in some infertile groups when compared to the fertile group. * P<0.05 * *  P<0.01
3.9 Summary
A summary (Table 3-4) of all findings in the three studies measuring RNA, 
intracellular and extracellular protein were utilized to explore the different 
expression patterns of the adhesion complex in the endometrium of infertile 
pathologies compared to fertile endometrium.
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The results of this study indicate that expression differences in the adhesion 
complex exist in infertile pathology compared to fertile endometrium. Expression 
differences at the mRNA and protein level suggest that the adhesion complex may 
be a good candidate to explore infertility. Further work will be conducted to 
understand the regulation of these genes in fertile and infertile endometrium.
3.10 Discussion
In this study a detailed IHC analysis to investigate protein expression patterns was 
undertaken. It was demonstrated that the levels of OPN expressed in fertile women 
in the glandular compartment increased significantly in the secretory phase of the 
menstrual cycle compared to the proliferative phase. This is in agreement with 
previous studies (Franchi et al. 2008). CD44 expression in the glands was 
significantly up-regulated in the secretory phase when compared to the 
proliferative phase, which has been noted (Goshen et al. 1996). In the stromal 
compartment, CD44 expression in the secretory phase was decreased compared to 
the proliferative phase and again these findings have been noted previously (Albers 
et al. 1995). An important observation was that the levels of CD44 as measured by 
H-score were lower across all compartments when compared to OPN. Interestingly, 
the spatial distribution of OPN and CD44 differed in the three distinct cellular types. 
In glands and luminal epithelium OPN levels were higher than in the stroma, 
conversely, CD44 levels were higher in the stroma than the glands and luminal 
epithelium. In contrast to the IHC study mRNA levels of OPN and CD44 isolated 
from whole tissue samples were not significantly different between the two phases 
of the menstrual cycle (Figure 3-18) which is consistent with previous reports. This 
observation is likely due to the analysis not being conducted on the different 
component structures individually (DuQuesnay et al. 2009; Behzad et al. 1994). 
Although separating the epithelial cells from the stroma cells can be achieved, the 
limited amount of tissue collected in this study prohibited this and therefore lead to 
evaluation at the mRNA level of the glands, lumen and stroma simultaneously.
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In anPCOS, little published literature exists that evaluates the expression of OPN 
and CD44 in the human endometrium by individual molecules. The findings in this 
study suggest that at the RNA level there appears to be differential expression of 
OPN, CD44 and ITGB3, in whole biopsy tissues and that expression is decreased in 
anPCOS. It has been demonstrated previously that anPCOS women have decreased 
levels of aVP3, although the study group were taking the therapeutic drug 
clomiphene citrate which may have influenced the expression (Apparao et al. 
2002). Clomiphene citrate is a drug commonly used to stimulate ovulation in PCOS 
women. By blocking the effect of estrogen, other hormones such as FSH and LH 
increase to induce ovulation. Blocking estrogen signalling would also induce 
progesterone signalling, which has been shown to regulate aV|33 expression 
(Apparao et al. 2001). The difference in expression of aVP3 in the anovulatory PCOS 
groups in this study could suggest a role in regulation of these adhesion genes by 
ER, as these women do not ovulate and therefore ER continually influences the 
endometrial tissue.
OPN expression has been analysed previously in a cohort (n=10) of ovPCOS women, 
where the study illustrated that glandular and luminal OPN protein expression 
(measured by IHC) was significantly decreased compared to fertile women 
(DuQuesnay et al. 2009). Here we present data showing that OPN protein 
expression is similar in the luminal epithelium and glands of ovPCOS and fertile 
women. It is possible that the small sample number in each study and differences in 
mean age and sample collection timing (day of cycle) have resulted in these 
differing observations. Additionally, all biopsies were taken during the window of 
implantation (around day 21-22) in the previous study. In this study samples range 
from day 15-28 as these were the only samples available from the tissue archives. 
CD44 expression in the ovPCOS group showed that glandular expression was 
significantly decreased. OPN is thought to be secreted from the glands (Chaen et al. 
2012) allowing it to form the adhesion complex with CD44 and aV|33 (Singh and 
Aplin 2009). Therefore, glandular expression differences of OPN may have a
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significant consequence on the adhesion complex of OPN-CD44-aV|33 in 
implantation.
This study presents data that support a trend of increased expression (non­
significant) of OPN in the glands of both PCOS cohorts with no differences in CD44 
expression compared to fertile women. This probably reflects functions of OPN 
other than regulating implantation. It has been described that neutralization of OPN 
with specific antibodies improves insulin sensitivity (Kiefer et al. 2010). A recent 
publication provided evidence that genetic OPN deficiency improves diet-induced 
insulin resistance (Nomiyama et al. 2007). In this context, a slight up-regulation of 
OPN may reflect the insulin sensitivity status of the PCOS patient's recruited. Insulin 
resistance is one of the features of the PCOS syndrome, among others like obesity 
which has also been linked with high OPN expression (Gomez-Ambrosi et al. 2007). 
Our patient cohort did not differ significantly in BMI, excluding this factor as an 
influence to OPN expression in these women. Further studies will clarify whether 
the observed changes in endometrial OPN expression correlate to the insulin 
sensitivity of patients.
In the endometriosis group, this study found that stromal expression of OPN was 
significantly increased in the proliferative phase and significantly decreased in the 
secretory phase when compared to the fertile group. This suggests a pattern of 
disrupted regulation throughout the menstrual cycle may occur in the 
endometriosis group. A study conducted by Cho indicated that at the mRNA level 
endometrial OPN was increased in endometriosis women when compared to fertile 
controls, although this was not observed when the data was split into proliferative 
and secretory phase expression. However, systemic levels of secreted OPN in blood 
plasma were significantly increased in both phases of the menstrual cycle when 
compared to fertile controls (Cho et al. 2009). Collectively this indicates that OPN 
levels are increased in women with endometriosis and this could be linked to 
inflammation. OPN has been shown to have a role in inflammatory diseases such as 
Crohn's disease, atherosclerosis, lupus and rheumatoid arthritis (Lund et al. 2009;
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Uede 2011; Cho et al. 2009). Moreover, OPN has been associated with roles in cell 
migration, cell survival and metastasis. It has also been hypothesised that 
endometriosis may be caused by dysregulation of stem cell function through 
spreading of endometrial progenitor cells (Maruyama and Yoshimura 2012). 
Although endometriotic cells are not characterised by uncontrolled differentiation, 
they show some features of malignant tissues such as invasion, induction of 
metastasis and the ability to evade apoptosis. In this context, our data describing 
increased OPN expression in eutopic endometrium of endometriosis patients may 
reflect the migratory and anti-apoptotic properties of these cells in the ectopic 
lesions and supports a common progenitor cells origin (Lagana et al. 2013; 
Aznaurova et al. 2014).
In the secretory phase, ITGB3 mRNA expression is down regulated in women with 
endometriosis when compared to fertile women in agreement with findings from 
Gonzalez (Gonzalez et al. 2006). This further indicates disrupted adhesion complex 
expression throughout the menstrual cycle. This could impact on the receptivity of 
the endometrium during the window of implantation. Lessey found that aVp3 to be 
up regulated in the secretory phase of healthy cycling fertile women (Lessey 2002). 
This study also demonstrated that aVP3 complex partner ITGB3 was decreased in 
expression in the secretory phase of the menstrual cycle in all related infertile 
pathologies.
We hypothesise that differences in OPN and CD44 expression in PCOS and 
endometriosis pathologies could be related to inflammatory environments in these 
patient groups. Inflammation is present at the systemic and local levels and low- 
grade chronic inflammation and pelvic inflammatory disease are common in these 
two pathologies (Ruan and Dai 2009; Gonzalez et al. 2006; Diamanti-Kandarakis et 
al. 2006; Weiss et al. 2009). In both pathologies inflammatory cytokines are present 
in the peritoneal fluid that surrounds the reproductive organs, effectively bathing 
the uterus in a pro-inflammatory environment (Halis and Arici 2004). This could 
affect how cytokines are regulated locally in addition to increasing the amount of
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pro-inflammatory cytokines in the uterine environment. Obesity is common in 
patients with PCOS and it is a contributing factor to the disease, a BMI of 36 was 
noted in the ovPCOS group of the gene expression study. This association has been 
linked to insulin resistance, which has been observed in these women (Dhindsa et 
al. 2004). As described previously, several reports have shown that OPN is 
responsive to glucose, insulin resistance, obesity-induced adipose tissue 
inflammation and pro-inflammatory cytokines in animal models (Gong et al. 2009a; 
Nomiyama et al. 2007). In addition CD44 has been described to be a target gene of 
WT1, a key transcription factor that mediates the decidualization process in the 
human uterus (Kim et al. 2011, Makrigiannakis et al. 2001; Anthony et al. 2003). 
Our group has recently published that WT1 targets the expression of genes in the 
uterine epithelial and stromal compartments and that WT1 expression is 
significantly downregulated in ovPCOS patients (Gonzalez et al., 2012). Accordingly 
we observed a statistically significant decrease of CD44 expression in ovPCOS 
glands suggesting a link between CD44 expresion and the WT1 signalling pathway 
and a role for CD44 in the decidualization process.
OPN and CD44 have not been studied extensively in patients with unexplained 
infertility. Here the novel observations that women diagnosed with unexplained 
infertility have significantly less CD44 expression at the mRNA level and significantly 
more OPN expression in the stroma of the secretory phase endometrium has been 
made. In the stromal cells of the secretory phase CD44 protein expression was 
significantly down regulated in the proliferative phase and significantly up regulated 
in the secretory phase in the UIF group when compared to the fertile group. These 
differences at the protein level suggest that expression of CD44 may be altered 
throughout the menstrual cycle and functionally could lead to disrupted CD44 
signalling in the stroma cells. The WT1 gene has been identified as having a key role 
in the decidualization process of the endometrial tissue (Makrigiannakis et al. 2001; 
Anthony et al. 2003). WT1 gene encodes the WT1 protein, a transcription factor 
that regulates the expression of many genes including CD44 (Kim et al. 2012). 
Although a specific role for CD44 during decidual transformation has not been
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attributed its expression has been described in pregnant decidua implying a role for 
CD44 to sustain pregnancy. In this context, a significantly lower expression of CD44 
may influence the successful decidualization of the endometrium and the 
immunological dialogue between maternal and embryo tissues 
(endometrium/blastocyst) resulting in poor maternal support of the embryo, poor 
placentation and ultimately infertility. This is further supported by our data at the 
mRNA level. In the UIF group the adhesion complex expression at the mRNA level 
was significantly decreased in the secretory phase; CD44 was decreased 5-fold, 
ITGAV was decreased 48-fold and ITGB3 26-fold compared to the fertile women. 
The decreased levels of ITGAV and ITGB3 in UIF are consistent with previous 
observations showing integrin aVp3 was significantly decreased in expression at 
the protein level in unexplained infertility (Tei et al. 2003).
The secreted protein study was conducted in order to correlate data with the IHC 
study. A study that used an intrauterine device to collect endometrial secretions 
found that secreted OPN increased in the secretory phase of the menstrual cycle 
when compared to the proliferative phase (Wolff, Thomas Strowitzki, et al. 2001). 
As OPN is a linker molecule between aVp3 and CD44 examining the secreted levels 
provided information on the levels of OPN that could become functional 
components of the protein complex involved in recruiting the trophoblast to the 
endometrium. If a profile of secreted OPN could be built for each pathology it could 
then be possible to develop this technique for use as a less invasive diagnostic 
technique using uterine flushing's. In this pilot study decreased levels of OPN were 
detected in PCOS and UIF samples. However, due to access to limited numbers of 
samples these preliminary observations were not shown to be significant.
Of note is the imbalance of OPN and CD44 expression in the infertile pathologies 
included in this study. As OPN can only bind to the endometrial epithelium via aVP3 
or CD44, disrupted CD44 expression in the luminal epithelium cells combined with 
disrupted glandular secretion of OPN could lead to the inability of the aVP3-OPN- 
CD44 complex to form between the embryo and endometrial epithelia. OPN and
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CD44's interaction on the surface influences signalling patterns (autocrine and 
paracrine signalling) for cell survival, cell proliferation, homing and migration 
(Bellahcene et al. 2008). Altered expression of OPN and CD44 could result in these 
signalling events being disrupted and perturbation of cell homeostasis leading to 
increased proliferation, migration, cell survival, poor embryo recognition and 
deficient endometrial differentiation, all ultimately leading to infertility and poor 
pregnancy outcome.
The work conducted in this chapter indicates that the expression of the aV(33-OPN- 
CD44 adhesion complex components is altered in infertile pathologies compared to 
fertile endometrium. These differences could be a result of different hormone, 
metabolite and cytokine expression described for these pathologies which all have 
an inflammatory component. Therefore, an in vitro model system was employed to 
examine the effects of hormones (Chapter 4) and glucose and cytokines (Chapter 5) 
on the adhesion complex components expression in the endometrium.
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Chapter 4
Hormonal regulation of 
adhesion complex 
components
4.1 Introduction
The proposed functions of OPN to form an adhesion complex with CD44 and aVp3, 
and adhere the blastocyst to the endometrial lining make it an excellent candidate 
to study in terms of fertility. Expression of this adhesion complex peaks on the 
endometrial epithelial surface during the window of implantation, where the 
correct hormone expression could be important to its regulation (Figure 1-5). 
Regulation of OPN by sex steroid hormones has been investigated in a diverse 
range of human and animal tissues such as the ovine uterus (G. Johnson et al. 
2000), murine uterus (Peyghambari et al. 2010), bovine uterus (Johnson et al. 2003) 
and human uterine tissue (Lessey 2003; Brown et al. 1992; Qu et al. 2008). It has 
been shown in renal tissue of male rats that testosterone promotes kidney stone 
formation, through suppression of OPN. Conversely, in female rats estrogen 
appeared to inhibit urinary stone formation by increasing OPN expression in the 
kidneys (Yagisawa et al. 2001). The binding partner of OPN, CD44 and its many 
variants, is also expressed in a range mammalian of tissues (Section 1.7.6) however 
regulation of its expression by sex steroid hormones in normal tissues has only been 
studied in the human endometrium. Expression of CD44 has been characterised in 
the menstrual cycle of healthy women (Goodison et al. 1999; Saegusa et al. 1998; 
Koo et al. 2013; Afify et al. 2005). The expression of aV(33 has also been extensively 
studied in the endometrium, with the 33 subunit in particular being regarded as a 
marker of implantation (Section 1.8.3).
There is evidence to suggest that estrogen and progesterone are key regulators of 
OPN and CD44 in the endometrium. OPN has been found to be expressed 
throughout the duration of the menstrual cycle, with low expression patterns 
observed in the proliferative phase, and high expression in the secretory phase 
(Wolff, Thomas Strowitzki, et al. 2001). Micro-array analysis conducted in three 
independent studies all found OPN expression to be significantly increased in the 
mid-secretory phase in endometrial tissue when compared to the early secretory 
phase (Carson et al. 2002; Kao et al. 2002; Riesewijk 2003). A potential
consequence of these observations is that OPN is involved in implantation. Spatial 
distribution of OPN expression is localized to the glandular, luminal and stromal 
tissue. In addition, OPN expression was found to be increased in endometrial 
leukocytes and in uterine secretions (Wolff, Thomas Strowitzki, et al. 2001). Again, 
expression was increased in the mid- and late-secretory phase of the menstrual 
cycle in healthy cycling women (Apparao et al. 2001). CD44 expression has also 
been reported throughout the endometrium (Behzad et al. 1994). In the healthy 
cycling endometrium the expression pattern of CD44 was found to be similar to 
that of OPN, although CD44 is additionally expressed in the early secretory phase. 
CD44 has many isoforms, and recent studies have found and focused on the 
expression of CD44v6 in the endometrium (Yaegashi et al. 1995; Afify et al. 2005; 
Poncelet et al. 2002). There is however evidence in the literature that other 
isoforms are also expressed in the endometrium. CD44v3 expression has also been 
observed in the endometrium (Saegusa et al. 1998). Whereas CD44v7-8 isoform 
variants have been shown to be expressed on the trophoblast surface (Goshen et 
al. 1996).
The correct expression of these molecules could be key in the receptivity of the 
endometrium; infertility could therefore be caused by ovarian dysfunction where 
disrupted menstrual cycles could reduce endometrial receptivity. An example of 
this is amenorrhea; when a woman of reproductive age does not menstruate. The 
primary cause has been linked to a lack of ovulation. A sub group of women who 
suffer from PCOS experience problems with ovulation. Disrupted hormonal 
expression has been linked to secondary causes of amenorrhea. It has also been 
found to cause very heavy and prolonged menses in addition to abnormal blood 
clotting in some women, this is associated with dysmenorrhea (Proctor and 
Farquhar 2006). This is a common complaint in women who are diagnosed with 
endometriosis, which is often associated with pelvic pain. Therefore the correct 
balance of E2 and P4 signalling in the endometrium is crucial for maintenance of 
tissue morphology, ovulation and the secretion of cytokines and proteins from the 
endometrial surface to prepare for embryo implantation.
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E2 and P4 are the ligands for the ER and PR receptor. These nuclear receptors 
contain DNA binding domains that are capable of interacting with receptor specific 
DNA promoter elements to enhance or repress transcription of a gene (Section 
1.9.2). In this chapter, the role of E2 and P4 signalling through their respective 
steroid hormone receptors is investigated using endometrial epithelial cell line 
models and treatment regimes representative of healthy cycling women. Of 
particular interest is the effect on the expression and location of OPN and CD44 
during the window of implantation. OPN and CD44 expression following treatment 
with physiologically relevant concentrations of E2 and P4 was monitored. CD44 
protein expression patterns were detected using IHC. Additionally, secreted OPN 
protein levels were established to determine its expression in relation to the 
adhesion complex as a linker molecule, at the basal levels and in response to E2 and 
P4 treatment. Finally, the direct involvement of ERa in the regulation of these 
expression patterns was monitored using ChlP.
The work presented in this chapter aims to establish an appropriate cell line model 
using physiological E2 and P4 concentrations to mimic conditions in healthy cycling 
women, to determine the regulation of OPN and CD44 by these hormones, and in 
addition to understanding the role of ERa in the expression patterns of these genes 
in Ishikawa and Heraklio cells.
4.2 Results
4.2.1 Basal expression levels in endometrial cell lines
To determine which were the most appropriate cell models for the regulation of 
OPN and its adhesion complex partners, the basal expression of OPN, CD44 and 
aVp3 was investigated in the epithelial endometrial cell lines Ishikawa, Heraklio, 
HEC-1A, HEC-1B and RL925. A suite of techniques was used to determine the basal 
expression level of OPN mRNA, tissue localized protein and secreted proteins. CD44 
expression was determined at the mRNA and protein level. The expression of aVp3 
was investigated at the mRNA level by studying ITGAV and ITGB3. To quantify the
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basal gene expression levels of OPN, CD44 and ITGAV and ITGB3, total RNA was 
extracted from the endometrial epithelial cells Heraklio, Ishikawa, HEC-1A, HEC-1B 
and RL925. All five endometrial epithelial cell lines expressed OPN and its adhesion 
complex partners (Figure 4-1, panels A-E). As anticipated, expression patterns 
differed between the cell lines, with Heraklio displaying the highest expression 
levels of each tested gene relative to the other cell lines. The Ishikawa and Heraklio 
cell lines were chosen for further investigations due to the differential expression of 
genes of interest between the cell lines. These cell lines were selected based on 
their relative expression levels of the adhesion complex components. The cell lines 
are established in the literature to differentially express ERa (and ER|3). These cell 
lines are therefore useful models to relate to endometrial pathology where high 
expression of the adhesion complex components (Heraklio) is present but infertility 
persists where levels of OPN in Ishikawa resemble the fertile women. The 
difference in ER receptor expression allows for investigations into regulation of the 
adhesion complex components by ER.
The highest level of basal (untreated) OPN mRNA expression was in Heraklio cells 
(Figure 4-1). A significant 1000-fold higher expression of OPN was observed in 
Heraklio cells compared to Ishikawa cells (p<0.01). Hec-IA and Hec-IB cells also 
exhibited higher OPN levels than Ishikawa cells; 274 and 556-fold greater 
respectively (p<0.001; p<0.05). RL925 cells expressed significantly less OPN 
compared to Ishikawa (p<0.05).
CD44 was found to be expressed most abundantly in Heraklio cells (Figure 4.1B). 
When compared to Ishikawa expression was 11-fold higher (p<0.01). CD44 
expression in the HEC-IA and HEC-IB cells was 3 and 4-fold higher than Ishikawa 
(p<0.01; p<0.05). Expression of CD44 was also higher in RL925 compared to 
Ishikawa (p<0.01).
The highest expression level of ITGAV was observed in Heraklio cells (Figure 4.1C), 
where expression levels were 2.4-fold higher than in Ishikawa (p<0.01). HEC-IA and 
RL925 cells had similar basal expression levels of ITGAV to Ishikawa cells (p>0.05).
I l l
HEC-IB cells had a 3-fold lower levels of ITGAV expression compared to Ishikawa 
(p<0.05).
ITGB3 was expressed at the greatest level in the Heraklio cells; when compared to 
Ishikawa cells the expression was 12-fold higher (p<0.01) (Figure 4.ID). HEC-IA cells 
showed no significant difference in ITGB3 expression pattern compared to Ishikawa 
cells (p>0.05). ITGB3 expression was significantly lower in both HEC-IB and RL925 
cells (4 and 2054-fold respectively) compared to Ishikawa cells (p<0.001; p<0.001).
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Figure 4-1 Basal OPN and adhesion partner gene expression in EEC lines.
Quantitative PCR was conducted to measure basal gene expression in absolute 
starting quantities of OPN, CD44, ITGAV and ITGB3. Analysis was conducted in five 
ECC lines (A) Ishikawa, (B) Heraklio, (C) HEC-IA, (D) HEC-IB and (E) RL925. All five 
cell lines showed variable expression levels of the four target genes. Values are 
average and SD. Statistical analysis of the data was performed using a Student's t- 
test (e.g. OPN cell line X Vs. OPN cell line Ishikawa). *, P<0.05, ** , P<0.01 and * * * ,  
P<0.001 are considered significant. Results are representative of three biological 
repeats.
4.2.2 Basal expression of osteopontin isoforms
The expression of OPNs five splice isoforms at the mRNA level has not been 
previously characterized in the human endometrium. To assess if the differential
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expression of OPN observed between Ishikawa and Heraklio was due to differences 
in the expression of OPN splice isoforms, each was measured using primers 
designed to specifically amplify each isoform individually (Figure 4-2). The 
expression patterns of the individual isoforms were very similar in both cell lines, 
despite Heraklio cells expressing significantly higher amounts of each isoform, 
Ishikawa is graphed separately to emphasise the difference in scale of expression 
(Figure 4-2B). Isoform D was expressed at the highest level in both cell lines. 
Isoform B had the second highest expression in both cell lines. Levels o f isoform C 
and E were low in both cell lines; both isoforms about 20-fold less than isoform A. 
Due to the similarity in the ratio of isoform expression pattern observed between 
the cell lines primers were designed spanning a region common to all five isoforms 
in order to evaluate total OPN expression in aii subsequent experiments.
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Figure 4-2 Absolute starting quantities of OPN splice isoforms in Ishikawa and 
Heraklio cells.
Quantitative PCR was used to measure basal gene expression of OPN variants 
using isoform specific primers to amplify OPN isoforms A-E in (A) Ishikawa and 
Heraklio (B) Ishikawa alone. Values are average and SD. Statistical analysis of the 
data was performed using a Student's t-test (Isoform X Ishikawa Vs. Isoform X 
Heraklio). No significant differences in the isoform expression pattern were 
observed between the cell lines.
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4.2.3 Basal osteopontin protein expression
Immunohistochemistry and ELISA were conducted to assess the cellular and 
secreted levels of OPN protein in Ishikawa and Heraklio cells (Figure 4-3). OPN 
staining in Ishikawa cells appeared strong in the nucleus and cytoplasm compared 
to  Heraklio cells (Figure 4-3A,B). Ishikawa cells exhibited significantly more nuclear 
and cellular OPN at the basal level when compared to Heraklio cells (p<0.001) 
(Figure 4-3C). The level of OPN secreted by the cells when in culture was 
determined using ELISA. Heraklio cells secreted 370-fold more OPN than Ishikawa 
cells (p>0.01). Secreted OPN levels in Heraklio cells measured 741 ng/mL of OPN, 
compared to 2 ng/mL in Ishikawa cells (Figure 4-3D).
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Figure 4-3 Basal expression of OPN in the Ishikawa cell line.
IHC stained slides for OPN (A) Ishikawa and (B) Heraklio cells. Magnification, X40, 
black scale bar represents 20pm. (C) Nuclear OPN was increased in Ishikawa (H = 
3) compared to Heraklio (H = 2). Cellular component OPN expression increased in 
Ishikawa (H = 4.5) compared to Heraklio (H = 4). (D) Secreted OPN, Heraklio cells 
secreted 370-fold more OPN protein compared to Ishikawa cells (P<0.01). Values 
are average and SD. Statistical analysis of the data was performed using a 
Student's t-test (Ishikawa Vs. Heraklio). * * , P<0.01 and * * * ,  P<0.001 are 
considered significant.
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OPN expression measured at the mRNA level correspond with those found at the 
secreted level for Ishikawa and Heraklio. The intracellular levels are very similar 
between the cell lines and do not reflect this difference in expression. Thus, for the 
remainder of the experiments secreted OPN was used as a measure of protein 
expression.
4.2.4 Basal CD44 protein expression
Immunohistochemistry was conducted on cell lines to measure the basal levels of 
CD44 protein expression (Figure 4-4). CD44 staining in Ishikawa (Figure 4-4A) was 
less abundant than in Heraklio (Figure 4-4B) where expression was clearly identified 
around the cell membrane. H-SCORE analysis showed that Heraklio CD44 
expression (H = 8) was significantly higher than in Ishikawa cells (H = 2; p<0.05) 
(Figure 4-4C).
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Figure 4-4 Basal expression of CD44 in the Ishikawa cell line.
IHC stained slides for CD44 on (A) Ishikawa and (B) Heraklio cells. Magnification, 
X40, black scale bar represents 20pm. (C) Cellular CD44 was 4-fold lower in 
Ishikawa (H = 2) compared to Heraklio (H = 8). Values are average and SD. 
Statistical analysis of the data was performed using a Student's t-test (Ishikawa 
Vs. Heraklio). *, P<0.05 ** , P<0.01 and * * * ,  P<0.001 are considered significant.
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4.3 Hormonal regulation of osteopontin, CD44 and integrin aV63
Having established the basal expression levels for the three target molecules at the 
mRNA and protein levels, the hormonal regulation of these molecules was 
investigated. To better understand any hormonal response, hormone receptor 
expression patterns of ERa, ER[3 and PR were measured at the mRNA level in both 
cell lines (Figure 4-5). ERa expression was undetectable in Heraklio cells compared 
to Ishikawa cells (p<0.05). ERf> expression was significantly higher (2-fold) in 
Heraklio than Ishikawa (p<0.05). PR expression was 12-fold lower in Heraklio cells 
compared to Ishikawa cells (p<0.05). This confirms the ERa negative status of 
Heraklio and suggests that ER$ may play more of a role in signalling in this cell line 
therefore any E2 responses will be attributed to E/?3 in this cell line. Therefore, for 
the remainder of the study, the role of ERa in the regulation of the adhesion 
complex components will be conducted using Ishikawa as a model for ERa +ve 
expression and Heraklio as ERa -ve expression. Ishikawa cells had more prominent 
expression of PR than Heraklio cells (p<0.05).
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Figure 4-5 Basal hormone receptors levels in Ishikawa and Heraklio.
Quantitative PCR was conducted to measure basal gene expression in absolute 
starting quantities of ERa, ER(3 and PR in Ishikawa and Heraklio cells. Significant 
differences in each hormone receptor were observed between Ishikawa and 
Heraklio cells. Values are average and SD. Statistical analysis of the data was 
performed using a Student's t-test (Ishikawa Vs. Heraklio). *, P<0.05, was 
considered significant.
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4.3.1 Hormonal regulation models
During the secretory phase of the menstrual cycle P4 expression is dominant with 
reduced expression of E2. In order to model in vitro the effect of E2 and P4 on the 
regulation of OPN and CD44 during the secretory phase, two in vitro culture models 
were established. The first model tested involved treating cells with E2 (lOnM), P4 
(lOOnM) or E2 and P4 (lOnM; lOOnM) in combination. A 48hr treatment period was 
used to imitate the secretory phase window of implantation. First, to establish the 
effectiveness of hormonal treatments on ER and PR signalling, downstream target 
genes of both signalling pathways were measured in response to estradiol and 
progesterone treatment.
GREB1 is a gene that is activated early in estrogen receptor response to E2 and 
expression has been found in hormone responsive tissues (Hnatyszyn et al. 2010; 
Bourdeau et al. 2004; Stossi et al. 2004). AREG is a progesterone regulated 
paracrine growth factor that is increased in response to PR receptor signalling (Khan 
et al. 2012; Byun et al. 2008). GREB1 expression in Ishikawa cells increased by 8-fold 
following treatment with E2, and 4-fold with E2+P4 in combination (p<0.01; p<0.01) 
(Figure 4-6). Expression of AREG was significantly increased 4.8 and 2.4-fold 
following treatment with P4 alone and E2+P4 (p<0.01). In Heraklio cells, GREB1 
expression was significantly increased by 5.4-fold after E2 treatment and increased 
by 4-fold after E2+P4 (p<0.01). Expression levels of AREG in Heraklio cells increased
3-fold following P4 treatment and 2-fold following E2+P4 treatment (p<0.01; 
p<0.01). After establishing that hormone receptor signalling was active in Ishikawa 
(ERa +ve) and Heraklio cells (ERa -ve), the hormonal regulation of OPN and its 
adhesion partners was investigated. Gene expression levels in Ishikawa (Figure 4-7) 
cells were analyzed in response to the treatment with physiological concentrations 
of E2 and P4. Both cell lines, despite differing ER expression, responded similarly to 
estradiol and progesterone stimulation of known ER and PR target genes.
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Figure 4-6 Gene expression of GREB1 and AREG in response to hormones.
Quantitative PCR was conducted to measure hormone stimulated fold increases 
in GREB1 and AREG in Ishikawa and Heraklio cells. Significant differences in the 
expression levels were observed after treatment with hormones compared to 
control. Values are average and SD. Statistical analysis of the data was performed 
using a Student's t-test (control Vs. treatment). * * , P<0.01, was considered 
significant.
4.3.2 Secretory phase model
Due to the very similar expression patterns observed in both cell lines the secretory 
phase model was initially evaluated using only Ishikawa. In Ishikawa cells (ERa +ve) 
OPN expression was significantly increased 2.6-fold in response to E2 treatment 
alone (p<0.001) (Figure 4-7). P4 treatm ent alone increased OPN expression 1.6-fold 
and when the two hormones were combined an additive effect was observed with 
a 3.3-fold increase in expression (p<0.001; p<0.001 respectively). Similarly, CD44 
expression increased with all three treatments, expression increased 2.3-fold in 
response to E2 alone and 3-fold in response to P4 (p<0.001; p<0.001 respectively). A
4-fold increase in CD44 expression was observed with the combined E2 and P4 
treatment (p<0.001). A similar response was observed w ith ITGAV expression 
where a 2-fold increase was observed after treatm ent w ith E2 alone (p<0.01). When 
treated with P4 alone a 3-fold increase was noted (p<0.001). The combination of
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both hormones increased ITGAV expression 9-fold (p<0.001). ITGB3 expression was 
increased in response to E2 treatm ent by 1.3-fold (p>0.05). A further 2.2-fold in 
response to P4 treatment (p<0.001) and 3.6-fold in response to the combination of 
E2 and P4 treatment in Ishikawa cells (ERa +ve) (p>0.01).
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Figure 4-7 Gene expression of the adhesion complex in response to steroid 
hormone treatments in Ishikawa cells (ERa +ve).
Quantitative PCR was conducted to measure hormone stimulated levels of OPN, 
CD44, ITGAV and ITGB3 in Ishikawa cells (ERa +ve) after 48hrs. Significant 
differences in each gene occur between treatment with hormones and the 
control. Values are average and SD. Statistical analysis of the data was performed 
using a Student's t-test (control Vs. treatment). *, P<0.05 * * , P<0.01, * * * ,  P<0.001 
was considered significant.
4.3.2.1 Secreted osteopontin in response to hormone treatments
To determine the secreted levels of OPN in response to hormone treatments an 
ELISA was conducted using the samples collected after 48hrs. IHC was not 
conducted on treated cells as the basal levels of OPN in both cell lines was high (H =
5-6) therefore detecting any increases from treatm ent would be difficult (
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). Additionally the secreted levels detected reflected the differences found at the 
mRNA level (Figure 4-7). Ishikawa cells showed no increase in OPN expression 
following treatm ent w ith E 2  or P4 treatment (Figure 4-8). Flowever when E 2 + P 4  were 
combined, levels of secreted OPN increased significantly 1.5-fold (p<0.05).
Control E2 lO nM  P4 lOOnM E2 lOnM  +
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Figure 4-8 Secreted OPN levels secretory phase model in Ishikawa (ERa +ve).
ELISA was conducted to measure sex steroid hormone stimulated levels of 
expression of OPN in Ishikawa cells (ERa +ve). Values are average and SD. 
Statistical analysis of the data was performed using a Student's t-test (control Vs. 
treatment). *, P<0.05 was considered significant.
4.3.2.2 CD44 protein expression
CD44 protein expression was assessed by IHC in response to sex steroid hormone 
treatments (Figure 4-9). CD44 staining in Ishikawa cells (ERa +ve) was stronger in 
response to E2+P4 treatment. E2treatment increased CD44 protein expression 2-fold 
however this increase was not significant (p>0.05). P4 treatm ent increased CD44 
expression 2.8-fold however this increase was not significant (p>0.05).
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Figure 4-9 Ishikawa (ERa +ve) expression of CD44 protein in response to sex 
steroid hormone stimulation after 48hrs.
IHC was used to semi-quantitatively assess the effect of hormones on CD44 
protein expression. CD44 protein H-SCORE for Ishikawa cells (ERa +ve indicated 
that CD44 expression increased with treatment regimes however only the 
treatment with E2+P4 was significant. Values are average and SD. Statistical 
analysis of the data was performed using a Student's t-test (control Vs. 
treatment). *, P<0.05 was considered significant.
4.3.3 Estrogen priming model
An alternate model that aimed to mimic in vitro  the complete menstrual cycle from
proliferative to secretory phase, involving E2 and P4 signalling prior to and during
the window of implantation was investigated. This was done in order to determine
whether early signalling effects in the cycle had an important role in regulating the
expression of the adhesion complex components. Ishikawa cells (ERa +ve) were first
primed with E2 (lOnM) for a 24hr period and then treated with P4 (lOOnM) or E2+P4
(lOnM;lOOnM) for a further 48hrs. This treatment regime attempted to recreate
the up-regulation in E2 signalling in the proliferative phase of the menstrual cycle
before P4 signalling becomes predominant in the secretory phase (Figure 1-5).
Treatment with P4 post priming represents the physiological E2 and P4 levels in the
early secretory phase. Treatment with E2+P4 post priming was representative of the
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mid- and late- secretory phase. The adhesion complex gene targets were analyzed 
in the estrogen primed model in Ishikawa cells (ERa +ve) previously shown to 
respond to hormones (Figure 4-10). OPN expression increased 1.3-fold after E2 
priming alone and 1.2-fold after E2 priming followed by lOOnM of P4, however these 
expression changes were not significant (P>0.05; P>0.05 respectively). A 1.3-fold 
increase in OPN was observed after E2 priming and the combination treatment of 
E2+P4, which was not significant (p>0.05). CD44 expression was significantly 
increased by all treatment regimes. CD44 was increased 1.7-fold by E2 priming 
alone (P<0.01). A 1.9-fold increase was observed after treatment to E2 priming plus 
lOOnM of P4 (p<0.01). After E2 priming and the combination of E2 and P4 a 
significant 2.2-fold increase in CD44 expression was observed (p<0.05). ITGAV 
expression in Ishikawa cells (ERa +ve) was increased in the E2 priming model. E2 
priming alone increased ITGAV expression 1.2-fold, however this was not significant 
(p>0.05). E2 followed by P4 treatment, significantly increased ITGAV expression 2.5- 
fold (p<0.01). E2 combined with P4 following E2 priming significantly increased 
ITGAV expression 1.6-fold (p<0.01). ITGB3 expression is unchanged with E2 priming 
alone however after exposure to lOOnM of P4 ITGB3 expression is significantly 
increased 1.7-fold (p<0.01). When E2 and P4 were combined after priming ITGB3 
expression was significantly decreased 2-fold compared to the control (p<0.01).
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Figure 4-10 Ishikawa cell (ERa +ve) gene expression in response to E2 primed 
model.
Quantitative PCR was conducted to measure hormone stimulated levels of 
expression of OPN, CD44, ITGAV and ITGB3 in Ishikawa cells after 72hrs. 
Significant differences in each gene occur between treatment with hormones and 
the control. Values are average and SD. Statistical analysis of the data was 
performed using a Student's t-test (control Vs. treated). *, P<0.05 * * , P<0.01, was 
considered significant.
4.3.3.1 Secreted osteopontin expression
Cells were first primed with E2 for 24hrs and then exposed to E2 or P4 alone or in 
combination for 48hrs (Figure 4-11). Secreted OPN, was measured by ELISA and was 
found to have increased 1.2-fold in response to treatm ent with E2 priming alone 
(p<0.001). Post priming treatm ent with P4 alone for 48hrs resulted in a 1.2-fold 
decrease in secreted OPN expression (P<0.001). No significant changes were 
observed in secreted OPN with the combination of E2+P4 after priming (p>0.05).
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Figure 4-11 Secreted OPN levels in response to E2 primed model in Ishikawa.
The ELISA technique was conducted to measure hormone stimulated levels of 
expression of OPN in Ishikawa cells. Significant differences in each gene occur 
between treatment with hormones and the control. Values are average and SD. 
Statistical analysis of the data was performed using a Student's t-test (control Vs. 
treated). *, P<0.05 **, P<0.01, was considered significant.
4.3.3.2 Intracellular CD44 expression
CD44 protein expression was assessed by IHC in response to sex steroid hormone 
treatments (Figure 4-12). CD44 staining in Ishikawa (ERa +ve) was stronger in 
response to all treatments, however these expression changes were not significant 
(p>0.05). In response to E2 priming CD44 expression increased 1.4-fold (H = 8.5) 
when compared to the control (p>0.05). Treatment with P4 after E2 priming 
increased CD44 expression 1.3-fold (H = 8), however treatm ent with E2+P4 after E2 
priming further increased CD44 expression 1.6-fold (H = 9.5) (p>0.05; p>0.05).
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Figure 4-12 CD44 protein expression in Ishikawa cells (ERa +ve) in response to E2 
primed model.
IHC was used to semi-quantitativeiy assess the effect of hormones on CD44 
protein expression. Values are average and SD, statistical analysis of the data was 
performed using a Student's t-test (control Vs. treatment) data are representative 
of three biological repeats.
4.3.4 Heraklio (ERa -ve) hormone regulation
The Ishikawa (ERa +ve) cell line showed greater increased expression of the 
adhesion complex components after the secretory phase treatment regime. 
Therefore, this treatment regime was used to establish the requirement for ERa 
and any role of ER(3 in the regulation o f the adhesion complex. To achieve this 
Heraklio (ERa -ve) cells were treated with identical concentrations and treatm ent 
periods (Figure 4-13), and a markedly different response to hormone stimulation 
was observed when compared to Ishikawa (ERa +ve). OPN mRNA expression in the 
Heraklio cell line was 10-50-fold greater depending on the specific treatm ent than 
the other adhesion complex components. For this reason OPN is graphed 
separately (Figure 4-13A). OPN expression was significantly increased 1.2-fold after 
treatm ent with E2 alone and with the combination of E2 and P4 (p<0.05). This 
increase was much less than that observed in Ishikawa in terms of fold change. This 
suggests an important role for ERa in the regulation of OPN. CD44 expression was
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significantly decreased when exposed to E2 alone and w ith the combination of E2+P4 
(p<0.05) (Figure 4-13B). ITGAV expression was significantly decreased by 1.5 fold in 
response to  E2 (p<0.01). In the presence of P4, ITGAV expression increased 1.4-fold 
and with the E2+P4 combined treatm ent by 1.5-fold (p<0.01; p<0.01 respectively). 
No changes in ITGB3 expression were observed in Heraklio cells.
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Figure 4-13 Gene expression analysis of OPN and its complex targets in the 
Heraklio (ERa -ve) model of secretory phase endometrium.
Quantitative PCR was conducted to measure hormone stimulated levels of 
absolute starting quantities of OPN, CD44, ITGAV and ITGB3 in Heraklio cells. 
Significant differences in each gene occur between treatment with hormones and 
the control. Values are average and SD. Statistical analysis of the data was 
performed using a Student's t-test (control vs. treatment). *, P<0.05 ** , P<0.01, 
was considered significant.
4.3.4.1 Secreted osteopontin expression
In Heraklio cells, secreted OPN levels altered following all treatments (Figure 4-14). 
Treatment with P4 alone resulted in a decrease o f 1.7-fold in the level of secreted 
OPN (p<0.05). This was consistent with the trend observed at the mRNA level. The 
combination of E2+P4, increased secreted OPN levels 1.6-fold (p<0.05). Whilst E2 
treatment resulted in an increase similar to E2+P4, this increase was not significant.
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The general trends seen at the secreted protein level reflect the trends observed at 
the mRNA level after each treatment.
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Figure 4-14 Secreted OPN expression levels in a secretory phase model in Heraklio 
(ERa -ve) cells.
ELISA was conducted to measure hormone stimulated levels of expression of OPN 
in Heraklio cells. Significant differences in each gene occur between treatment 
with hormones and the control. Values are average and SD. Statistical analysis of 
the data was performed using a Student's t-test (control vs. treatment). *, P<0.05, 
was considered significant.
4.3.4.2 CD44 protein expression
CD44 protein expression in response to the secretory phase treatm ent regime in 
Heraklio (ER(3 +ve) cells (Figure 4-15) was considerably different to the response in 
Ishikawa (ERa +ve). In response to E2 treatment, CD44 expression decreased 1.2- 
fold (H = 7) when compared to the control (H = 8.5). However, this was not 
significant (p>0.05). Treatment with both P4 alone and in combination with E2 
decreased CD44 expression 1.3-fold (H = 6.5), this decrease in expression was not 
statistically significant (p>0.05; p>0.05 respectively).
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Figure 4-15 CD44 protein expression in a secretory phase model in Heraklio (ERa - 
ye) cells.
IHC stained slides for CD44 protein expression in response to secretory phase 
model treatments in Heraklio cells (ERa -ve). Values are average and SD. 
Statistical analysis of the data was performed using a Student's t-test (Control Vs. 
treatment), data are representative of three biological repeats.
4.4 Osteopontin and CD44 promoter analysis
The hormonal regulation models of adhesion complex components suggested that 
OPN and CD44 were most responsive to hormone stimulation in Ishikawa cells, 
which could be a result of ERa expression. The Heraklio cell line had negligible 
expression levels of ERa suggesting that ER(3 may have a more prominent role in 
the Heraklio cell line. It should also be noted that the levels of OPN in Heraklio were 
very high (>300-fold) than in Ishikawa, suggesting a very different mode of 
regulation. Therefore to understand the regulation of OPN and CD44 in the 
Ishikawa cell line by ERa, a promoter analysis was conducted to establish which ERE 
existed on each gene's promoter (Figure 4-16 and Figure 4-17). Following this, ChIP 
was conducted to measure the transcriptional activity of estrogen response 
element on the OPN and CD44 promoters at the basal level in Ishikawa. The absent 
ERa in the Heraklio cell line allowed for this to be used as a background control.
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4.4.1.1 Osteopontin promoter
Analysis of the OPN promoter revealed 7 putative and 1 previously described 
regulatory element (site 2) (Sharma et al. 2010; Wang et al. 2000a; Bidder et al. 
2002) that qPCR primers were designed to amplify (Figure 4-16). Primers sets were 
designed to amplify 4 regions on the OPN promoter that contained 2 ERa, 6 AP-1 
and 1 SP-1 spanning from -2.7KB to -200bp before the translation start site in exon 
4. Each primer set is identified by a site (Figure 4.16, sites 1-4).
Osteopontin
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Figure 4-16 Promoter analysis of the human OPN gene.
The OPN promoter was analysed for ERa, AP-1 and SP-1 binding sites, -3KB from 
the translation start site to +0.5KB after the start site. Primers were designed to 
amplify two putative regulatory elements for ERa, five for AP-1 and one SP-1 
element.
4.4.1.2 CD44 promoter
The CD44 promoter included 5 putative ER regulatory elements that primers were 
designed to amplify (Figure 4-17). The CD44 promoter contained fewer estrogen 
responsive elements than OPN and primers were designed to amplify regions 
containing 2 putative regulatory elements for ERa, 1 AP-1 site in addition to one SP-
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1 site. Each primer set is identified by a site (Figure 4.17, sites 1 and 2). The CD44 
promoter contained estrogen regulatory elements downstream of the translation 
start site in exon 1.
CD44 CD44 PROTEIN
CD44 GENE
'5KB 105KB
Figure 4-17 Promoter analysis of the human CD44 gene promoter.
The CD44 promoter was analysed for ERa, AP-1 and SP-1 binding sites, -2KB from 
the translation start site to +1KB after the start site. Primers were designed to 
amplify two putative sites for ERa, two for AP-1 and one for SP-1.
4.4.2 Chromatin immunoprecipitation
To validate the enrichment of chromatin (Figure 4.18) a high abundance target, 
RNA polymerase II was selected and qPCR primers designed to determine binding 
to a known site on the GAPDH promoter (Figure 4-19A). Polymerase II enrichment 
showed no difference between the two cell lines, demonstrating consistent 
regulation between cell lines of a positive control target. ERa recruitment to a 
region of the promoter sequence of X-box binding protein (XBP1), a known ERa 
target, was also evaluated. ERa enrichment clearly demonstrated in the ERa66 
Ishikawa cells, and as expected no recruitment was seen in Heraklio cells which are 
ERa -ve (Figure 4-5).
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Figure 4-18 Sheared chromatin from Heraklio cells.
1% agarose gel of sheared chromatin from Heraklio cells using 800R sonicator 
(QSonica, UK). The first lane on the left has a 1KB ladder, the next four lanes show 
the fragment sizes of sheared chromatin ranging from 800-100bps.
Ishikawa Heraklio Ishikawa Heraklio
Figure 4-19 Chromatin immunoprecipitation for positive control targets.
Quantitative PCR was conducted on GAPDH and XBP1 promoter regions for Pol II 
or ERa occupancy respectively. Values are average and SD for Pol II and fold for 
ERa.
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4.4.2.1 ChIP for estrogen receptor a  on osteopontin promoter regions
ERa ChIP was performed for the sites identified (Figure 4-16 and Figure 4-17) in the 
OPN and CD44 promoters (Figure 4-20 and Figure 4-21). Heraklio (ERa -ve) was 
used to establish background IP levels as it does not express ERa for the Ishikawa 
(ERa +ve) cell line. The binding sites in the first ERa site (containing ERa/AP-l/AP-1 
elements approximately 2.5K upstream) identified in this study are 
indistinguishable by ChIP due to its 500bp resolution. There was a 25 fold increase 
in ERa recruitment signal in Ishikawa. This indicates that ERa is recruited to these 
sites even in the absence of E2. In contrast at site 2 containing a previously 
identified SP-1 regulatory element at approximately 2KB upstream (Wang et al. 
2000a; Sharma et al. 2010) no recruitment of ERa was observed. Sites 3 and 4 also 
showed no occupancy. Therefore a novel binding site for ERa on OPN has been 
identified. High resolution mapping would be necessary to determine the exact 
binding site.
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Heraklio 
■ Ishikawa
Site 4
Figure 4-20 ERa chromatin immunoprecipitation on the OPN promoter.
Quantitative PCR was conducted for ERa on OPN promoter to measure, in fold, 
ERa occupancy in Ishikawa (ERa +ve) normalised to Heraklio (ERa -ve). Values are 
fold normalised to Heraklio (ERa -ve).
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4.4.2.2 CD44 estrogen receptor a  chromatin immunoprecipitation
Similar ChIP analysis was conducted for ERa on the CD44 promoter in the Ishikawa 
(Figure 4-21). For the first set of regulatory sites, there was a significant increase in 
ERa recruitment by 9-fold to the CD44 promoter in Ishikawa cells, and an 8-fold 
increase in the binding levels of the second set of sites between the cell lines. 
Again, a novel binding site for ERa has been identified, this time in the CD44 
promoter at approximately 2KB upstream. High resolution mapping would be 
necessary to determine the exact site involved in ERa recruitment.
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Figure 4-21 ERa chromatin immunoprecipitation on the CD44 promoter.
Quantitative PCR was conducted for ERa on CD44 promoter to measure, in fold, 
ERa occupancy in Ishikawa (ERa +ve) normalised to Heraklio (ERa -ve). Values are 
fold normalised to Heraklio (ERa -ve).
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4.5 Discussion
The work conducted in this chapter aimed to determine if OPN and CD44 
expression in the endometrial epithelium was regulated by the ovarian derived 
hormones, estrogen and progesterone. The cell lines Ishikawa and Heraklio were 
utilised to deduce the role of ERa and possible contribution of ERp in the estrogen 
signalling pathway regulation of the adhesion complex components. They were also 
used to determine potential contributions of PR signalling. Both cell lines were 
shown to have active estrogen and progesterone signalling by measuring 
downstream targets of ER and PR signalling GREB1 and AREG. GREB1 induction at 
48hrs through the ERa and ERp receptors are consistent with previous reports 
(Stossi et al. 2004). In the secretory phase model, induction of OPN and CD44 
through E2 and P4 signalling in the Ishikawa cell line saw larger fold changes in gene 
expression than in the Heraklio cell line. It is important to note that aV(33 was used 
only in the regulation studies, it has been well documented in the literature and 
served to provide a control for hormone induction in cell lines.
The first important observation of the adhesion complex components was the 
differential basal expression levels in Ishikawa (ERa +ve) and Heraklio (ERP +ve) 
cells. The high levels of ERa in the Ishikawa cell line (or more prominent ER(3 
expression in the Heraklio cell line suggests a role in the regulation of the adhesion 
complex components; OPN, CD44 and aVP3) correlate with decreased adhesion 
complex expression. Basal expression levels of OPN and CD44 in the cell lines 
Ishikawa and Heraklio differed markedly. Low expression patterns were observed in 
the Ishikawa cell line, and very high levels of expression for OPN were observed in 
the Heraklio cell line which correlate with hormone receptor expression in each cell 
line. Ishikawa cells expressed ERa, whereas ERp was predominately expressed in 
Heraklio. PR expression was observed in both cell lines with the Ishikawa cell line 
expressing higher levels of PR.
When the cell lines were treated with hormones, OPN expression in the Ishikawa
cell line was significantly increased by lOnM of estradiol (2.6-fold) in agreement
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with previous work (DuQuesnay et al. 2009). OPN mRNA has been shown to localise 
to the glandular epithelium of the sheep endometrium, upon stimulation with 
progesterone. The study hypothesised that PR had a function in regulating OPN 
however a down-regulation of PR in the epithelium is required for secretory glands 
to up regulate protein expression of OPN (G. Johnson et al. 2000).
Different expression in the OPN isoforms between the cell lines was ruled out as a 
cause of this differential expression pattern. The relative expression levels of OPN 
isoforms A-E were similar between the two cell lines whilst the expression in 
Heraklio was higher overall, although the expression levels of OPN were ~300-fold 
greater in Heraklio than Ishikawa. To explore these interesting findings, ChIP was 
conducted to establish if ERa binding to the promoter regions of both genes 
differed between the cell lines. Distinct patterns of ERa, AP-1 and SP-1 regulatory 
elements were observed on the OPN and CD44 promoters in Ishikawa, with the ERa 
negative cell line Heraklio used as a background control. Site 1 on the OPN 
promoter had significantly increased ERa binding in Ishikawa. This site flanks a 
previously identified site (Site 2) shown active through luciferase and 
electrophoretic gel shift assays (Sharma et al. 2010; Wang et al. 2000a). However 
no ERa binding was detected in either of the cell lines on this site of the OPN 
promoter. Sites 3 and 4 also had no ERa occupancy as they had the same 
occupancy in both ERa +ve and ERa -ve cells.
It appears that ERa plays a very prominent role in the regulation of OPN. The 
presence of ERa in cells maintains OPN at very low levels. However treatment of 
these ERa +ve cells with E2 causes an increase in the expression of OPN. ERa may 
therefore modulate OPN expression by activating the expression of a potent 
repressor of OPN expression which E2 treatment counteracts. This has been 
observed by the increased levels of ERa binding to the OPN promoter in Ishikawa 
cells (Figure 4-20), in addition to the increase in OPN expression as a result of E2 
treatment (Figure 4-7). To determine which of the three potential sites (ERa, AP-1
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or SP-1) ERa is binding to, high resolution EMSA mapping or promoter detection 
analysis could determine the precise binding sites.
ChIP analysis also revealed that the CD44 promoter was occupied ERa, where it was 
observed bound to site 1 and site 2 in Ishikawa cells. These novel sites suggest that 
ERa also plays an important role in the regulation of CD44 in endometrial cells. 
Again the data suggests that ERa maintains CD44 expression at low levels as CD44 
expression was ~ 10-fold higher in ERa -ve Heraklio cells. This repression is likely to 
be indirect, as treatment in Ishikawa cells with E2 results in increased CD44 
expression (Figure 4-7).
CD44 expression has been shown previously to be up-regulated in ER negative 
breast cancer cell lines (Hole et al. 1997). However it is also possible that the affect 
observed is ER|3 driven.
The hormone driven regulation of OPN, CD44 and other adhesion complex 
molecules has been shown here. Whilst E2+P4 drive only subtle changes in 
expression of these target molecules, it is likely that they play an important role in 
preparing the endometrial surface in a receptive state. Excitingly novel 
ERa regulatory elements have been identified in the promoters of both OPN and 
CD44 genes. Further characterisation of these elements in clinical samples using 
emerging technologies such as formalin fixed paraffin embedded tissue for ChIP 
analysis will determine their importance in the endometrium. It would be possible 
to establish if any differences through this potential regulatory mechanism can be 
detected in fertile and infertile women.
Chapter 5
Glucose and
pro-inflammatory cytokine 
regulation of Osteopontin
and CD44
5.1 Introduction
The hormone driven process of the regenerative menstrual cycle has parallels to 
that of the inflammatory response in tissues. The changes that occur in the vascular 
compartment of the endometrium mirror that of the inflammatory response in 
tissue regeneration (King and Critchley 2010). Migratory peripheral blood 
leukocytes such as monocytes and tissue resident macrophages that differentiate 
form monocytes have also been shown to have a role on the epithelial surface to 
protect the epithelium from pathogen invasion in addition to communicating with 
the epithelium to maintain its integrity (Sze et al. 2010). Monocytes and 
macrophages expressed on the epithelial surface have the ability to phagocytose 
pathogens, whilst other mechanisms for pathogen defence involve steric hindrance, 
provided by mucins, which are also expressed on the luminal epithelial surface 
(Ransohoff et al. 2003; Dechaud et al. 1998).
Noyes first described immune cell trafficking into the endometrium during the 
secretory phase in 1950. In the mid to late secretory phase macrophages and 
natural killer cells have been found to accumulate in the tissue. It has been 
hypothesized by Mueller et al that cyclic recruitment and turnover of uterine 
immune cells is achieved through endocrine signals inducing chemokines and 
immunomodulatory proteins (Mueller et al. 2000).
Cytokines released by the leukocytes such as monocytes, macrophages and 
lymphocytes include TNFa, IL-lp and IFNy (Bliss et al. 1999; Cole et al. 2007). In the 
endometrial vasculature monocytes have shown to increase secretion of cytokines 
IL-lp and TNFa after ovulation in the menstrual cycle in healthy, cycling women 
(Willis 2003; Desai 2007). This suggests that the epithelial and stromal cells are 
surrounded by cytokine expressing leukocytes (Figure 5-1). The resulting paracrine 
signalling through the stroma and epithelial components in the endometrial tissue 
may have consequences on the expression of adhesion proteins on the epithelial 
surface. Expression of cytokines such as TNFa and IL-ip have been shown during
the implantation process and these are thought to aid uterine receptivity however 
the function of these cytokines is yet to be elucidated (Makrigiannakis et al. 2006).
Lumen
Epithelium
Capillaries
Glands
Functional layer 
Leukocytes
Myometrium
Uterine artery
Figure 5-1 Leukocyte expression in the uterus.
Leukocyte expression on the luminal epithelia and in the epithelia tissue. 
Leukocytes such as monocytes (shown in green) migrate from the circulatory 
blood into the endometrial tissue where they mature into macrophages. Adapted 
from (The Feria Journal of Medicine, 2011).
Pro-inflammatory cytokines have also been shown to be up regulated in 
endometrial pathology (Weiss et al. 2009). Peritoneal fluid in women with 
endometriosis showed an increased level of white blood cell populations and 
specifically macrophages and these are thought to be linked with endometriosis- 
associated pelvic inflammation. Peritoneal fluid aspirated from women with 
endometriosis during laparoscopy had increased levels of pro-inflammatory 
cytokines IL-1 and TNFa (Taketani et al. 1992; Fakih et al. 1987; Montagna et al. 
2008). Similarly, another study indicated that peritoneal levels of TNFa could be 
used to predict endometriosis in women (Bedaiwy et al. 2002). Levels of TNFa have
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been shown to be increased in circulating blood of patients suffering with 
endometriosis, which may lead to increased TNFa induced proliferation, cell 
adhesion or angiogenesis. Further to this endometriotic lesions have been found to 
secrete TNFa and IL-1 (Kyama et al. 2003).
Women with PCOS have been found to have elevated levels of C-reactive protein, a 
standard test for inflammation (Ruan and Dai 2009; Kelly et al. 2001). Described as 
a low-grade inflammatory disorder, higher levels of TNFa and IL-6 have been found 
in circulating blood and follicular fluid in women with PCOS when compared to 
healthy, fertile controls (Amato et al. 2003).
Insulin resistance, commonly associated with PCOS is often found to exacerbate the 
syndrome along with other metabolic disorders including obesity and elevated 
fasting plasma glucose (Fanta 2013; Essah et al. 2007). In hyperglycaemic conditions 
(10 and 15mM), as experienced by a sub-set of PCOS women, TNFa expression is 
increased in the mononuclear cells isolated from peripheral blood of obese 
(ovulating, oligoamenorrhea) PCOS women (Gonzalez et al. 2006). A study 
conducted to measure circulating TNFa levels in PCOS women had found that as 
BMI increased, TNFa expression too increased when compared to BMI matched 
fertile controls (Gonzalez et al. 1999). The interplay between inflammatory and 
metabolic environments in PCOS and endometriosis women suggest that they may 
be key in influencing the expression of the adhesion complex. Chronic exposure to 
TNFa has been shown to decrease functionality in GLUT4 or to decrease the levels 
of transporter proteins for example (Gonzalez et al. 1999).
Over expression of adhesive proteins which could impact on the receptivity of the 
endometrium during the window of implantation has been suggested as a factor 
impacting receptivity in endometrial pathology (Weiss et al. 2009). OPN has been 
shown to be up-regulated in the blood plasma of inflammatory diseases such as 
Crohn's disease (Agnholt et al. 2007) and cancer (El-Tanani et al. 2006). The 
expression of OPN has been shown to be modulated by IL-1(3, TNFa and IFNy 
cytokines in pancreatic cells of rat cell line models (Gong et al. 2009b; Foster et al.
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1998). IL-lp, TNFa and IFNy have all been shown to up-regulate the expression of 
CD44 at the gene level in rat aortic smooth muscle cells (Foster et al. 1998). 
Additionally OPN and CD44 expression has been shown to be directly or indirectly 
(as discussed in section 1.9.3) regulated by glucose expression in many different 
tissues (Kawamura et al. 2004; Takemoto et al. 2000; Tamada et al. 2012; Weiss et 
al. 2008). Shown to be associated with disrupted metabolic environments and high 
BMI, PCOS women have complications such as insulin resistance (Dunaif et al. 1989; 
Legro et al. 1998; Tan et al. 2010).
Differential OPN and CD44 expression was detected in the target pathology groups 
of this study, at both the mRNA and protein level (Chapter 3), leading to an 
investigation into the uterine environments of these patients. Cell culture models 
(Chapter 4) indicated that estradiol and signalling through ERa is important in the 
regulation of OPN and CD44. Other studies show that a decrease in the circulating 
blood levels of IL-lp and IL-6 were found to coincide with an increase in E2 levels, 
suggestive of a link between E2 signalling and inflammation (Pellicer et al. 1999).
In this chapter, the role of altered glucose and pro-inflammatory cytokine 
environments on levels of OPN and CD44 expression are investigated in an in vitro 
model. Glucose concentrations and time course experiments were chosen based on 
the study conducted by Gong et al., 2009, which had shown modulation of OPN 
expression. The glucose levels chosen also reflect those in previous studies and are 
matched to distinct physiologies. Concentrations of 5.6mM are considered the cut 
off for detecting abnormal glucose tolerance in PCOS women therefore the 5mM 
concentration represents healthy non diabetic women (Gagnon and Baillargeon 
2007). The World Health Organisation classes fasting glucose levels over 7mM as 
diabetic (type II) (Heuck et al. 2002) and represented in this study by 17mM a 
heightened level of glucose as in diabetics, where 25mM represents an extreme 
level and serves as a positive control level proven to initiate an OPN response (Gong 
et al. 2009b). The Ishikawa and Heraklio cell line were treated with varying
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concentrations of glucose and the effect on OPN and CD44 expression quantified by 
qPCR, IHC for CD44 and ELISA for secreted OPN.
Both cell lines are also grown in the presence and absence of pro-inflammatory 
cytokines (IL-lfS, TNFa and IFNy), according to previous studies conducted to 
investigate expression of adhesion molecules in the endometrium (Dharmaraj et al.
2010). After establishing the effect of pro-inflammatory cytokines on OPN and CD44 
expression, investigation into the regulatory mechanisms of these genes was 
conducted. NFkB and STAT1 are transcription factors activated through IL-1(3, TNFa 
and IFNy signalling. The promoters of OPN and CD44 were analysed, revealing 
regulatory elements for both NFkB and STAT1 binding within both the promoters of 
OPN and CD44 respectively.
5.2 Results
5.2.1 Glucose regulation of osteopontin and CD44
Glucose concentrations of 4-7.8mM in the blood after eating are observed in 
healthy patients and are considered to be normal, while patients with Type II 
diabetes can experience levels up to 25mM (Kelly et al. 2001; American Diabetes 
Association 2011). To assess the effect of these altered glucose levels on OPN and 
CD44 expression, Ishikawa and Heraklio cells were grown in culture media 
supplemented with 5, 17 and 25mM of glucose respectively. The lowest dose of 
5mM replicating the situation in normal, healthy, non-diabetic women and higher 
than normal levels (17 and 25mM of glucose), to mimic the conditions of insulin 
resistance observed in those with type II diabetes (American Diabetes Association
2011). OPN and CD44 expression levels were assessed at the gene and protein 
level, with secreted OPN protein measured using ELISA, while the intracellular 
expression of CD44 was measured using IHC.
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5.2.2 Osteopontin gene expression
No significant alteration in OPN expression at the RNA level was observed in 
Ishikawa cells in the presence of 17mM glucose at 4 or 24 hours compared to the 
5mM reference treatment (Figure 5-1). When higher levels of glucose (25mM) were 
present, a significant increase in OPN expression was detected after 4hrs (p=0.006) 
and this effect was not observed after 24hrs. In the Heraklio cell line OPN mRNA 
expression levels showed a significant 2.6-fold increase after a 4-hour treatment 
with 25mM of glucose compared to the normal levels (5mM of glucose; p=0.0001). 
After twenty-four hours however, this effect was lost, with OPN expression showing 
no significant alteration in the presence of either 4 or 25mM of glucose.
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Figure 5-2 OPN gene expression in endometrial epithelial cell lines following 
glucose treatment.
Quantitative PCR was conducted to measure the levels of OPN expression in 
response to 5mM, 17mM and 25mM of glucose for 4 and 24hrs in (A) Ishikawa 
and (B) Heraklio. Values are average and SD of a minimum 3 independent 
biological repeats. Statistical analysis of the data was performed using a Student's 
t-test (control Vs. treatment). * * , P<0.01 and * * * ,  P<0.001 are considered 
significant.
Under basal conditions, grown in the presence of normal (5mM) levels of glucose, 
the ERa Heraklio cells demonstrated significantly higher levels of OPN expression at
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the mRNA level (100-fold; p<0.0001). This suggests that the observed glucose 
response is likely to be ERa independent. Despite the observed expression pattern, 
the levels of OPN were reduced after 24 hours, even at the higher glucose 
concentration, suggesting a short lived temporal effect.
5.2.3 Secreted osteopontin expression
The ELISA method was used in order to establish the basal levels of OPN protein 
secretion from both cell lines and to compare them to those observed in the 
presence of increasing glucose concentrations over both a 4 and 24hr period. This 
allowed the comparison between secreted protein expression levels and those 
observed at the RNA level.
In contrast to the RNA level, secreted OPN levels decreased in the presence of 
increasing concentration of glucose, in both cell lines (Figure 5-3). In the ERa +ve 
Ishikawa cells levels of secreted OPN following 24hrs increased ~5-fold from when 
compared to the 4hr group in the presence of all glucose concentrations. While the 
presence of 17mM of glucose did not significantly alter levels of OPN expression at 
4 or 24 hours, secreted OPN showed significant decreases (2 and 1.4-fold 
respectively) in response to treatment with 25mM of glucose, when compared 
directly to the 5mM reference point (p=0.03; p=0.02).
No significant change in secreted OPN levels were detected in the ER(3 +ve Heraklio 
cell line after four hours in the presence of either 17 or 25mM glucose (Figure 5-3B; 
p>0.05). A significant 17-fold increase in secreted OPN was observed after 24hrs in 
the presence of all glucose concentrations. At twenty-four hours the levels of OPN 
were significantly decreased by both 17mM and 25mM (1.5 and 1.4-fold 
respectively) relative to 5mM sample (p=0.001; p=0.001).
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Figure 5-3 Secreted OPN expression in endometrial epithelial cell lines following 
glucose treatment.
The ELISA technique was conducted on cell supernatants to measure the levels of 
secreted OPN expression in response to treatment with 17mM and 25mM of 
glucose for 4 and 24hrs in (A) Ishikawa and (B) Heraklio. Glucose levels at 5mM 
are used as the reference point. Values are average and SD. Statistical analysis of 
the data was performed using a Student's t-test (control Vs. treatment). *, P<0.05, 
* * , P<0.01 and * * * ,  P<0.001 are considered significant.
5.2.4 CD44 expression
CD44 expression was investigated at the RNA level, in order to further understand 
the role o f increased glucose concentration, relative to that observed in PCOS 
patients with increased BMI, on its regulation. The levels of CD44 mRNA were 
analysed by qPCR differences in ERa +ve (Ishikawa) and ER(3 +ve (Heraklio) cells in 
response to glucose (Figure 5-4).
Similar to OPN, the expression levels of CD44 detected were significantly 10-fold 
higher in the ERa -ve Heraklio cells when compared to Ishikawa cells (p<0.0001). In 
the Ishikawa cell line the levels of CD44 detected in the presence of 5mM glucose 
decreased after twenty four hours when compared to 4hrs (Figure 5-4A). Significant 
increases in CD44 expression (1.4 and 1.3-fold respectively) were detected in the 
presence of 17mM and 25mM of glucose for 4hrs (p=0.006; p=0.01). At 24 hours
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Figure 5-4 CD44 gene expression in ERa +ve and ERa -ve cells following glucose 
treatment.
Quantitative PCR was conducted to measure the levels of CD44 expression in 
response to 5mM, 17mM and 25mM of glucose for 4 and 24hrs in (A) Ishikawa 
ERa +ve and (B) Heraklio ER(S +ve. Values are average and SD. Statistical analysis 
of the data was performed using a Student's t-test (control Vs. treatment). *, 
P<0.05, ** , P<0.01 and * * * ,  P<0.001 are considered significant.
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5.3 Cytokine regulation o f osteopontin and CD44
Pro-inflammatory cytokines IL-ip, TNFa and IFNy were chosen to study their effect 
on the regulation of OPN and CD44, due to their increased expression in women 
with infertile pathologies such as PCOS and endometriosis. Again to assess the role 
of ERa and ERP signalling in inflammatory environments the cell lines Ishikawa and 
Heraklio cells were used and grown in the presence of IL-lp, TNFa and IFNy alone 
or in combination. Cells were exposed to cytokines for 48hrs and qPCR was used to 
quantify OPN and CD44 expression at the RNA level. Once again, ELISA technology 
was used to determine secreted OPN levels while IHC was used to determine the 
protein expression levels of CD44.
5.3.1 Osteopontin gene expression
Ishikawa cells were treated with IL-lp over a forty eight hour period, showed a 
significant 1.4-fold decrease in OPN expression at the RNA level compared to the 
| untreated control (p<0.05; Figure 5-5A). Similarly, a 4-fold decrease in OPN
I
expression was observed following treatment with TNFa for 48hr compared to the 
untreated control (p<0.001). No significant effect on OPN expression was observed 
in the Ishikawa cells when treated with IFNy alone (p>0.05). When treated with 
! combinations of cytokines, differential OPN expression patterns were observed,
suggesting that multiple signalling pathways may affect OPN regulation in these 
cells. TNFa treatment in combination with IFNy resulted in a significant 2-fold 
down-regulation of OPN expression at the RNA level (p<0.001), suggesting that IFNy 
is capable of suppressing the effect of TNFa alone. IL-ip treatment in combination 
with TNFa and IFNy resulted in a significant 3-fold reduction in OPN expression 
compared to the untreated control (p<0.001) and interestingly enhanced the effect 
compared to IL-ip treatment in isolation.
While basal, untreated control levels of OPN expression at the RNA level are 
significantly lower in Ishikawa cell compared to Heraklio cell lines, Heraklio cells 
treated with exactly the same combinations and concentrations of pro-
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Figure 5-5 Expression of OPN in response to treatment with pro-inflammatory 
cytokine in Ishikawa and Heraklio cells.
Quantitative PCR was conducted on reverse transcribed total RNA after exposure 
to cytokines IL-lp, TNFa and IFNy for 48hrs. (A) in the Ishikawa cell line and (B) in 
the Heraklio cell line. Values are average and SD. Statistical analysis of the data 
was performed using a Student's t-test (control Vs. treatment). *, P<0.05, and 
* * * ,  P<0.001 are considered significant.
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5.3.2 Osteopontin protein secretion
As was the case at the RNA level, significantly higher secreted OPN expression was 
detected in the ERa -ve Heraklio cells when compared to the ERa +ve Ishikawa, in 
the untreated control sample. Significantly, the patterns of secreted OPN 
expression as a result of cytokine treatments were dramatically altered in both the 
cell lines, when compared to the RNA level.
Ishikawa cells treated with IL-lp, TNFa and IFNy in isolation, over 48hrs, showed 
significantly decreased levels of secreted OPN (Figure 5-6A; p<0.05). 1.2, 2 and 1.4- 
fold decreases in secreted OPN expression were detected respectively (p<0.01; 
0.001 and 0.001). Co-treatment with TNFa and IFNy, had a synergistic effect, 
resulting in a further 4-fold decreased expression of OPN (p<0.001). When IL-ip 
was added to this combination the effect was greater with a 6-fold decrease in OPN 
secretion observed (p<0.001).
In contrast to the RNA level once again, a differential response profile was observed 
in the Heraklio cell line after 48hr treatments with the same cytokine combinations 
(Figure 5-6B). 1.6 and 1.5-fold increases in OPN secretion were observed in 
response to IL-ip and TNFa treatment alone when compared to the untreated 
control samples (p<0.001; p<0.001 respectively). A slight but significant 1.2-fold 
increase in OPN secretion was observed when Heraklio cells were exposed to IFNy 
alone OPN (p<0.05). The co-treatment of TNFa and IFNy resulted in a 1.4-fold 
decrease in OPN secretion and when all three cytokines were added in 
combination, a 3.3-fold decrease in secreted OPN was observed (p<0.001).
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Figure 5-6 Secreted OPN in response to treatment with pro-inflammatory 
cytokines in Ishikawa and Heraklio cells.
ELISA was conducted on media samples from cell lines after exposure to cytokines 
IL-ip (5ng/mL), TNFa (25ng/mL) and IFNy (200IU) for 48hrs. (A) in the Ishikawa 
(pg/ml) and (B) in the Heraklio cell lines (ng/ml). Values are average and SE. 
Statistical analysis of the data was performed using a Student's t-test (control Vs. 
treated). ** , P<0.01, and * * * ,  P<0.001 are considered significant.
5.3.3 CD44 gene expression
All cytokines when administered alone exhibited a different effect in the both cell 
lines. In Ishikawa cells, decreased OPN expression was observed, however in 
Heraklio their presence resulted in increased expression, suggesting a possible 
interaction between ERa and cytokine signalling.
CD44 expression was analysed by qPCR in response to cytokine treatm ent in the 
Ishikawa and Heraklio cells using the same treatment regime as for OPN (Figure 
5-7). In the Ishikawa cell line CD44 expression was increased by all cytokines alone 
and in combination (Figure 5-7A). Treatment with IL-1(3 alone resulted in CD44 
expression increasing 1.6-fold (p=0.001). When treated with TNFa, CD44 expression 
significantly increased 1.5-fold (p=0.02) and when treated with IFNy CD44 
expression was significantly increased 1.4-fold (p=0.01). The combination of 
cytokines TNFa and IFNy resulted in a small additive effect and CD44 expression 
significantly increased 1.7-fold (p=0.001). When all three cytokines were used in
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combination, again a small additive effect was observed, CD44 expression 
significantly increased 2-fold (p=1.6 -ll). In the Heraklio cell line (Figure 5-7B) when 
treated with the same cytokines in combination or isolation only TNFa increased 
CD44 expression 1.2-fold (p=0.05). Treatment with IL-1(3, IFNy alone or in
combination with TNFa did not significantly change CD44 expression (p>0.05).
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Figure 5-7 Expression of CD44 in response to treatment with pro-inflammatory 
cytokine in Ishikawa and Heraklio cells.
Quantitative PCR was conducted on reverse transcribed total RNA after exposure 
to cytokines IL-lp (5ng/mL), TNFa (25ng/mL) and IFNy (200IU) for 48hrs. (A) in the 
Ishikawa (ERa +ve) and (B) Heraklio (ERP +ve) cell lines. Values are average and 
SD. Statistical analysis of the data was performed using a Student's t-test (control 
Vs. treatment). *, P<0.05, ** , P<0.01 and * * * ,  P<0.001 are considered significant.
5.3.4 CD44 protein expression
Detected by IHC, significant alterations in the level o f CD44 protein expression were
detected in response to the cytokine treatments, in both cell lines (Figure 5-8). In
the Ishikawa cells, CD44 expression was increased following cytokine treatm ent 
(Figure 5-8A). Each cytokine, administered in isolation resulted in increased CD44 
expression IL-lp (H = 5), TNFa (H = 7) and IFNy (H = 6.5) when compared to the 
untreated control (H = 4), however these increases were not statistically significant 
(p>0.05). When cytokine treatments were administered in combination, TNFa+ IFNy
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(H = 6.5) and TNFa+IFNy+IL-lp (FI = 6.5) each resulted in increased CD44 expression, 
however, again these increases were not statistically significant compared to the 
untreated control (p>0.05).
In the FHeraklio cell line treatment with cytokines alone had different effects on 
CD44 expression. When treated with IL-lp (H = 4) or TNFa (FI = 6) alone, decreased 
levels of CD44 expression levels were detected compared to the untreated control 
(FI = 7), however this decrease was not significant (p>0.05). When treated with IFNy 
alone, increased CD44 expression (FI = 11) was observed, however when TNFa and 
IFNy were combined, CD44 expression decreased (FI = 5). Once again however, 
none of these detectable alterations in protein expression were statistically 
significant (p>0.05). Combined treatment of IL-lp, TNFa and IFNy resulted in 
increased CD44 expression (FI = 7.5; p>0.05).
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Figure 5-8 CD44 intracellular protein expression following treatment with pro- 
inflammatory cytokine treatment in Ishikawa and Heraklio cells.
IHC stained slides for CD44 protein expression in response to pro-inflammatory 
cytokine treatments IL-ip (5ng/mL), TNFa (25ng/mL) and IFNy (200IU) for 48hrs in 
Ishikawa (ERa +ve) and Heraklio (ERa -ve) cells. H-SCORE values are average and 
SD. Statistical analysis of the data was performed using a Student's t-test (Control 
Vs. treatment), data is representative of three biological repeats.
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5.4 Chromatin Immunoprecipitation
Treatment by pro-inflammatory cytokines indicated that OPN and CD44 expression 
could be regulated through TNFa and IFNy signalling. The regulation appeared to 
differ between the Ishikawa and Heraklio cell lines, suggesting an additional role, 
via ERa signalling. NFkB and STAT1 transcription factors have been shown to be 
activated through TNFa and IFNy signalling. To determine therefore if TNFa and 
IFNy signalling directly influences the transcriptional regulation of OPN and CD44 
through NFkB and STAT1, putative promoter analysis was conducted to identify 
appropriate response element positions with the promoters of OPN and CD44, 
followed by ChIP assays to detect binding.
5.4.1 Osteopontin regulation
To determine if transcription factors known to be activated in response to pro- 
inflammatory cytokine signalling were capable of regulating OPN and CD44, 
through binding to appropriate response elements, a promoter analysis was 
conducted. The OPN promoter region spanning from 3KB upstream to the 
transcription start site (ATG site) was analysed for identified regulatory elements. In 
this region, one putative (site 5) and one previously identified NFkB site (site 6) 
(Samant et al. 2007) were identified in addition to a putative STAT1 site (site 7) 
(Figure 5-9). Primers were then designed to amplify identified regions containing 
these sites for specific amplification via qPCR following ChIP isolation of DNA 
fragments through NFkB and STAT1 specific antibodies respectively.
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Figure 5-9 Promoter analysis of the human OPN gene promoter.
The Osteopontin promoter was analysed using Alggen Promo for NFkB and STAT1 
binding sites, -3KB from the translation initiation start site to +0.5KB after the 
start site. Additional primers were designed to amplify two putative regulatory 
elements for NFkB and two STAT1 binding sites in addition to previously 
described estrogen regulatory sites.
After establishing that these direct regulation elements were present on the OPN 
and CD44 promoter, identical cytokine treatments as those in section 5.3 were 
conducted on both cell lines. To determine the role of ERa the Ishikawa and 
Heraklio cells were utilised to investigate if ERa has a role in cytokine signalling. The 
cells were fixed, and chromatin was extracted and immunoprecipitation conducted 
(Section 2.7). After reverse cross-linking to separate DNA from antibody/protein 
complexes, qPCR was performed and amplification Cq values were calculated, 
directly proportional to the amount of transcription factor binding in any given 
treatm ent or control, at the time of fixation. This was used to analyse the role of 
NFkB and STAT1 signalling in the action of pro-inflammatory cytokines on the 
expression levels of OPN and CD44 in endometrial epithelial cell lines.
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5.4.2 NFkB ChIP
ChIP for NFkB signal binding to the OPN promoter showed that TNFa administered 
in isolation over a 48hr period resulted in increased NFkB binding in Ishikawa cells 
(Figure 5-10). At site 5 and site 6 on the OPN promoter, significant 2.9 and 1.8-fold- 
increased levels of NFkB binding were detected respectively (p=0.01; p=0.02). 
When administered in combination, TNFa+IFNy induced significant 1.9-fold 
increase in NFkB binding at site 5, however at site 6, significant 0.7-fold decreased 
NFkB binding was detected (p=0.04; p=0.002 respectively).
In the Heraklio cell line, treatment with TNFa alone resulted in significantly 
decreased NFkB occupancy of the OPN promoter at site 5 (p=0.007). This was also 
observed when TNFa was administered in combination with IFNy (p=0.006). 
Flowever, in contrast to site 5, significant 7-fold increased NFkB binding was 
detected at site 6 at site 6 on the OPN promoter compared to the control, in 
response to the combined TNFa+IFNy treatm ent (p=0.04; Figure 5-10).
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Figure 5-10 NFkB ChIP on the OPN promoter.
Quantitative PCR was conducted on NFkB immunoprecipitated promoter of OPN 
to measure, in fold, NFkB occupancy in Ishikawa and Heraklio cells after cytokine 
treatment TNFa (25ng/mL) and IFNy (200IU) for 48hrs. Significant differences in 
occupation on regulatory sites occurred between the control and treatment. 
Values are average and SD. Statistical analysis of the data was performed using a 
Student's t-test (Control Vs. treatment). *, P<0.05 * * , P<0.01, was considered 
significant.
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5.4.3 STAT1 ChIP
ChIP for STAT1 presence at the OPN promoter in Ishikawa cells, in the presence of 
IFNy demonstrated an average 8-fold increase in NFkB recruitment to site 7, 
however due to the variation in the three biological replicates this effect was not 
significant (P>0.05;Figure 5-11). The combination treatm ent of TNFa+IFNy however, 
resulted in significant 3.4-fold increased STAT1 occupancy at site 7 (p=0.01). In the 
Heraklio cells, no significant alteration in the level of STAT1 occupancy of the OPN 
promoter was observed following treatm ent with IFNy alone. When administered in 
combination however, a combined TNFa+IFNy treatment resulted in a significant 
2.5-fold increase in STAT1 occupancy on site 7 (p=0.006).
■ Control 
IFNy
■ TNFa+IFNy
Ishikawa Heraklio
Figure 5-11 STAT1 ChIP on the OPN promoter.
Quantitative PCR was conducted on STAT1 immunoprecipitate of OPN promoter 
to measure, in fold, STAT1 B occupancy in Ishikawa and Heraklio cells after 
cytokine treatment TNFa (25ng/mL) and IFNy (200IU) for 48hrs. Significant 
differences in occupation on regulatory sites occurred between the control and 
treatment. Values are average and SD. Statistical analysis of the data was 
performed using a Student's t-test (Control Vs. treatment). *, P<0.05 ** , P<0.01, 
was considered significant.
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5.4.4 CD44 regulation
The CD44 promoter site was analysed from 2KB upstream of the ATG site to 1Kb 
downstream (+). One putative NFkB (site 6) binding site and six putative STAT1 
binding sites (sites 3-5) were identified on the CD44 promoter. Primers were then 
designed around these sites to specifically amplify these identified regions for qPCR 
after the ChIP procedure (Figure 5-12).
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Figure 5-12 Promoter analysis of the human CD44 gene promoter.
The CD44 promoter was analysed using Alggen Promo for NFkB and STATI binding 
sites, -2KB from the translation initiation start site to +1KB after the start site. 
Additional primers were designed to amplify one putative regulatory element for 
NFkB and six STAT1 binding sites in addition to previously described estrogen 
regulatory sites.
5.4.5 NFkB ChIP
NFkB binding to the CD44 promoter (Figure 5-13) is increased in both cell lines in
response to cytokine treatment. In the Ishikawa cell line NFkB binding was
significantly increased 10-fold upon treatment with TNFa alone (p=0.03). Although
binding was increased 3-fold with the combined cytokine treatm ent was not
significant (P>0.05). In the Heraklio cell line treatm ent w ith TNFa significantly
increased NFkB occupancy to the CD44 promoter 2.8-fold (p<0.001). TNFa+IFNy
significantly increased NFkB occupancy 2.2-fold (p<0.001).
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Figure 5-13 NFkB ChIP on the CD44 promoter.
Quantitative PCR was conducted on NFkB immunoprecipitate of OPN promoter to 
measure, in fold, NFkB occupancy (site 6) in Ishikawa and Heraklio cells after 
cytokine treatment TNFa (25ng/mL) and IFNy (200IU) for 48hrs. Significant 
differences in occupation on regulatory sites occurred between the control and 
treatment. Values are average and SD. Statistical analysis of the data was 
performed using a Student's t-test (Control Vs. treatment). *, P<0.05 * * * ,  
P<0.001, was considered significant.
5.4.6 ST ATI ChIP in Ishikawa
ChIP performed to assay for the presence of STAT1 binding on the CD44 promoter 
in Ishikawa resulted in differential binding patterns in response to the cytokine 
treatments (Figure 5-14). No significant changes in STAT1 binding were observed 
between the treated and untreated control group at site 3, although IFNy 
treatm ent appeared to increase STAT1 occupancy (p>0.05). Significantly, 2-fold 
decreased STAT1 occupancy was observed at site 4 on the CD44 promoter following 
treatm ent with IFNy (p=0.01). In contrast, a significant 2.5-fold increase in STAT1 
occupancy of the CD44 promoter following IFNy treatm ent was observed at site 5 
(p=0.002). The combination treatment of TNFa+IFNy had no influence on STAT1 
occupancy to the CD44 promoter in the regions tested.
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Figure 5-14 STAT1 ChIP on the CD44 promoter in Ishikawa cells.
Quantitative PCR was conducted on STAT1 immunoprecipitate of the CD44 
promoter to measure, in fold, STAT1 occupancy (sites 3-5) in Ishikawa cells after 
cytokine treatment TNFa (25ng/mL) and IFNy (200IU) for 48hrs. Significant 
differences in occupation on regulatory sites occurred between the control and 
treatment. Values are average and SD. Statistical analysis of the data was 
performed using a Student's t-test (Control Vs. treatment). *, P<0.05 ** , P<0.01, 
was considered significant.
5.4.7 STAT1 ChIP in Heraklio
Treatment with pro-inflammatory cytokines influenced STAT1 binding to the CD44 
promoter in the Heraklio cell line (Figure 5-15). Both pro-inflammatory cytokine 
treatm ent regimes decreased STAT1 binding to site 3 on the CD44 promoter. 
Significant 1.5 and 2-fold decreases in STAT1 binding were observed following 
treatm ent with IFNy and TNFa+IFNy respectively (p<0.05). At site 4 both treatments 
resulted in 1.4-fold (P>0.05) and 1.6-fold (p=0.03) significantly increased STAT1 
occupancy. IFNy treatment alone resulted in significant 2.4-fold increased STAT1 
binding to the CD44 promoter, at site 5 (p=0.0002). When TNFa+IFNy were 
administered in combination, an increase in STAT1 occupancy was observed at site 
5, however this increase was not significant (P>0.05).
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Figure 5-15 STAT1 ChIP on the CD44 promoter in Heraklio cells.
Quantitative PCR was conducted on STATI immunoprecipitate of CD44 promoter 
to measure, in fold, STAT1 occupancy (site 3-5) in Heraklio cells after cytokine 
treatment TNFa (25ng/mL) and IFNy (200IU) for 48hrs. Significant differences in 
occupation on regulatory sites occurred between the control and treatment. 
Values are average and SD. Statistical analysis of the data was performed using a 
Student's t-test (Control Vs. treatment). *, P<0.05 ** , P<0.01, was considered 
significant.
5.5 Discussion
Common characteristics of PCOS and endometriosis include disrupted cytokine 
expression levels, released by both leukocytes, such as monocytes, macrophages 
and lymphocytes and the endometrial vasculature monocytes (Dimitriadis et al. 
2005; Dominguez et al. 2005). While the expression of cytokines such as TNFa and 
IL-1(3 has been detected during the window of implantation and is thought to aid 
implantation, their functions are not fully elucidated (Laird et al. 1996; Sarapik et al.
2012). Their detected elevated expression levels in both circulating blood and local 
peritoneal fluid, associated with pelvic inflammation, may indeed disrupt the 
expression levels of key adhesion molecules involved in the implantation cascade 
(as discussed in Section 5.1).
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In this chapter the effect of elevated glucose and pro-inflammatory cytokine 
treatment on the expression of OPN and CD44 in selected endometrial epithelial 
cell lines was monitored in an in vitro model, mimicking the disrupted cytokine 
environment observed in endometrial pathology. ERa positive and ERa negative cell 
lines Ishikawa and Heraklio were grown in the presence of increasing glucose 
concentrations, to mimic the levels hypothesized in those suffering with type II 
diabetes. Levels of OPN increased at the mRNA level in response to 25mM of 
glucose in both cell models after four hours however this was not observed at the 
secreted protein level. CD44 expression too increased in response to 17mM of 
glucose in both cell lines after four hour treatment.
Bioinformatic analysis of both the OPN and CD44 gene promoters revealed known 
and putative binding sites for NFkB and STAT1, prominent transcription factors, 
known to be induced in the presence of pro-inflammatory cytokines IL-ip and TNFa 
and IFNy. Primers were designed to amplify regions of the promoters around these 
regulatory sites identified in this study along with sites previously identified. 
Treatment with TNFa, IFNy and IL-lp over a 48hr period resulted in differential 
expression levels of OPN and CD44 at the RNA and protein level, dependent on the 
presence of ERa. The two cell line models responded differently to treatment with 
pro-inflammatory cytokines, the most striking differences were the response of 
OPN to TNFa and IFNy. TNFa treatment in the Ishikawa decreased levels of OPN 
mRNA, while no effect on OPN was observed in Heraklio cells. Whilst IFNy 
treatment in the Ishikawa cell line had no effect on altering OPN expression 
however in the Heraklio cell line, expression of OPN mRNA was increased. In order 
to elucidate the signalling mechanisms being induced in the presence of TNFa and 
IFNy, ChIP analysis was conducted. In response to TNFa treatment in the Ishikawa 
cell line NFkB occupancy increased at site 5 and 6 whilst in the Heraklio cell line no 
increase in occupancy was observed by NFkB. CD44 mRNA in response to pro- 
inflammatory cytokines increased in the Ishikawa cell line however TNFa was the 
only cytokine to increase CD44 expression in the Heraklio cell line. NFkB occupation 
on the CD44 promoter is increased in response to treatment with TNFa in the
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Ishikawa and Heraklio cell lines. In response to treatment with IFNy, STAT1 
occupancy on the CD44 promoter in the Ishikawa cell line increases at site 3 and 5. 
In the Heraklio cell line occupancy by STAT1 on the CD44 promoter at site 5.
In the Ishikawa and Heraklio cell line the effect observed in response to 25mM of 
glucose at 4hrs was diminished by 24hrs possibly in response to the cells 
metabolising the glucose by the 24hr time point. Alternatively levels of OPN may 
not increase further in response to this treatment as a negative feedback 
mechanism. This is suggestive of OPN transcription being activated quickly 
following glucose stimulation and the effect lost after 24hrs. In the Heraklio cell 
line, where there was no ERa expression, a 2.6-fold increase in expression was 
observed compared to a 1.3-fold increase in Ishikawa. These changes were not 
reflected at the secreted protein level, which could be a result of the short time 
period, not allowing enough time for protein secretion to occur to a detectable 
level.
In the Ishikawa cell line, levels of CD44 increase after four and twenty four hours in 
response to 17mM and 25mM of glucose. However the levels after 24hrs did not 
increase as they did for OPN. This suggests a role for CD44 in glucose metabolism. 
However in the Heraklio cell line levels of CD44 mRNA only increase in response to 
17mM at four hours. It could therefore be possible that CD44 could have a 
requirement for ERa in sustaining the elevated levels of CD44 following glucose 
treatment. It may therefore be important to determine the ERa status in patients 
with infertility.
A study conducted by Von Wolf et al in 2003 showed the presence of glucose 
transporter facilitators in the human endometrium throughout the menstrual cycle 
(Wolff 2003) thus, suggesting the healthy cycling endometrium may be responsive 
to glucose. Increased CD44 expression was also observed at the RNA level, as a 
result of increasing glucose concentrations in the Ishikawa cell line. CD44 has been 
indicated to play a role in glucose metabolism (Tamada et al. 2012; Kodama et al. 
2012) and therefore the increase in CD44 observed could be due to a negative
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feedback mechanism, leading to decreased glucose in the cells. CD44 levels have 
also been shown to be increased in obese insulin resistant mice compared to 
healthy mice (Kodama et al. 2012). This effect has been observed in animal models 
(mice), when CD44 cDNA was introduced to peripheral circulating blood (Weiss et 
al. 2008). Insulin resistance and diabetes observed in PCOS patients with high BMI, 
may have higher levels of circulating glucose. This in turn may increase OPN and 
CD44 expression if glucose levels were above those tested here (17mM to 25mM), 
disrupting the adhesion protein patterning of the uterine surface. It may therefore 
be possible for patients prescribed regular insulin, to control their levels of glucose, 
according to the data shown here should also control their expression of both OPN 
and CD44.
Under conditions of high glucose and therefore chronic exposure, as represented 
by the 25mM group, OPN expression may be decreased, as shown after 24 hours. In 
comparison, the expression of CD44 in these circumstances may be constantly 
increased, in an attempt to lower the cellular glucose levels and thus disrupting the 
ratio of adhesion protein present at the surface of the endometrium. In addition, 
GLUT4 RNA expression in adipocytes has been shown to be decreased in PCOS 
women compared to fertile controls (Jensterle et al. 2008). If GLUT4 levels are 
decreased then the transport of glucose into the cells would decrease, therefore 
lowering the cellular glucose concentration and that of CD44 expression, but 
increase secreted OPN resulting in altered adhesion complex balance once again.
In the Ishikawa cell line IL-ip and TNFa treatment decreased OPN expression, and 
this is likely to be through the NIK->IKK->IkB pathway (Figure 1-16). IkB is degraded 
by IKKs, which release NFkB allowing it to dimerise and translocate in the nucleus to 
alter gene transcription. Binding of NFkB in the nucleus to the novel site 5 response 
element, as well as the previously identified site 6 at the OPN promoter is clearly 
demonstrated here (Samant et al. 2007). Binding to the novel NFkB site in the OPN 
promoter significantly increased after TNFa treatment. OPN signalling can influence 
the phosphorylation of NIK and IKK0, which are involved in activating NFkB, which
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in turn leads to IkB degradation and NFkB activation (Wang and Denhardt 2008). 
High levels of OPN could therefore result in high levels of NFkB, a negative feedback 
mechanism in Heraklio, which may explain the lack of OPN gene activation upon 
dual treatment with both TNFa and IL-lp treatment. However the turnover of OPN 
at the protein level may not be very rapid and added to the high levels of OPN 
protein observed result in no significant alteration in OPN secretion within the 
48hrs of the experiment.
IFNy shows no determinable regulatory effect on OPN after a 48hr treatment in 
Ishikawa cells, however a significant 6-fold increase in secreted protein levels are 
observed. This could be a result of gene transcription of OPN in response to IFNy 
STAT1 signalling being very rapid and therefore not observed in the forty eight hour 
time frame observed. This is supported by the presence of increased STAT1 
occupancy on the OPN promoter following dual treatment with TNFa and IFNy, in 
Ishikawa cells. The STAT1 sites (OPN site 7) are located in close proximity to an 
NFkB site (OPN site 6), suggesting the possibility that NFkB is bound to the OPN 
promoter at site 6 preferentially. This would in turn lead to an inability of STAT1 
binding at site 7 due to steric hindrance blocking the response element and 
resulting in no induction of signal.
In Heraklio cells there is a significant increase in OPN expression at both the RNA 
and secreted protein levels in response to IFNy. This effect is also noted with the 
co-treatment of TNFa+IFNy, however the response in slightly diminished at both 
the RNA and secreted protein level. No other cytokines alone or in combination 
significantly affected OPN transcript levels. This may be due to the fact that a 
negative feedback system for OPN expression may result in its decreased 
expression after 48hrs. However protein secreted into the media in the 48hr period 
is increased when compared to the control by all treatments, except when all three 
are used in combination.
The occupancy of NFkB and STAT1 transcription factors differed from that observed
in Ishikawa, and a decrease in NFkB occupancy was observed at the OPN promoter
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at site 5 in Heraklio. As a result, no change in the RNA level of OPN was detected 
when treated with TNFa after forty-eight hours. However when TNFa and IFNy 
treatment were administered together, NFkB occupancy on the OPN promoter 
increased significantly at site 6. This suggests a role for the control of OPN gene 
transcription by NFkB as an increase in OPN mRNA levels were observed.
This mechanism supports the mRNA data, where Heraklio cells treated with IFNy or 
TNFa+IFNy show an up-regulation in OPN expression. The ChIP data for STAT1 
suggests that it may be responsible for this increase in gene activation. STAT1, IFNy 
and OPN expression has been co-localised in the lumina cells in cross sections of a 
porcine model (Bazer et al. 2008). Re-enforcing the IFNy signalling pathway, 
phosphorylation of STAT1 occurs via TYK2 and JAK1 pathway resulting in STAT1 
activation by allowing dimerization to occur. The resultant translocation into the 
nucleus enables STAT1 to bind and activate the transcription of OPN. In the Heraklio 
cells OPN expression is only modulated by IFNy signalling. When treated with IFNy 
alone, OPN expression is increased 2.4-fold. STATI binding to the OPN promoter is 
increased upon IFNy treatment and at the mRNA level OPN expression is increased. 
When co-treatment of IFNy and TNFa was used in combination, no change in the 
binding of STAT1 was observed, at the OPN promoter and the RNA level remained 
unchanged.
NFkB has been shown previously to bind the CD44 promoter (Hinz et al. 2002) and 
this result is suggestive of a similar mechanism of gene regulation in the 
endometrium, in the presence of increased TNFa. Increased expression of CD44 
expression was observed with all treatments and this was enhanced with combined 
treatments. ChIP detected significantly increased NFkB binding at the CD44 
promoter following TNFa treatment, when compared to the control. This however, 
was not observed following co-treatment with TNFa+IFNy; suggesting NFkB is not 
solely responsible for the increase in gene activation observed following dual 
treatment STAT1 binding to the CD44 promoter changed significantly. At STAT1 site 
3, a trend of increased binding was observed, while a significant decrease in STATI
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occupancy was observed at site 4 on the CD44 promoter. However a significant 
increase in STATI occupation/binding to the CD44 promoter was observed site 5.
In contrast to Ishikawa cells, a significant increase in NFkB occupancy on the CD44 
promoter was observed as a result of both TNFa and combined TNFa+IFNy 
treatments in the Heraklio cells. This is supportive of NFkB activation of CD44 
expression and that the mechanism is through traditional, accepted NFkB response 
elements. STAT1 occupancy was affected by treatment with IFNy alone and when 
added in combination with TNFa. At site 3 on the CD44 promoter STAT1 occupancy 
significantly decreases in response to treatment with IFNy alone or TNFa+IFNy in 
combination. At site 4 STAT1 occupancy is increased as a result of IFNy treatment 
alone and significantly increased as a result of the combination treatment of 
TNFa+IFNy. At site 5 STAT1 occupancy is significantly increased as a result of IFNy 
treatment alone and a similar effect was observed following dual treatment with 
TNFa+IFNy. Although at the mRNA level CD44 expression was not increased in 
response to these treatment regimes, it suggests that the interplay between the 
pathways may have the effect of decreasing gene transcription of CD44 in Heraklio 
cells. Alternatively this lack of gene activation could be linked with the ERa/ERP/PR 
status of this cell line, which differs from the hormone status of the Ishikawa cell 
line.
Regulation of OPN and CD44 appears to differ at the transcriptional level by NFkB 
and STAT1 in the Ishikawa (ERa +ve) and Heraklio (ERa -ve) cell lines. This suggests 
a role for ERa in the regulation of these adhesion complex genes in addition to a 
cross talk between the signalling pathways investigated, this is discussed further in 
chapter 6.
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Chapter 6 
General Discussion
The work described in this thesis furthers the existing knowledge of the expression
of the adhesion complex components by evaluating their expression in infertility
simultaneously. OPN and CD44 were shown to be differentially expressed in the
endometrium of fertile and infertile women. The mechanisms of regulation of OPN
and CD44 have started to become elucidated and may provide an insight into the
adhesion complex regulation in infertile pathology. Chapter 3 demonstrated the
levels of adhesion complex expression in infertile women relative to women of
proven fertility. The first observation was that in UIF the adhesion complex
expression was decreased in the secretory phase the expression of adhesion
complex components CD44, ITGAV and ITGB3 were decreased in whole biopsy
tissue samples obtained from infertile women. Down-regulation of ITGAV and
ITGB3 are consistent with previous observations indicating that at the protein level
integrin avp3 was decreased in UIF (Tei et al. 2003). CD44 stromal protein
expression was down regulated in the secretory phase endometrium of UIF, down-
regulation of CD44 has not been demonstrated previously at the mRNA or protein
level proving to be an exciting novel result. In the anovulatory PCOS women it was
observed that expression of OPN, CD44 and ITGB3 mRNA were decreased in the
secretory phase endometrium. Consistently, decreased levels of avp3 in
anovulatory PCOS have previously been reported in the literature (Apparao et al.
2002). In addition women diagnosed with ovulatory PCOS showed that levels of
CD44 protein were down regulated in the endometrial glands of the secretory
phase, an observation not reported previously. This work has demonstrated that in
women with endometriosis stromal OPN protein expression in the proliferative
phase was decreased. Whilst this contrasts to a previous study that indicated
endometrial mRNA endometrial levels and blood plasma levels of OPN were
increased in endometriosis (Cho et al. 2009), tissue protein levels were measured in
this study and this may suggest that regulation of OPN in tissues is post
transcriptional. In the endometriosis group ITGB3 expression was decreased at the
mRNA level in the secretory phase, again another novel observation as levels of
ITGB3 have not been described previously in endometriosis throughout the
menstrual cycle (Chapter 3). To relate these observations to ER status, increased
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ERa expression has been identified in PCOS and endometriosis pathologies in the 
glands, lumina cells and stroma (Margarit et al. 2010). This study has shown that 
high ERa expression could impact on the regulation of OPN and CD44, resulting in 
decreased expression of the adhesion complex. This may affect its function as a 
linker complex between the epithelial and trophoblast cells during implantation 
(Yen and Jaffe 2009; Singh and Aplin 2009).
6.1 Regulation of adhesion complex components by nuclear receptor 
signalling
This study has indicated, using an in vitro model that OPN and CD44 are regulated 
by hormones E2 and P4; and that expression is ERa dependent in endometrial 
epithelial cells Ishikawa and Heraklio (Chapter 4). The markedly different expression 
of OPN and CD44 between the Ishikawa and Heraklio cell lines could be due to their 
differential expression of ERa, ERp and PR (Table 6-1).
Ishikawa Heraklio
ERa +++ -
ERP + ++
PR +++ -
OPN + +++
CD44 + ++
Table 6-1 Summary of Ishikawa and Heraklio cell line expression status
Ishikawa cells are characterised as ERa/ERp/PR +ve, whilst Heraklio are ERa/PR -ve, 
ERP +ve. As no PR regulatory elements on the OPN or CD44 promoter have been 
identified in the literature, our studies have focused on the role of EREs, ERa, SP-1 
and AP-1 found in the OPN promoter (Sharma et al. 2010; Wang et al. 2000b; 
Bidder et al. 2002). At the basal level (i.e. in the absence of exogenous E2) more ERa 
was found to bind to the OPN binding site 1 for ERa and the CD44 binding sites 1 
and 2 for ERa in Ishikawa when compared to Heraklio suggesting that ERa is 
required in Ishikawa to maintain OPN and CD44 basal expression levels. OPN
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promoter analysis revealed that ERa binding to  site 1 was preferential to site 2 
(Sharma et al. 2010; Wang et al. 2000b; Bidder et al. 2002) suggesting that in 
endometrial epithelial cells site 1 is highly important in the regulation of OPN.
Preliminary data has shown that following E2 treatm ent the occupancy of ERa on 
site 1 of the OPN promoter was increased 40-fold (Figure 6-1). This indicates that 
the increase in OPN mRNA expression observed in chapter 4, was likely due to E2 
driven binding of ERa at this site. Site 1 contains 1 ERE and two AP-1 elements and 
it remains to be determined which of these sites is key for E2 regulation of OPN.
45 -| S  Ishikawa Control
■  Ishikawa E2 lOnM  
□  Heraklio Control 
Heraklio E2 lO nM
Site 1 Site 4
OPN
Figure 6-1 E2 induced ERa occupancy on the OPN promoter.
ChIP was conducted on ERa precipitate of the OPN promoter to measure, ERa 
occupancy in Ishikawa and Heraklio cells after treatment with E2 (lOnM). Values 
from one biological repeat.
Regulation of OPN and CD44 expression by hormones E2 and P4 was demonstrated 
in ERa positive Ishikawa cells. Both cell lines were shown to be responsive to E2 and 
P4/ as well characterised targets of ER and PR signalling pathway were shown to be 
activated. A study by Stossi evaluated the expression of levels of genes regulated by 
ERa and ERp in response to E2 (lOnM) in cell lines transfected to stably express ERa 
or ERp. Of the four genes measured GREB1 expression increased in a time 
dependant manner with expression peaking at 48hrs. The levels of GREB1 
expressed were also very consistent between the ERa and ERp stable cells (Stossi et 
al. 2004). In this study increases in GREB1 (Figure 4-6) were shown to be consistent
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at 48hrs with that of Stossi's study re-enforcing the active signalling of ERa in 
Ishikawa cells, and ERp in Heraklio cells. The increases noted in the Ishikawa cells in 
response to hormones were not mirrored in Heraklio cells. In the context of the 
findings from chapter 4 this suggests a very different role for OPN and CD44 by the 
ERa and ERp receptors.
6.2 Regulation of the adhesion compiex by glucose
Glucose regulation of OPN and CD44 was demonstrated in chapter 5 and shown to 
be ERa independent for OPN and ERa dependent for CD44. Similar responses were 
observed in OPN and CD44 expression in both the Ishikawa and Heraklio cells as a 
result of glucose treatments (Chapter 5). In response to 25mM of glucose OPN 
mRNA expression increased in both cell lines after 4hrs. This effect was lost at 24hrs 
in both cell lines possibly due to decreased glucose levels following cellular 
metabolism. The expression of CD44 was modulated by glucose treatment; 
however levels were still high at 24hrs, this maybe a result of CD44 regulating 
glucose expression in cells. A recent study suggested that ablation of CD44 
increased the levels of glucose and its related metabolites in the glycolysis pathway 
suggesting that CD44 could have a role in the regulation of glucose (Tamada et al. 
2012).
6.3 Regulation of the adhesion complex by pro-inflammatory 
cytokines
The regulation of OPN and CD44 by pro-inflammatory cytokines was explored in
chapter 5 and demonstrated that both OPN and CD44 expression were regulated by
TNFa, IL-lp and IFNy. Further to this, the direct regulation of NFkB and STAT1
through TNFa and IFNy signalling was characterised. The direct modulation of these
transcription factors was shown to differ between the ERa +ve and -ve cell lines.
Treatment of cells with TNFa and IFNy showed the most striking differences
between the cell lines, and suggested a role for ERa. TNFa treatment in the
Ishikawa cells decreased levels of OPN mRNA, while no effect on OPN was observed
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in Heraklio cells. Whilst IFNy treatment in the Ishikawa cell line had no effect on 
altering OPN expression however in the Heraklio cell line, expression of OPN mRNA 
was increased. Therefore these treatments were chosen to investigate the direct 
regulation of OPN and CD44 utilising ChIP. Putative regulatory elements on the OPN 
promoter were identified. These sites include ERa/AP-1 (site 1), NFkB (site 5) and 
STAT1 (site 7). A binding site for NFkB on the OPN promoter (site 6) had been 
identified previously to contain 9 conserved and 3 non-conserved bases (GGG GAA 
GTC CAA) when compared to the consensus NFkB sequence (GGG AAA GTC CCC). 
Using EMSA and ChIP to demonstrate that the p65 unit of NFkB was capable of 
binding to this sequence (Samant et al. 2007). A novel NFkB site (site 5) was 
identified in this study, and positive binding by NFkB was demonstrated by ChIP 
(CGG ACT TTC CCT). Putative regulatory elements were also identified in the CD44 
promoter. These include sites for ERa, AP-1 and SP-1 (Site 1 and 2), STAT1 (site 5) 
and NFkB (site 6). The putative CD44 NFkB site 5 (GGG GAG GGG CTG) was bound 
by NFkB following TNFa treatment suggesting this site plays an important role in 
CD44 regulation in response to TNFa signalling in the endometrium. Novel binding 
sites for ERa, AP-1, NFkB and STAT1/IRF-1 have been identified.
6.4 Conclusion
The main aim of this study was to understand the regulation of the adhesion 
complex components OPN and CD44 in clinical samples and cellular models.
The study of clinical samples clearly demonstrated that the expression patterns of
both OPN and CD44 were perturbed in the tissues of patients diagnosed with PCOS,
endometriosis and UIF. Using the adhesion complex component expression as a
panel of markers enables the distinction of different infertile pathologies. For the
first time a specific marker was unveiled for UIF, where levels of CD44 were down
regulated in stroma of these patients. As this change is unlikely to directly affect
trophoblast attachment, further investigations to determine effects on signalling to
the uterine surface, or establishment of implantation will be required.
Nevertheless, it is now important to conduct a larger study of UIF patients to
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determine whether CD44 can be used as an effective marker to characterise and 
potentially stratify these patients.
The study of three distinct signalling pathways; hormones (E2 and P4), glucose and 
pro-inflammatory cytokines (IL-1(3, TNFa and IFNy), revealed that regulation of OPN 
and CD44 was incredibly complex, with each pathway having a subtle role in the 
control of these key adhesion complex components. This is the first time that the 
three pathways have been investigated simultaneously in an unbiased way in a 
single study. This approach has demonstrated the need to now investigate the 
regulation of OPN and CD44 in model systems that even more closely mimic the 
local environment experienced by endometrial cells in healthy tissue, as well as 
samples originating from PCOS, endometriosis, and UIF patients. This notion is 
further supported by the analysis that was undertaken to consider the direct 
regulation of OPN and CD44 by the key transcription factors ERa, NFkB, and STAT1, 
that are known to control the response to E2, and the pro-inflammatory cytokines 
TNFa and INFy. The detailed observations made in this study revealed that these 
transcription factors occupied the promoters of both OPN and CD44. More 
importantly this analysis revealed novel regulatory elements within the promoter 
region of the genes encoding these two proteins (Figure 6-2).
KB OPN Promoter
B
1111 1  I 1 I II I I I  I I I 
ATG
Figure 6-2 OPN and CD44 promoter regulatory elements.
These elements had adjacencies to one another which further supports the 
suggestion of a subtle balance of co-regulation (or dysregulation) by hormones and 
cytokines of OPN and CD44. Close monitoring of circulating levels of cytokines, 
hormones and blood glucose, the regulation of these factors by treatment with 
combinations of anti-inflammatory, insulin sensitising, and hormone balancing 
therapies could result in the re-balancing of the expression levels of adhesion 
complex components, and contribute to restoring fertility. However there is much 
work to be done before reaching this point.
6.5 Further work
To establish the role ERa plays in the regulation of OPN and CD44 the Ishikawa cell 
line could be transfected with RNAi to knock out the expression of ERa, similar 
results to that of Heraklio regulation of OPN and CD44 would suggest regulation via 
ERa. Alternatively, the Heraklio cell line could be transfected to express ERa and 
results similar to that in Ishikawa would hint to regulation via ERa.
High resolution mapping or EMSA would distinguish which of multiple sites 
detected by some primer sequences were responsible for the regulation of OPN 
and CD44, allowing further work to be conducted.
To determine if the co-factors associated with ERa, AP-1, SP-1, STAT1 and NFkB 
play a role, sequential ChIP could be conducted. This would involve an initial ChIP 
for example on ERa, this would be subject to ChIP again but for a co-factor such as 
SRC. This would establish which of the transcription factors are bound to co­
activators and may elucidate the interplay between co-factors and transcription 
factors that are located very close to one another on the promoter sequence 
(Figure 6-2).
Finally results from these experiments would inform more specific regulation tests 
that could be conducted on biopsy samples, leading to a greater understanding of
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the mechanisms of expression and possibly to a therapeutic solution to restore 
receptivity.
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Appendicies
A: RNA Protocol for RNeasy Kit Qiagen
1. Cells grown in a monolayer (do not use more than 1 x 107 cells): Cells can be 
either lysed directly in the cell-culture vessel (up to 10 cm diameter) or trypsinized 
and collected as a cell pellet prior to lysis.
2. Disrupt the cells by adding Buffer RLT. For pelleted cells, loosen the cell pellet 
thoroughly by flicking the tube. Add the appropriate volume of Buffer RLT (see 
Table 5). Vortex or pipette to mix, and proceed to step 3.
3. Pipette the lysate directly into a QIAshredder spin column placed in a 2mL 
collection tube, and centrifuge for 2min at full speed. Proceed to step 4.
4. Add 1 volume of 70% ethanol to the homogenized lysate, and mix well by 
pipetting. Do not centrifuge.
5. Transfer up to 700pL of the sample, including any precipitate that may have 
formed, to an RNeasy spin column placed in a 2mL collection tube (supplied). Close 
the lid gently, and centrifuge for 15 s at 8000xg Discard the flowthrough.
6. Add 700pL Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15s at 8000xg to wash the spin column membrane. Discard the flow­
through.
7. Add 500pL Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15s at 8000xg to wash the spin column membrane. Discard the flow­
through.
8. Add 500pL Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 2min at 8000xg to wash the spin column membrane.
9. Optional: Place the RNeasy spin column in a new 2mL collection tube (supplied), 
and discard the old collection tube with the flow-through. Close the lid gently, and 
centrifuge at full speed for lmin.
10. Place the RNeasy spin column in a new 1.5mL collection tube (supplied). Add 
30-50pL RNase-free water directly to the spin column membrane. Close the lid 
gently, and centrifuge for lmin at 8000xg to elute the RNA.
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B: Qiaquick DNA purification
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix. For example, 
add 50pL of Buffer PB to lOOpL PCR sample.
2. If pH Indicator I has been added to Buffer PB, check that the color of the mixture 
is yellow. If the color of the mixture is orange or violet, add lOpL of 3M sodium 
acetate, pH 5.0, and mix. The color of the mixture will turn to yellow.
3. Place a QIAquick spin column in a provided 2mL collection tube.
4. To bind DNA, apply the sample to the QIAquick column and centrifuge for 30 -  
60s.
5. Discard flow-through. Place the QIAquick column back into the same tube. 
Collection tubes are re-used to reduce plastic waste.
6. To wash, add 0.75mL Buffer PE to the QIAquick column and centrifuge for 3 0 -  
60s.
7. Discard flow-through and place the QIAquick column back in the same tube. 
Centrifuge the column for an additional lmin.
IMPORTANT: Residual ethanol from Buffer PE will not be completely removed 
unless the flow-through is discarded before this additional centrifugation.
8. Place QIAquick column in a clean 1.5mL microcentrifuge tube.
9. To elute DNA, add 50pL Buffer EB (10 mM Tris-CI, pH 8.5) or water (pH 7.0-8.5) 
to the center of the QIAquick membrane and centrifuge the column for lmin. 
Alternatively, for increased DNA concentration, add 30pL elution buffer to the 
center of the QIAquick membrane, let the column stand for lmin, and then 
centrifuge.
Note: All centrifugation steps are carried out at 17,900xg
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C: RNA normality test
Probability Plot o f anovulatory PCOS
99
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-0.05 0.00 0.05 0.10 0.15
Mean 0.04355
StDev 0.04233
N 10
AD 1.050
P-Value 0.005
anovulatoryPCOS
Normality testing using the Anderson Darling test. Data distribution analysis for 
each patient cohort group. All data obtained for RNA starting quantity were 
grouped and the normality of the distribution of the data assessed. The data for 
anovulatory PCOS patients is shown here and is significantly different from a 
normal distribution (p<0.005). This example is representative and indicative o f the 
observed heterogeneity in the clinical data obtained.
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